US20170128076A9 - Catheter-assisted tumor treatment - Google Patents

Catheter-assisted tumor treatment Download PDF

Info

Publication number
US20170128076A9
US20170128076A9 US14/101,171 US201314101171A US2017128076A9 US 20170128076 A9 US20170128076 A9 US 20170128076A9 US 201314101171 A US201314101171 A US 201314101171A US 2017128076 A9 US2017128076 A9 US 2017128076A9
Authority
US
United States
Prior art keywords
implant
catheter
lumen
component
distal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US14/101,171
Other versions
US20140371716A1 (en
US9737308B2 (en
Inventor
Leon Rudakov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Artventive Medical Group Inc
Original Assignee
Artventive Medical Group Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Artventive Medical Group Inc filed Critical Artventive Medical Group Inc
Priority to US14/101,171 priority Critical patent/US9737308B2/en
Priority to AU2013392058A priority patent/AU2013392058B2/en
Priority to PCT/US2013/076964 priority patent/WO2014200563A1/en
Priority to CA2915267A priority patent/CA2915267A1/en
Priority to ES13886735T priority patent/ES2957207T3/en
Priority to EP13886735.3A priority patent/EP3007756B1/en
Assigned to ARTVENTIVE MEDICAL GROUP, INC. reassignment ARTVENTIVE MEDICAL GROUP, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: RUDAKOV, LEON
Priority to CA2915223A priority patent/CA2915223A1/en
Priority to US14/304,868 priority patent/US9737306B2/en
Priority to US14/304,869 priority patent/US9636116B2/en
Priority to AU2014277882A priority patent/AU2014277882A1/en
Priority to PCT/US2014/042427 priority patent/WO2014201434A2/en
Priority to EP14810987.9A priority patent/EP3007656A2/en
Publication of US20140371716A1 publication Critical patent/US20140371716A1/en
Priority to US14/622,729 priority patent/US20150157329A1/en
Priority to US14/973,414 priority patent/US10149968B2/en
Priority to US15/583,956 priority patent/US10441290B2/en
Publication of US20170128076A9 publication Critical patent/US20170128076A9/en
Publication of US9737308B2 publication Critical patent/US9737308B2/en
Application granted granted Critical
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12131Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
    • A61B17/1214Coils or wires
    • A61B17/1215Coils or wires comprising additional materials, e.g. thrombogenic, having filaments, having fibers, being coated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12027Type of occlusion
    • A61B17/12031Type of occlusion complete occlusion
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12027Type of occlusion
    • A61B17/12036Type of occlusion partial occlusion
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12027Type of occlusion
    • A61B17/1204Type of occlusion temporary occlusion
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12099Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder
    • A61B17/12109Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder in a blood vessel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12131Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
    • A61B17/12136Balloons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12131Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
    • A61B17/1214Coils or wires
    • A61B17/12145Coils or wires having a pre-set deployed three-dimensional shape
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12131Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
    • A61B17/1214Coils or wires
    • A61B17/12154Coils or wires having stretch limiting means
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12131Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
    • A61B17/12168Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device having a mesh structure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12131Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
    • A61B17/12168Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device having a mesh structure
    • A61B17/12172Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device having a mesh structure having a pre-set deployed three-dimensional shape
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12131Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
    • A61B17/12168Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device having a mesh structure
    • A61B17/12177Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device having a mesh structure comprising additional materials, e.g. thrombogenic, having filaments, having fibers or being coated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12131Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
    • A61B17/12181Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device formed by fluidized, gelatinous or cellular remodelable materials, e.g. embolic liquids, foams or extracellular matrices
    • A61B17/12186Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device formed by fluidized, gelatinous or cellular remodelable materials, e.g. embolic liquids, foams or extracellular matrices liquid materials adapted to be injected
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/00491Surgical glue applicators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12131Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
    • A61B17/1214Coils or wires
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B2017/00831Material properties
    • A61B2017/00893Material properties pharmaceutically effective
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B2017/1205Introduction devices
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B2017/1205Introduction devices
    • A61B2017/12054Details concerning the detachment of the occluding device from the introduction device
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00Catheters; Hollow probes
    • A61M25/0021Catheters; Hollow probes characterised by the form of the tubing
    • A61M25/0023Catheters; Hollow probes characterised by the form of the tubing by the form of the lumen, e.g. cross-section, variable diameter
    • A61M25/0026Multi-lumen catheters with stationary elements
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00Catheters; Hollow probes
    • A61M25/0067Catheters; Hollow probes characterised by the distal end, e.g. tips
    • A61M25/0068Static characteristics of the catheter tip, e.g. shape, atraumatic tip, curved tip or tip structure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/005Devices for introducing or retaining media, e.g. remedies, in cavities of the body for contrast media

Definitions

  • the present disclosure is related to endovascular apparatuses and methods, and more specifically, to apparatuses and methods for delivering a material to a target region of a body lumen and regulating blood flow therethrough.
  • Blood vessels can be accessed to deploy embolic agents, contrast agents, and medications to target regions of the body.
  • Some target regions include the blood vessels themselves, as well as organs or other tissue being fed by blood vessels.
  • embolization blood flow can be reduced to encourage atrophy or infarction of a target region of the body.
  • target regions can include tumors, fibroids, and vascular malformations, such as arteriovenous malformations (“AVM”) or arteriovenous fistulas (“AVF”).
  • AVM arteriovenous malformations
  • AVF arteriovenous fistulas
  • embolization of blood vessels can also be achieved to slow or stop bleeding in emergency situations.
  • Embolic agents can be used to treat cancer.
  • embolics can be used to occlude the vasculature feeding a tumor.
  • Drug-loaded embolics such as drug-loaded microspheres, can be used to deliver chemotherapeutic agents and/or therapeutic agents designed to treat inflamed or diseased tissue.
  • clinicians have administered chemotherapeutic agents in combination with embolic polyvinyl alcohol (“PVA”) particles.
  • PVA polyvinyl alcohol
  • Various embodiments of medical methods and apparatus disclosed herein enable a clinician to provide a targeted delivery of a material, such as an embolic material, contrast agent, or drug, to a select body region.
  • a material such as an embolic material, contrast agent, or drug
  • Some embodiments relate to vessel occlusion and tissue ablation or infarction by delivery of radially expandable implant frames that can be used to deliver a material to a downstream target area, such as a blood vessels or tissue.
  • the implant can be positioned to achieve immediate total occlusion of blood flow to ensure high material concentration in the target area, precise or calibrated control of delivered material, and specific targeting of certain structures and protection of others, which is especially useful for smaller target vessels and tissues.
  • Some embodiments also provide for secondary procedures to be performed after an initial implant and material has been deployed at a target region.
  • some embodiments of the present system can help close a bodily lumen or vessel rapidly and with confidence.
  • various frame configurations, expected delivered and expanded dimensions, and a description of target anatomy of some embodiments are provided.
  • Aspects of implants and delivery devices that can be utilized in combination with the implants and features disclosed herein are disclosed in applicant's co-pending U.S. patent application Ser. No. 14/044,794, filed on Oct. 2, 2013; U.S. Patent Application No. 61/904,376, filed Nov. 14, 2013, titled Implantable Luminal Devices and Methods (086538-0041); U.S. Patent Application No. 61/904,379, filed on Nov. 14, 2013, titled Torque Resistant Distal Catheter Tip (086538-0043); U.S. patent application Ser. No.
  • Some embodiments can provide vascular implantation for vessels that are from about 2 mm to about 16 mm, from about 5 mm to about 13 mm, and in some embodiments, from about 7 mm to about 11 mm.
  • the target delivery profile can be from about 2 Fr to about 8 Fr, about 3 Fr to about 7 Fr, from about 4 Fr to about 6 Fr, or in some embodiments, about 5 Fr.
  • expansion of the implant can provide sufficient radial force against the inside wall of a vein.
  • Some embodiments can comprise features or means configured to minimize backflow of blood or minimize venous insufficiency.
  • treatment applications for embodiments of the implant can include ilio-femoral venous obstruction and chronic iliac venous outflow obstruction as a result of venous disease.
  • the implant can provide enhanced control of the delivery of a material or agent.
  • a material or agent can depend exclusively upon distal flow patterns.
  • Some embodiments disclosed herein can enable control of material delivery, prevent reflux of the material, and permit calibrated delivery of the material, which can often be limited by early reflux along a delivery platform.
  • the material can comprise liquid embolic agents such as N-butyl cyanoacrylate (“NBCA”), Onyx, or other liquid agents, radioembolization particles, and microspheres, such as microspheres filled with the radioactive isotope Yttrium Y-90.
  • NBCA N-butyl cyanoacrylate
  • Onyx or other liquid agents
  • radioembolization particles such as microspheres filled with the radioactive isotope Yttrium Y-90.
  • a material delivery device comprising: an expandable support member having a lumen and an outflow end, the support member being configured to expand from a collapsed configuration to an expanded configuration for placement in a body lumen; a cover component, extending along the support member, defining an aperture; and a valve component coupled to the cover component and disposed at the outflow end, the valve component permitting outflow of a material through the aperture and restricting backflow of the material into the aperture.
  • Clause 2 The device of Clause 1, wherein the cover component comprises a tubular membrane coupled to the support member and the valve component comprises a free end of the tubular membrane extending away from the support member at the outflow end, the free end of the tubular membrane being configured to permit outflow of the material through the outflow end and to invert or fold onto itself to restrict backflow of the material into the outflow end.
  • Clause 3 The device of any one of Clauses 1 to 2, wherein the tubular membrane comprises inner and outer portions that extend along respective interior and exterior surfaces of the support member.
  • Clause 4 The device of Clause 3, wherein the free end of the tubular membrane extends from the outer portion, and the inner portion comprises a second free end.
  • Clause 5 The device of Clause 4, wherein the free end is coupled to the second free end.
  • Clause 6 The device of any one of Clauses 1 to 5, wherein the cover component comprises a tubular membrane coupled to the support member and the valve component comprises a free end of the tubular membrane extending away from the support member at the outflow end, wherein the tubular membrane comprises a tubular outer portion extending along a support member exterior and a segmented inner portion, comprising a plurality of strips, extending along a support member interior.
  • Clause 7 The device of Clause 6, wherein the free end is coupled to at least one of the plurality of strips.
  • Clause 8 The device of Clause 7, wherein the coupling comprises a suture.
  • Clause 9 The device of any one of Clauses 1 to 8, wherein the valve component is movable between open and closed positions, the valve component permitting flow of the material through the outflow end when in the open position and restricting backflow of the material through the outflow end when in the closed position.
  • Clause 10 The device of Clause 9, wherein in the open position, at least a portion of the valve component is spaced apart from the aperture to permit flow through the aperture.
  • valve component in the closed position, has a sealing relationship with at least one of the support member or cover component to close the aperture at least partially and restrict flow through the device.
  • Clause 12 The device of any one of Clauses 1 to 11, wherein the valve component comprises a mesh material.
  • Clause 13 The device of Clause 12, wherein the mesh material is coupled to an outer surface of the cover component adjacent to the outflow end.
  • valve component comprises a flap structure coupled to the cover component adjacent the outflow end, the flap structure being movable away from the aperture to permit flow therethrough.
  • Clause 15 The device of any one of Clauses 1 to 14, wherein the valve component comprises a plurality of deflectable panels.
  • Clause 16 The device of any one of Clauses 1 to 15, wherein the valve component comprises a split dome.
  • Clause 17 The device of any one of Clauses 1 to 16, wherein the support member comprises a helical body.
  • Clause 18 The device of any one of Clauses 1 to 17, wherein the support member comprises a deflectable frame configured to expand from a substantially linear collapsed configuration to the expanded configuration.
  • a method of delivering a material to a target region of a body lumen comprising: advancing an implant to the target region, the implant having first and second sections engaged with a catheter at respective first and second engagement points; releasing the implant first section from engagement with the catheter at the first engagement point; permitting the implant first section to expand against a lumen wall at the target region such that the lumen becomes at least substantially occluded; and injecting a material through a portion of the implant.
  • Clause 20 The method of Clause 19, wherein the implant first section comprises an implant distal section, and wherein the releasing comprises disengaging a first engagement member from the distal section.
  • Clause 21 The method of Clause 20, wherein the portion of the implant comprises a valve component and the permitting comprises causing the valve component to contact a distal end of the catheter such that the catheter distal end moves the valve component to an open position.
  • Clause 22 The method of Clause 21, wherein the injecting comprises advancing the material out through the valve component after the valve component is in the open position.
  • Clause 23 The method of any one of Clauses 19 to 22, further comprising, after the material is injected into the lumen, releasing the implant second section and moving the catheter proximally relative to the implant such that the valve component moves to a closed position.
  • Clause 24 The method of Clause 23, wherein the moving the catheter relative to the implant comprises proximally withdrawing the catheter within the lumen.
  • Clause 25 The method of any one of Clauses 19 to 24, wherein the implant first section comprises a proximal section, and wherein the releasing comprises disengaging a first engagement member from the proximal section.
  • Clause 26 The method of Clause 25, wherein the permitting further comprises flushing the implant with a fluid to facilitate expansion of the proximal section.
  • Clause 27 The method of any one of Clauses 19 to 26, further comprising releasing the implant second section into apposition with the lumen wall such that the implant is disengaged from the catheter.
  • Clause 28 The method of any one of Clauses 19 to 27, further comprising proximally withdrawing the assembly from the lumen.
  • Clause 29 The method of Clause 28, wherein the withdrawing comprises withdrawing the assembly into a guide catheter such that expanded first section collapses within the guide catheter.
  • Clause 30 The method of any one of Clauses 19 to 29, further comprising, prior to releasing the implant first section, releasing a blocking implant into contact against the lumen wall downstream of the target region, the blocking implant occluding flow through the lumen beyond the target region.
  • Clause 31 The method of Clause 30, further comprising, after injecting a material, allowing the material to flow into the target region, and removing the blocking implant from the lumen.
  • a method of delivering a material to a target region of a body lumen comprising:
  • Clause 33 The method of Clause 32, wherein contacting the implant comprises advancing an adjustment member through the implant to pierce a cover component of the implant.
  • Clause 35 The method of any one of Clauses 32 to 34, wherein the implant is a first implant, and the method further comprises: after contacting the first implant, advancing a second implant to the target region, the second implant having first and second sections engaged with a catheter at respective first and second engagement points; releasing the first section from engagement with the catheter at the first engagement point; and before injecting a material, permitting the implant first section to expand against a lumen wall at the target region such that the lumen becomes at least substantially occluded.
  • Clause 36 The method of Clause 35, further comprising releasing the second implant adjacent to the first implant.
  • Clause 37 The method of Clause 35, further comprising releasing the second implant within the first implant.
  • Clause 38 The method of any one of Clauses 32 to 37, wherein contacting the first implant comprises contacting a mesh component of the first implant with a material to dissolve coagulated material on the mesh component, thereby restoring flow through the mesh component.
  • a delivery assembly for delivering an expandable member to a body lumen or luminal structure of a patient, comprising: a carrier member, positionable in a luminal structure of a patient, comprising a lumen having a cross-sectional area comprising a first portion and a second portion that are separated by a line segment intersecting a circumference of the carrier member, the carrier member comprising a slot extending through the carrier member into the lumen and bounded by the line segment and the circumference, within the first portion; an elongate member extending through the carrier lumen and across the slot; and an expandable member configured to expand within and engage the luminal structure, the expandable member comprising a coupling portion that fits within the slot, the coupling portion comprising an aperture configured to receive the elongate member therethrough when the coupling portion is positioned within the slot; wherein the elongate member is configured to move axially through the carrier lumen to be removed from the aperture and permit release of the coupling portion from the slot.
  • Clause 40 The assembly of Clause 39, wherein the carrier lumen extends to and is open at a distal end of the carrier member.
  • Clause 41 The assembly of any one of Clauses 39 to 40, wherein the carrier member comprises a second slot, distal to the slot, configured to receive a distal coupling portion of the expandable member.
  • Clause 42 The assembly of Clause 41, wherein the distal coupling portion comprises an aperture configured to receive an elongate member therethrough when the distal coupling portion is positioned within the second slot.
  • Clause 43 The assembly of any one of Clauses 39 to 42, wherein the elongate member is configured to be refracted by an operator such that the elongate member permits the release of the first portion.
  • Clause 44 The assembly of any one of Clauses 39 to 43, wherein the slot comprises a slot depth of between about 1 ⁇ 3 and about 2 ⁇ 3 of a carrier member diameter.
  • Clause 45 The assembly of any one of Clauses 39 to 44, wherein the slot comprises a slot depth of about 1 ⁇ 2 of a carrier member diameter.
  • Clause 46 The assembly of any one of Clauses 39 to 45, further comprising a cover member extending at least partially over the expandable member.
  • Clause 47 The assembly of any one of Clauses 39 to 46, wherein the slot comprises distal and proximal faces that extend in substantially parallel planes, the slot defining a slot width between the distal and proximal faces.
  • Clause 48 The assembly of Clause 47, wherein the distal and proximal faces extend substantially perpendicularly relative to a longitudinal axis of the carrier member.
  • Clause 49 The assembly of Clause 47, wherein the distal and proximal faces are obliquely oriented relative to a longitudinal axis of the carrier member.
  • Clause 50 The assembly of any one of Clauses 39 to 49, wherein the coupling portion comprises a flat cross-sectional shape.
  • Clause 51 The assembly of any one of Clauses 39 to 50, wherein the slot width is less than twice a thickness of the coupling portion.
  • An expandable implant for placement in a body lumen or luminal structure of a patient via a carrier member, comprising: an expandable member configured to expand within and engage the body lumen, the expandable member comprising proximal and distal end portions, the proximal end portion comprising an aperture configured to receive an elongate member therethrough for coupling the proximal end portion relative to a carrier member for delivery to the body lumen; and a cover member extending at least partially over the proximal and distal end portions, the cover member comprising an open end for permitting fluid flow therethrough.
  • Clause 53 The implant of Clause 52, wherein the expandable member comprises a coil.
  • Clause 54 The implant of any one of Clauses 52 to 53, wherein the expandable member comprises a flat coil.
  • Clause 55 The implant of any one of Clauses 52 to 54, wherein the expandable member comprises a flat coil and the aperture extends radially through the proximal end portion of the flat coil.
  • Clause 56 The implant of Clause 55, wherein the proximal end portion comprises a substantially planar portion, the aperture extending through a center of the proximal end portion.
  • Clause 57 The implant of any one of Clauses 52 to 56, wherein the proximal end portion defines an average width that is approximately equal to an average width of the expandable member between the proximal and distal end portions.
  • Clause 58 The implant of any one of Clauses 52 to 57, wherein the distal end portion comprises a second aperture configured to receive an elongate member therethrough for coupling the distal end portion relative to the carrier member for delivery to the body lumen.
  • Clause 59 The implant of Clause 58, wherein the distal end portion comprises a substantially planar portion, the second aperture extending through a center of the distal end portion.
  • a method of delivering an expandable member to a luminal structure of a patient comprising: advancing a carrier member through a luminal structure of a patient to a target area, the carrier member being coupled to an expandable member via an elongate member, the elongate member extending through a lumen of the carrier member to engage an end portion of the expandable member within a slot of the carrier member; proximally retracting the elongate member from an aperture of the end portion to release the end portion; and permitting release of the expandable member against the luminal structure.
  • Clause 61 The method of Clause 60, further comprising proximally retracting an elongate member from a second aperture of a second end portion of the expandable member.
  • Clause 62 The method of any one of Clauses 60 to 61, wherein the proximally retracting comprises proximally retracting a second elongate member from a second aperture of a second end portion of the expandable member.
  • Clause 63 The method of any one of Clauses 60 to 62, performed in combination with the method of any one of Clauses 19 to 38.
  • Clause 64 The method of any one of Clauses 60 to 63, performed using the implant of any one of Clauses 1 to 18 or Clauses 52 to 59.
  • Clause 65 The method of any one of Clauses 59 to 63, performed using the assembly of any one of Clauses 39 to 51.
  • Clause 66 A method of manufacturing an expandable member for delivery into a luminal structure of a patient via a carrier member, comprising: positioning an expandable member onto a carrier member; placing an end portion of the expandable member into a slot of the carrier member; and inserting an elongate member into an aperture of the end portion to engage the end portion within the slot.
  • Clause 67 The method of Clause 66, wherein the end portion comprises a flat cross-sectional shape, and the placing the end portion comprises twisting the end portion such that the flat shape is aligned with the slot, in a side, cross-sectional view.
  • Clause 68 The method of Clause 67, wherein the slot comprises distal and proximal faces extending in a substantially parallel planes.
  • Clause 69 The method of Clause 68, wherein the substantially parallel planes are oriented substantially perpendicular relative to a longitudinal axis of the carrier member.
  • Clause 70 The method of Clause 68, wherein the substantially parallel planes are obliquely oriented relative to a longitudinal axis of the carrier member.
  • Clause 71 The method of any one of Clauses 66 to 70, further comprising: placing a second end portion of the expandable member into a second slot of the carrier member; and inserting a second elongate member into a second aperture of the second end portion to engage the second end portion within the slot.
  • Clause 72 The method of any one of Clauses 66 to 71, performed using the implant of any one of Clauses 1 to 18 or Clauses 52 to 59.
  • Clause 73 The method of any one of Clauses 66 to 72, performed using the assembly of any one of Clauses 39 to 51.
  • FIG. 1 is a perspective view of an implant carrier assembly, according to some embodiments.
  • FIG. 2 illustrates a perspective view of another implant carrier assembly, according to some embodiments.
  • FIG. 3 is a perspective view of an implant having a valve component, according to some embodiments.
  • FIG. 4 is a perspective view of the implant of FIG. 3 , illustrating a support component thereof, according to some embodiments.
  • FIG. 5A is a perspective view of a support frame mounted on a catheter, according to some embodiments.
  • FIG. 5B is an end view of the catheter and support frame of FIG. 5A , according to some embodiments.
  • FIG. 6A is a perspective view of a support frame mounted on a catheter, according to some embodiments.
  • FIG. 6B is an end view of the catheter and support frame of FIG. 6A , according to some embodiments.
  • FIGS. 6C-6E are side, cross-sectional views of an aperture that extends through the catheter and engagement of an end of the support frame therein, according to some embodiments.
  • FIGS. 7A-7B are side, cross-sectional views of positions of an implant assembly having a valve component, according to some embodiments.
  • FIGS. 7C-7D are side, cross-sectional views of the implant assembly of FIGS. 6A-6B subsequent to deployment and illustrating the closure thereof, according to some embodiments.
  • FIGS. 8A-8D are side, cross-sectional views of positions of an implant assembly having a mesh-type valve component, according to some embodiments.
  • FIGS. 9A-9B are side, cross-sectional views of positions of an implant assembly having a valve component, according to some embodiments.
  • FIGS. 10A-10B are side, cross-sectional views of positions of an implant assembly having a valve component, according to some embodiments.
  • FIGS. 11A-11B are side, cross-sectional views of positions of an implant assembly having a valve component, according to some embodiments.
  • FIGS. 12A-12B are side, cross-sectional views of positions of an implant assembly having a valve component, according to some embodiments.
  • FIG. 13 shows a perspective view of a frame in a compressed state within a deliver catheter, according to some embodiments.
  • FIG. 14A shows a perspective view of a frame partially expanded from a delivery catheter, according to some embodiments.
  • FIGS. 14B-14C are perspective views of an implant having a valve component, according to some embodiments.
  • FIGS. 15A-15B are perspective views of an implant having a valve component, according to some embodiments.
  • FIGS. 16A-16B are perspective views of an implant having a valve component, according to some embodiments.
  • FIGS. 17A-17D are cross-sectional schematic views illustrating processes of depositing embolic particles into a target vessel region, according to some embodiments.
  • FIGS. 18A-18D are cross-sectional schematic views illustrating another process of depositing embolic particles into a target vessel region, according to some embodiments.
  • FIGS. 19A-19C are cross-sectional schematic views illustrating another process of depositing embolic particles into a target vessel region, according to some embodiments.
  • FIGS. 20A-20D are cross-sectional schematic views illustrating another process of depositing embolic particles into a target vessel region, according to some embodiments.
  • FIG. 21 is a cross-sectional schematic view illustrating deposition of embolic particles into a target vessel region, according to some embodiments.
  • FIG. 22 is a cross-sectional schematic view illustrating deposition of embolic particles into a target vessel region, according to some embodiments.
  • FIGS. 23A-23B illustrate schematic views illustrating alteration of an implanted occlusive device, according to some embodiments.
  • FIGS. 24A-24B illustrate schematic views illustrating alteration of an implanted first occlusive device and the insertion of a second device into the first device, according to some embodiments.
  • Some embodiments of the procedure, technique, and implant disclosed herein can enable a clinician, in one or a several clinical procedures, to occlude, dynamically control the flow through, or deploy a material through an implant.
  • procedures, techniques, and implants are provided by which an implant can be deployed into a body lumen in order to provide targeted delivery of a material, such as an embolic material, contrast agent, or drug.
  • a material such as an embolic material, contrast agent, or drug.
  • methods and implants are provided in which a clinician can deposit embolic material into a target area downstream of an implanted shunt while preventing upstream flow or backflow of the particles away from the target area.
  • an implant can be expanded into apposition with a luminal wall to at least partially occlude flow through the lumen, and embolic material can be released through an aperture or valve component of the implant, thereby isolating the flow of embolic material into the target region.
  • the valve component can comprise a one-way valve.
  • a clinician can place one or more implants into the vasculature and use of an implant to facilitate the delivery of a material, such as an embolic material, to a target region within the body.
  • a material such as an embolic material
  • a clinician can advance an implant to a location upstream of specific arteries and/or a target structure fed by the arteries. At least a portion of the implant can be expanded into apposition with the vessel wall, thereby reducing and/or eliminating any anterograde blood flow past the implant. Thereafter, a material can be passed through a valve component or aperture of the implant in order to pass the material toward the target region. Such embodiments advantageously enhance or increase the concentration of material delivered to the arteries and target structure. Further, in some embodiments, a distal implant can be released at a location immediately distal to the target region such that the distal implant prevents or mitigates any downstream migration of the material toward a downstream section of the vessel.
  • the flow regulating implant can comprise a generally tubular member.
  • the tubular member can further comprise a graft, cover, or other material attached to a frame.
  • Some implants that can be used in some embodiments are disclosed in applicant's co-pending U.S. patent application Ser. No. 12/906,933, filed on Oct. 18, 2010, Ser. No. 13/828,974, filed on Mar. 14, 2013, and 61/835,406, filed on Jun. 14, 2013, titled “Implantable Luminal Devices and Methods,” the entireties of which are incorporated herein by reference.
  • FIGS. 1 and 2 illustrate embodiments of an implant carrier assembly.
  • the implant carrier assembly 500 , 500 ′ can comprise a catheter 510 having a lumen that extends between a proximal portion 512 and a distal portion 514 of the catheter.
  • the catheter 510 can also comprise an engagement section 516 , which can be located along a distal portion of the catheter 510 , configured to engage and/or restrain an implant positioned therealong.
  • the implant can be supported, engaged, or restrained along an exterior surface of the catheter.
  • the catheter 510 can define a length from about 50 cm to about 200 cm, from about 70 cm to about 160 cm, or in some embodiments, about 120 cm, with a working length of from about 85 cm to about 140 cm, from about 95 cm to about 130 cm.
  • the total length of the implant carrier assembly (with handle) can be about 117 cm, with a working length of 97 cm.
  • the catheter 510 can be configured to move within a guide sheath when advancing the assembly 500 , 500 ′ into a patient for treatment.
  • the proximal portion 512 of the catheter 510 can be configured to be relatively stiff in order to enhance the pushability of the catheter 510 through the guide sheath.
  • the distal portion 514 can be relatively flexible in order to improve the maneuverability and trackability of the catheter 510 as it is advanced through the guide sheath.
  • the assembly 500 , 500 ′ can also comprise an implant or device 520 loaded on the engagement section 516 .
  • the implant 520 can be supported on the engagement section 516 of the catheter 510 .
  • the assembly 500 , 500 ′ can also comprise a deployment handle assembly 530 , 530 ′ attached to the catheter proximal portion 512 .
  • the deployment handle 530 shown in FIG. 1 includes two pull members 532
  • the deployment handle 530 ′ shown in FIG. 1 includes a single pull member 532 ′.
  • the pull members 532 , 532 ′ can be used to release the implant 520 from engagement with the engagement section 516 of the catheter 510 .
  • both deployment handles 530 , 530 ′ can be used to release distal and proximal portions of the implant 520 .
  • the deployment handle 530 can be configured to provide dedicated pull members 532 for releasing each of the distal and proximal portions of the implant 520 .
  • the deployment handle 530 ′ can be configured to provide a single pull member 532 ′ that can be, for example, moved a first distance to release the distal portion of the implant 520 and pulled a second distance to release the proximal portion of the implant 520 . Either embodiment can be used in performing the methods and procedures disclosed herein.
  • the implant 520 can be supported on the engagement section 516 of the catheter 510 .
  • the implant 520 can comprise one or more apertures or valve components that can be actuated to permit flow of a material, such as an embolic material, contrast agent, or drug, through the implant 520 .
  • the implant 520 can comprise a plurality of components, such as one or more support components 540 , a valve component 542 , and/or a cover member 544 .
  • the cover member 544 can comprise an aperture through which a material can be passed.
  • the valve component 542 can be coupled to the support component 540 and/or cover member 544 and can permit flow of a material therethrough.
  • FIGS. 5A-5B illustrate aspects of an engagement system between the catheter 510 , the support component 540 , and at least one engagement component 546 a , 546 b .
  • a single engagement component 546 can be used to engage and release proximal and distal portions 534 , 536 of the support component 540 .
  • two engagement components 546 a , 546 b can be used to engage and release the proximal and distal portions 534 , 536 of the support component 540 .
  • Various aspects of such embodiments are disclosed in co-pending U.S. patent application Ser. No. 14/044,794, filed Oct. 2, 2013, the entirety of which is incorporated herein by reference.
  • the implant 520 can be delivered using various embodiments of the carrier assembly 500 , 500 ′.
  • the engagement system can be configured such that the support component comprises one or more apertures that extend through one or more portions thereof to facilitate engagement with at least one engagement component when the support component is coupled to the catheter.
  • the engagement component can extend through the lumen of the catheter adjacent an aperture, notch, or slot of the catheter and pass through an aperture of a distal end portion of the support component in order to engage the distal end portion and secure the distal end portion relative to the aperture, notch, or slot of the catheter.
  • the aperture can extend through the support component at an end portion or other location between the end portions, such as a midportion thereof.
  • the support component can be coupled to the catheter with the engaged portion of the support component extending through the aperture, notch, or slot of the catheter.
  • the engagement between the support component and the engagement component within the catheter lumen can reduce the profile of the carrier assembly, thereby permitting the assembly to be compatible with small gauge catheters, such as sizes between about 3 Fr and about 8 Fr, about 4 Fr and about 7 Fr, or about 5 Fr and about 6 Fr.
  • the engagement component can extend radially external to or outwardly from the catheter lumen to engage the portion of the support component outside of the catheter lumen and still provide compatibility with small gauge catheters.
  • the implant carrier assembly can be configured to comprise at least one engagement member that extends at least partially through the catheter lumen.
  • the engagement member can engage at least a portion of, and in some embodiments, one or both the proximal and distal sections of the support component.
  • the engagement member can comprise a wire.
  • the engagement member can comprise a plug or other structure that can interact with one or both of the proximal or distal sections of the support component.
  • the engagement member can be actuatable or controllable using a handle assembly, as discussed further below.
  • an engagement section of the catheter can be configured to facilitate engagement between the support component and the engagement member extending from the handle assembly.
  • the engagement member can be selectively actuated or withdrawn in order to release engagement between the support component and the engagement member.
  • the movement of the engagement member can be configured to be a proximal withdrawal of the engagement member.
  • the engagement member can also be configured such that disengagement occurs when the engagement member is distally advanced (such as when a proximally oriented hook or segment of the engagement member engages with the support component).
  • the engagement member can be moved a first distance (whether proximally or distally) in order to release or disengage with one of the proximal or distal sections of the support component.
  • the engagement member can be moved a second distance, greater than the first distance (whether proximally or distally) in order to release or disengage with the other one of the proximal or distal sections of the support component.
  • the engagement section of the catheter can facilitate engagement between the implant and two or more engagement members extending from the handle assembly.
  • the engagement member is illustrated as extending between the proximal and distal sections of the support component, the engagement member can engage one of the proximal or distal sections while a second engagement member can be used to engage the other of the proximal or distal sections.
  • the catheter can comprise an engagement section and a lumen.
  • the assembly can comprise an implant or support component supported on the engagement section. Further, the assembly can comprise a first engagement member and a second engagement member 546 a , 546 b configured to engage with the support component, as shown in FIG. 5B . As shown in FIG. 5A , a distal portion of the engagement member 546 b can engage a proximal portion of support component and a distal portion of the engagement member 546 a can engage with a distal portion of the support component.
  • the engagement members can be actuated independently of each other in order to control the release of the respective proximal or distal sections of the support component or implant.
  • an engagement member extends through the catheter lumen and between at least one of the proximal or distal sections of the support component and the wall of the catheter.
  • the engagement member can be disposed radially between the proximal or distal section of the support component and the wall of the catheter.
  • FIG. 5B illustrates the configuration of the catheter and the aperture, notch, or slot in relation to the engagement member and the proximal section of the support component.
  • the proximal section can sit within the aperture and provide enough clearance between the proximal section and wall or the inner surface of the wall such that the engagement member can be positioned intermediate the wall and the proximal section.
  • the proximal section can extend across the entire diameter of the lumen in a transverse direction.
  • the proximal and/or distal sections can also be configured to extend across the lumen less than a diameter of the lumen (whether in the transverse direction or in a radial direction).
  • the engagement member can secure the proximal section within the aperture to prevent movement of the proximal section in an axial direction (shown in FIG. 5A ) and/or a radial direction (shown in FIG. 5B ).
  • the support component can be a resilient or self-expanding support component, such that the proximal section will tend to expand or move out of the aperture without the presence of the engagement member.
  • the proximal section can be retained or engaged within the aperture.
  • the engagement member is removed from between the catheter and the proximal section of the support component, the proximal section of the support component will no longer be constrained and can therefore expand out of the aperture, notch, or slot.
  • the engagement between the proximal section, the engagement member, and the aperture can also be present at the distal end of the support component, although it will not be discussed further herein. However, as noted, some embodiments can be implemented in which a single end of the support component is retained within an aperture or otherwise engaged by the engagement member.
  • FIGS. 6A-6E illustrate additional aspects of some embodiments of an engagement system.
  • FIG. 6A illustrates a support component 540 ′ having a proximal end region 541 that comprises an aperture 543 extending therethrough.
  • the aperture 543 can be configured to receive at least one engagement component therethrough.
  • the engagement component 546 b passes through the aperture 543 of the proximal end region 541 , thus securing the proximal end region 541 relative to the aperture, the notch, or slot 539 of the catheter 510 .
  • the proximal end region 541 can be radially secured (such that the proximal end region 541 does not radially expand out of the slot 539 ) and circumferentially or laterally secured (such that the proximal end region 541 does not slide out of the slot 539 ) relative to the catheter 510 .
  • the proximal end region 541 can comprise a flattened portion, as illustrated in the cross-sectional view of FIG. 6B . However, the proximal end region 541 can also extend along an arcuate path without having a discrete flattened portion.
  • FIG. 6B (and as generally shown in the embodiment of FIGS. 5A-5B ) also illustrates that the slot 539 formed in the catheter 510 can, in some embodiments, be defined by a line segment or chord 537 extending through the catheter lumen 517 .
  • the line segment or chord 537 can intersect with the circumference of the catheter 510 .
  • the line segment 537 can be a diameter of a circular cross-section, but need not be a diameter and can be a chord intersecting the circumference.
  • the line segment 537 can define a base or bottom of the slot 539 .
  • the orientation or spacing of the line segment 537 from an outer circumference of the catheter 510 can define a slot depth.
  • the slot depth can be measured as the distance from the line segment to the outermost point along the circumference of the catheter 510 .
  • the slot can have a depth that extends between about 1 ⁇ 5 and about 2 ⁇ 3 of the catheter outer diameter, such as about 1 ⁇ 4, 1 ⁇ 3, or 1 ⁇ 2 of the catheter outer diameter.
  • the slot 539 can extend only partially into the catheter lumen 517 , such that the lumen 517 provides sufficient space for material to pass therethrough.
  • the line segment can divide the lumen 517 into first and second portions.
  • the engagement component 543 and the proximal end region 541 can be positioned within a first portion of the lumen 517 .
  • a second portion of the lumen 517 can be a clear-through portion that allows material to be urged therethrough.
  • the proximal end region 541 can comprise at least one aperture extending therethrough.
  • the aperture can extend through the proximal end region in a direction transverse to a longitudinal axis of the support component.
  • the proximal end region can be flat, and the aperture can extend through the flat proximal end region, as illustrated in FIGS. 6A-6E .
  • the aperture can also extend through the proximal end region in a direction substantially parallel relative to a longitudinal axis of the support component.
  • the proximal end region can have a flat, square, rectangular, and/or twisted shape.
  • the proximal end region 541 can be deflectable in order to facilitate placement of the proximal end region 541 into the slot 539 of the catheter 510 .
  • the proximal end region 541 can define a width that is about equal to a width of the support component 540 ′.
  • the support component 540 ′ may not have a tapering width in the proximal end region 541 .
  • the support component 540 ′ can also taper toward a larger or smaller width in the proximal end region 541 .
  • a larger width in the proximal end region 541 can facilitate the accommodation of the aperture 543 thereat.
  • non-tapering or other tapering embodiments of the proximal end region 541 can define a width sufficient to accommodate the aperture 543 thereat.
  • the width of the proximal end region 541 can be at least about two times the width, size, or diameter of the aperture 543 . However, in other embodiments, the width of the proximal end region 541 can be three, four, five, or more times the width, size, or diameter of the aperture 543 .
  • FIGS. 6C-6E illustrate side, cross-sectional views of the embodiments of the catheter that can be used to couple the engagement component and the support component.
  • the aperture, notch, or slot of the catheter can have a V-shape.
  • the slot can comprise a slanted configuration and/or U-shaped configured to reduce and/or eliminate leakage of material from the slot when material is urged through the catheter lumen for deposition into the body lumen.
  • FIGS. 6C-6D illustrate slots 539 a , 539 b formed in the catheter 510 , which are slanted or extend transversely relative to a plane that is perpendicular relative to the longitudinal axis of the catheter 510 .
  • FIG. 6E illustrate a slot 539 c formed in the catheter 510 , which extends substantially within a plane that is perpendicular relative to the longitudinal axis of the catheter 510 .
  • the slots 539 a , 539 b , 539 c can have proximal and distal faces 513 , 515 .
  • the proximal and distal faces 513 , 515 can extend in respective planes.
  • the proximal and distal faces 513 , 515 can be defined by edges of the catheter through which the slot is cut.
  • the proximal and distal faces 513 , 515 (or the planes through which they extend) can be substantially parallel relative to each other (whereas the slot 539 of FIG. 6A illustrates proximal and distal faces (or the planes through which they extend) that are oriented transverse relative to each other).
  • proximal and distal faces 513 , 515 can be oriented substantially perpendicular relative to a longitudinal axis of the catheter. Further, in some embodiments, the proximal and distal faces 513 , 515 (or the planes through which they extend) can be obliquely oriented relative to a longitudinal axis of the catheter.
  • the slot 539 a can be configured such that the proximal and distal faces 513 a , 515 a have a forward slant or orientation.
  • the slot 539 a or the proximal and distal faces 513 a , 515 a can have a slope or taper that converges toward the longitudinal axis of the catheter 510 in a direction away from a supporting area 511 of the catheter 510 .
  • the proximal end portion 541 can be inserted into the slot 539 a at an angle relative to the longitudinal axis of the catheter 510 and, referring to the orientation illustrated in FIG. 6C , turned counterclockwise to an angled orientation in order to insert the proximal end portion 540 into the slot 539 a.
  • the slot 539 b of FIG. 6D can be configured such that the proximal and distal faces 513 b , 515 b have a reverse slant or orientation.
  • the slot 539 b or the proximal and distal faces 513 b , 515 b can have a slope or taper that converges toward the longitudinal axis of the catheter 510 in a direction toward or into a supporting area 511 of the catheter 510 .
  • the proximal end portion 541 can be inserted into the slot 539 b at an angle relative to the longitudinal axis of the catheter 510 and, referring to the orientation illustrated in FIG. 6D , turned clockwise to an angled orientation in order to insert the proximal end portion 540 into the slot 539 b.
  • the slot 539 c or proximal and distal faces 513 c , 515 c can extend generally perpendicular relative to the longitudinal axis of the catheter 510 .
  • the proximal end portion 541 can be inserted into the slot 539 c at a substantially perpendicular angle relative to the longitudinal axis of the catheter 510 and, referring to the orientation illustrated in FIG. 6E , turned clockwise or counterclockwise to an angled orientation in order to insert the proximal end portion 540 into the slot 539 a.
  • the slots 539 a , 539 b , 539 c each are configured such that the proximal and distal faces of the slots 539 a , 539 b , 539 c closely approximate the thickness of the proximal end portion 541 and the membrane 520 wrapped around the proximal end portion 541 when inserted into the slot. Accordingly, in embodiments of the catheter that do not comprise a dedicated or separate lumen for passage of material, the material passing through the catheter lumen 517 will not tend to leak from or exit the slot of the catheter lumen 517 .
  • the slots 539 a , 539 b , 539 c can define a slot width, between the proximal and distal faces, that is between about 0.004 inches and about 0.012 inches. Further, the slot width can be between about 0.005 inches and about 0.010 inches. Furthermore, the slot width can be between about 0.006 inches and about 0.008 inches, or about 0.007 inches. As shown in FIG. 6A , the slot may be tapered (have a trapezoidal shape, when viewed in a side view along the longitudinal axis of the catheter) with a wider end positioned toward the outer contour of the catheter. Further, as shown in FIGS. 6C-6E , the slot may be straight (have a rectangular or square shape, when viewed in a side view along the longitudinal axis of the catheter).
  • the thickness of the distal end portion 541 of the support component 540 can be between about 0.002 inches and about 0.008 inches. Further, the thickness of the distal end portion 541 can be between about 0.003 inches and about 0.006 inches. In some embodiments, the thickness of the distal end portion 541 can be about 0.004 inches.
  • the distal end portion 541 and cover member 520 can fit into the slot with high dimensional accuracy in order to reduce any gap in the slot wherethrough material can exit the catheter lumen.
  • the slots 539 a , 539 b , 539 c can define a slot depth or dimension indicative of the diametric or radial extent of the slot into or through the catheter 510 .
  • the slot depth can be between about 1 ⁇ 5 and about 2 ⁇ 3 of the catheter outer diameter, such as about 1 ⁇ 4, 1 ⁇ 3, or 1 ⁇ 2 of the catheter outer diameter.
  • the slot depth can be at least 1 ⁇ 3, 1 ⁇ 2, 2 ⁇ 3, or 3 ⁇ 4 of the width of the proximal end portion 541 .
  • the slot depth can be between about 0.004 inches and about 0.110 inches.
  • the slot depth can be between about 0.008 inches and about 0.090 inches.
  • the slot depth can be between about 0.010 inches and about 0.060 inches.
  • the slot depth can be between about 0.014 inches and about 0.040 inches.
  • the slot depth can be or between about 0.018 inches and about 0.030 inches.
  • the slot depth can be about 0.020 inches, about 0.024 inches, or about 0.028 inches.
  • the engagement component can have a diameter of between about 0.001 inches and about 0.020 inches, between about 0.003 inches and about 0.010 inches, or between about 0.004 inches and about 0.007 inches, such as 0.005 inches.
  • the proximal end portion can define a width of between about 0.010 inches and about 0.030 inches, between about 0.012 inches and about 0.020 inches, between about 0.014 inches and about 0.018 inches, and in some embodiments, about 0.015 inches.
  • the catheter lumen can have an inner diameter of between about 0.010 inches and about 0.080 inches, between about 0.015 inches and about 0.070 inches, between about 0.020 inches and about 0.060 inches, between about 0.025 inches and about 0.050 inches, or between about 0.030 inches and about 0.040 inches.
  • the catheter can have an outer diameter of between about 0.020 inches and about 0.160 inches, between about 0.030 inches and about 0.140 inches, between about 0.040 inches and about 0.120 inches, between about 0.050 inches and about 0.100 inches, or between about 0.060 inches and about 0.080 inches. In some embodiments, the catheter outer diameter is about 3 Fr, 4 Fr, 5 Fr, 6 Fr, 7 Fr, 8 Fr, 9 Fr, 10 Fr, 11 Fr, or 12 Fr.
  • the slot depth can be configured such that the proximal end portion can be inserted into the slot and a sufficient width of the proximal end portion can be received within the slot to allow the aperture to be accessible to the engagement component extending within the catheter lumen.
  • FIGS. 6C-6E illustrate embodiments of a single slot
  • the catheter can be configured to comprise two or more slots that can be used to couple the support component thereto.
  • One or both of the two or more slots be configured such as the slots illustrated by elements 539 , 539 a , 539 b , or 539 c .
  • the two or more slots can be identical or different in size, shape, or orientation.
  • the catheter can comprise a single or dual lumen structure.
  • the slot structures and embodiments illustrated in FIG. 6C-6E can be particularly advantageous for tending to reduce and/or eliminate leakage through the slots of a single lumen catheter structure.
  • the slot width, slot depth, catheter lumen inner diameter, catheter lumen inner diameter, engagement component diameter, aperture diameter, proximal end portion width, and proximal end portion thickness can be configured within any of the ranges disclosed herein.
  • a portion of the catheter can be configured to move beyond or through the distal portion of the implant in order to precisely deliver a material into the lumen downstream of the implant.
  • the implant distal portion e.g., a valve component of the implant
  • the catheter distal tip can have a close fit, thus allowing material to be injected into the lumen while avoiding dispersion or diffusion of the material upstream of the implant.
  • the implant proximal portion can be maintained engaged with the catheter while the implant distal portion is allowed to expand into contact with the vessel wall.
  • the expansion of the implant distal portion can cause the implant to foreshorten and thus cause the distal portion of the catheter to move beyond or through the distal portion of the implant, whereafter material can be injected into the lumen, thus avoiding dispersion or diffusion of the material upstream of the implant.
  • the implant distal portion can be maintained engaged with the catheter while the implant proximal portion is allowed to expand into contact with the vessel wall, whereafter material can be injected into the lumen, thus avoiding dispersion or diffusion of the material upstream of the implant.
  • the catheter can be urged distally relative to the implant distal portion such that the catheter distal tip extends beyond or through the implant distal portion.
  • the deployment handle and its pull member(s) can be interconnected with the engagement component(s) to allow desired actuation of the assembly and implant.
  • the proximal pull member can be interconnected with the engagement component that controls release of either the distal or proximal implant portion. Accordingly, some embodiments disclosed herein can allow a clinician to target specific regions and precisely control the flow and dispersion of the material.
  • FIGS. 7A-12B various embodiments of the implant 520 are illustrated in which the implant 520 comprises different valve components.
  • FIGS. 7A-7B illustrate an implant 520 a having a valve component 542 a that comprises a flap structure 550 a .
  • the flap structure 550 a can extend distally from the implant 520 a .
  • the flap structure 550 a can comprise one or more sections of material of a cover member 544 a .
  • the flap structure 550 a can comprise at least an outer layer of the cover member 544 a .
  • the cover member 544 a can comprise inner and outer sections 545 a , 545 b .
  • the inner and outer sections 545 a , 545 b can at least partially envelop, enclose, or cover the support component 540 .
  • the cover member 544 a can comprise a tubular membrane that is everted or inverted such that the outer section 545 b extends along an exterior of the support component 540 and the inner section 545 a extends along an interior of the support component 540 .
  • the cover member 544 a can be unitarily formed as an uncut, continuous tube or can comprise one or more longitudinal cuts or breaks such that the inner or outer sections 545 a , 545 b comprise one or more strips of material.
  • the cover member 544 a and/or the implant 520 a can comprise additional features such as those disclosed in co-pending U.S. patent application Ser. No. 14/044,794, filed Oct. 2, 2013, the entirety of which is incorporated herein by reference.
  • the inner section 545 a can comprise one or more strips of material that can be secured to the distal end portion of the outer section 545 b using a mechanical, thermal, or chemical coupling.
  • a suture, adhesive, or tie coupling 547 can be used to couple a strip of the inner section 545 a with the distal end portion of the outer section 545 b .
  • the flap structure 550 a can comprise the coupling 547 ; however, the coupling 547 can also be omitted from the flap structure 550 a and implant 520 a.
  • the coupling 547 can secure only a portion of the inner or outer sections 545 a , 545 b to each other. However, in some embodiments, the entire inner section 545 a can be secured to the entire outer section 545 b . As shown in FIG. 7B , a distal portion 548 a of the implant 520 a can be released (using the engagement component 546 a ) while a proximal portion 549 a is maintained in engagement (using the engagement component 546 b ). As the distal portion 548 a expands and the implant 520 a foreshortens, the coupling 547 can be drawn proximally.
  • a material e.g., embolic material, contrast agents, or drugs
  • a delivery lumen 570 of the catheter 510 shown by arrows 571
  • the material can also be delivered after the proximal portion 549 a has been released.
  • the distal tip 564 of the catheter 510 can then move distally beyond the distal portion 548 a of the implant 520 a to provide a clear outflow pathway for material injected through the catheter 510 .
  • the catheter can comprise a single or dual lumen structure in combination with any of the embodiments disclosed herein.
  • FIGS. 7A-7B and 8A-8C illustrate a single lumen structure while FIGS. 9A-10B illustrate a dual lumen structure.
  • FIGS. 7C-7D illustrate the release, closing, and sealing of the valve component 542 a in a lumen 561 .
  • These figures illustrate that the distal portions of the inner and outer sections 545 a , 545 b can be coupled together or closed on top of each other.
  • the inner and outer sections 545 a , 545 b can be closed using an adhesive material, which can be injected through the delivery lumen 570 of the catheter 510 . Applicant has found that such embodiments can advantageously provide a simple construction and at least a partially or fully complete seal to be achieved by adhering the inner and outer sections 545 a , 545 b to each other.
  • FIG. 7C illustrates an initial reflux or vacillation of the distal portions of the inner and outer sections 545 a , 545 b .
  • the distal portions can tend to adhere to each other until being coupled to each other to close the lumen 561 , thereby preventing flow therethrough, as shown in FIG. 7D .
  • the implant 520 a can at least partially or fully occlude the lumen 561 .
  • the procedure for expanding the cover component and support component of the implant can be modified such that the cover component expands into contact with the body lumen wall before the support component begins expanding.
  • the cover component can be inflated by flushing the cover component with saline or other material prior to releasing or permitting expansion of an end of the support component.
  • This inflating step can be performed in operating any of the implants that have a substantially closed end prior to expansion of the support component, which can permit an increase in fluid pressure within the cover component sufficient to inflate the cover component (see e.g., FIGS. 9A, 10A, 11A, and 12A that have valve components in a substantially closed position prior to support component expansion; but see e.g., FIG.
  • valve component of the cover component can draw closer to the distal end of the catheter, which can provide various advantages and permit operation of the valve component using the distal end of the catheter, according to some embodiments.
  • the valve component can satisfy to seemingly opposite goals: (1) to provide eventual occlusion of the vessel and prevent or reduce reflux of material into a proximal portion of the vessel, and (2) to provide a secondary opportunity to return at a later time to provide a further treatment of the vessel without removing, destroying, or otherwise damaging the valve component.
  • the valve component can comprise a mesh or fibrous material.
  • FIGS. 8A-8D illustrate an implant 520 b in a collapsed and expanded configurations.
  • the implant 520 b comprises a cover member 544 b that at least partially encloses, envelops, or covers the support frame 540 .
  • the implant 520 b can comprise distal and proximal portions 548 b , 549 b .
  • the implant 520 b can also comprise a mesh portion 550 b that is coupled to the distal portion 548 b of the implant 520 b.
  • the mesh portion 550 b can comprise a plurality of filaments, woven ePTFE strips or sutures, or other porous, biocompatible materials.
  • the mesh portion 550 b can be coupled to the distal portion 548 b , such as by being coupled to the distal portion of the cover member 544 b .
  • the mesh portion 550 b can comprise a layer of material that is coupled to an outer surface of the cover member 544 b along a distal portion of the cover member 544 b .
  • the mesh portion 550 b can be secured relative to the cover member 544 b using mechanical, thermal, or chemical bonding, such as adhesives.
  • a frictional engagement can secure the mesh structure 550 b relative to the cover member 544 b .
  • the mesh portion 550 b can be secured relative to the implant 520 b and support structure 540 by virtue of radial compressive force and frictional engagement against the vessel wall and the outer surface of the cover member 544 b.
  • the mesh portion 550 b can also be formed with the cover member 544 b from a single, continuous piece of material.
  • the mesh portion 550 b can be formed as a tubular body having an open end and a closed end, opposite the open end, that comprises a plurality of pores, cells, apertures, perforations, incisions, windows, or other cuts to provide a substantially mesh-type closed end.
  • the cover member 544 b can also be configured as a material having a closed mesh end.
  • the tubular mesh body can be moved onto the distal portion of the catheter 510 , with the catheter 510 entering the open end of the tubular body.
  • the support component 540 can then be positioned over a distal section of the tubular body and coupled relative to the catheter 510 . Further, a proximal section of the tubular body, extending proximally of the support component 540 , can thereafter be everted over the support component 540 to at least partially cover the support component 540 .
  • the proximal section can be at least partially coupled to a corresponding portion of the distal section of the tubular body or mesh portion. Further, in some embodiments, the proximal section of the tubular body can extend fully distally of the support component 540 .
  • the mesh portion 550 b can effectively protect against or tend to block proximal migration or reflux of material ejected into the downstream vasculature 559 of the vessel 561 .
  • the mesh portion 550 b can be sufficiently porous (e.g., have an average pore size) that is greater than the size of particles of a material passing therethrough, thrombosis and/or the use of materials, such as glues, can tend to close the size of the pores of the mesh portion 550 b . Accordingly, after the particles of the material have passed through the mesh portion 550 b , the mesh portion 550 b can tend to prevent proximal migration or reflux.
  • the mesh portion 550 b can thereby provide at least partial or full occlusion of the vessel 561 .
  • the embodiment shown in FIGS. 8A-8D can allow a secondary operation to be performed, such as to deposit additional material into the downstream vasculature 559 , by dissolving the clotted material on the mesh portion 550 b .
  • the mesh portion 550 b can be cleared such that additional material can be passed therethrough during the second operation.
  • the mesh portion 550 b can be cleared and flow through the implant can be restored by injecting a material, fluid, or saline through the mesh portion 550 b .
  • a catheter can be advanced until a distal end of the catheter is positioned adjacent to the mesh portion 550 b . Thereafter, a material, fluid, or saline can be ejected from the distal end of the catheter against the mesh portion 550 b . This ejection can serve to clear the thrombosed material mesh portion 550 b.
  • the clinician can clear or unblock the mesh portion 550 b to deposit further material in the target region in a second procedure without puncturing, piercing, or otherwise damaging the implant 520 b . After clearing the mesh portion 550 b , the clinician can inject additional material to the target region.
  • the clinician may elect to place a second implant at the site of the first implant (see e.g., FIGS. 24A-24B ) without puncturing, piercing, or otherwise damaging the implant 520 b.
  • the cover member 544 b of the implant 520 b can be initially expanded by introducing fluid or material 571 through the catheter lumen 570 into an interior chamber 573 formed between a layer of the cover member 544 b positioned against the catheter 510 and a layer of the cover member 544 b surrounding the support component 540 . Accordingly, the cover component 544 b can be inflated by flushing the cover component 544 b prior to releasing or permitting expansion of the support component 540 .
  • the substantially closed end formed by the mesh portion 550 b can allow an increase in fluid pressure within the interior chamber 573 sufficient to inflate the cover component 544 b until the cover component 544 b comes in contact with a vessel wall 561 .
  • the mesh portion 550 b can be configured to block or restrict flow therethrough when the fluid pressure is less than 240 mm Hg or 5 pounds per square inch (“psi”). However, for fluid pressures above 5 psi, the mesh portion 550 b can expand or deflect such that the plurality of pores, cells, apertures, perforations, incisions, windows, or other cuts opens to permit flow through the mesh portion 550 b.
  • a fluid or material 571 can be injected through the catheter lumen 570 and into the interior chamber 573 such that the fluid or material 571 in the interior chamber 573 is at a pressure greater than 5 psi, such as between about 10 psi and about 200 psi, between about 40 psi and about 180 psi, or between about 70 psi and about 140 psi.
  • the delivery pressure can be varied by using certain delivery mechanisms. For example, using a 5 mL syringe, the fluid or material can be delivered at between about 80 psi and about 100 psi.
  • the fluid or material can be delivered at between about 120 psi and about 140 psi. Furthermore, using a 1 mL syringe, the fluid or material can be delivered at about 200 psi.
  • the mesh portion 550 b can permit passage of the material 571 (shown in FIGS. 8B-8D as an embolic material) to the downstream portion 559 of the vessel when injected through the catheter lumen 570 .
  • the mesh portion 550 b can be configured to block or restrict flow through the mesh portion 550 b .
  • a glue or embolic material can be injected and can tend to occlude the pores, cells, apertures, perforations, incisions, windows, or other cuts of the mesh portion 550 b , thus sealing the mesh portion 550 b .
  • the “seal” of the mesh portion 550 b can be reversible, as discussed above.
  • the mesh portion 550 b can also be configured such that the pores, cells, apertures, perforations, incisions, windows, or other cuts of the mesh portion 550 b define an open configuration and a closed configuration.
  • the open configuration can be achieved when the cover member 544 b is in a generally unexpanded configuration, as illustrated in FIG. 8A .
  • material 571 can be passed through the mesh portion 550 b .
  • the support component 540 can be expanded, thus causing expansion of the mesh portion 550 b and, in some embodiments, shrinking of the pores, cells, apertures, perforations, incisions, windows, or other cuts of the mesh portion 550 b .
  • the glue or embolic material can act to further close or seal the pores, cells, apertures, perforations, incisions, windows, or other cuts of the mesh portion 550 b .
  • the “seal” of the mesh portion 550 b can be reversible, as discussed above.
  • FIG. 9A-10B illustrate embodiments of an implant 520 c being delivered using different catheters, which can provide unique benefits and advantages.
  • FIGS. 9A and 10A illustrate an implant 520 c having a valve component 542 c that comprises a flap structure 550 c .
  • the flap structure 550 c can comprise a flat plate that is attached to a distal end 560 of the cover member 544 c or to a distal end of the support component 540 .
  • the flap structure 550 c can be resiliently biased toward a closed position (as shown in FIGS. 9A and 10A ) in which the flap structure 550 c covers an aperture 562 of the implant 520 c.
  • proximal foreshortening of the implant 520 c can cause a distal tip 564 of the catheter 510 , 510 ′ to be advanced distally relative to the implant distal portion 548 c , thus contacting against the flap structure 550 c .
  • the flap structure 550 c will tend to deflect from the closed position, thus opening the lumen of the implant 520 c such that it is in fluid communication with the lumen of the vessel into which the implant 520 c is being deployed.
  • the distal tip 564 , 564 ′ of the catheter 510 , 510 ′ can then move distally beyond the distal portion 548 c of the implant 520 c , and as shown, have a clear outflow pathway for material injected through the catheter 510 , 510 ′.
  • the catheter 510 , 510 ′ can comprise a material delivery lumen 570 through which material can be passed toward the target region.
  • the catheter 510 can also comprise a distal port 572 , 572 ′ in communication with the lumen 570 .
  • the port 572 , 572 ′ will provide a clear outflow pathway for material injected through the lumen 570 .
  • the port 572 , 572 ′ can therefore be moved into a position in which it is in unobstructed, fluid communication with the target region, as illustrated in FIGS. 9B and 10B .
  • material can then be delivered through the lumen 570 and out through the port 572 , 572 ′ into the target region.
  • the lumen 570 can also be used to flush the implant or pass other fluids through the implant or toward a downstream section of the blood vessel.
  • FIGS. 9A-9B illustrate that the distal tip 564 of the catheter 510 can comprise a generally flat face that is oriented substantially orthogonal relative to the longitudinal axis of the catheter 510 .
  • the distal tip 564 can be moved relative to the distal portion 548 c of the implant 520 c until the flap structure 550 c is moved away from the closed position shown in FIG. 9A toward the open position shown in FIG. 9B , thereby allowing the port 572 to have a clear outflow pathway for material to be ejected from the lumen 570 .
  • FIGS. 10A-10B illustrate an embodiment of the distal tip 564 in which the port 572 ′ is facing generally downward or radially outward relative to the longitudinal axis of the catheter 510 ′.
  • Such embodiments can provide an advantageous beveled or angled configuration, which may need to move the flap structure 550 c only a short length or make a single point of contact in order to achieve a clear outflow pathway for the material to be ejected from the lumen 570 .
  • the bevel of the catheter 510 ′ can be modified such that the catheter 510 ′ defines a generally conical tip or the bevel can be removed entirely such that the distal tip 564 is generally flat, as illustrated in FIGS. 7A-7B, 9A-9B, and 11A-12B .
  • the implant 520 c can be entirely removed from the vessel or implanted at the target region. For example, a proximal portion 549 c of the implant 520 c can be released and allowed to expand into apposition with the vessel wall.
  • material can be released into the target region and flow through the vessel can be occluded using the implant 520 c , thereby inducing infarction of the target region.
  • FIGS. 11A-12B illustrate additional embodiments of an implant 520 c having a valve component 542 d and movement of the catheter distal end 564 distally beyond the implant distal end.
  • FIGS. 11A-11B illustrate a dome-shaped valve component 542 d .
  • the dome-shaped valve component 542 d can comprise a pair of opposing, flexible half-dome structures 580 that can be biased toward each other such that a slit or gap between the structures 580 is in a substantially closed position.
  • the distal end 564 of the catheter 510 can be urged or moved through the aperture 562 of the implant 520 d , thus contacting the structures 580 and causing separation thereof, such that the gap or slit between the structures 580 is opened and the lumen 570 of the catheter 510 is placed in fluid communication with the target region, as shown in FIG. 11B .
  • FIGS. 12A-12B illustrate an embodiment of an implant 520 e having a valve component 542 e , in the form of an iris diaphragm-type valve structure.
  • the valve component 542 e can comprise a plurality of flexible leaflets or structures 590 that can be biased toward each other such that an aperture 592 between the structures 590 is in a substantially closed position.
  • the distal end 564 of the catheter 510 can be urged or moved through the aperture 562 of the implant 520 d , thus contacting the structures 590 and causing separation thereof, such that the aperture 592 between the structures 590 is opened and the lumen 570 of the catheter 510 is placed in fluid communication with the target region, as shown in FIG. 12B .
  • the implant is delivered by distally advancing the implant through a lumen of the catheter.
  • the implant instead of engaging the implant externally to the catheter, the implant can be advanced internally to the catheter, such as by pushing or pulling the implant through the lumen.
  • support and valve components of the implant can be collapsed into an elongate position and released into an expanded position within the vessel.
  • any of the valve components disclosed herein can be used with a helical support component that can be coupled to a catheter (as shown in FIGS. 3-12B ) or a deflectable support component that can be at advanced within a catheter (as shown in FIGS. 13-16B ), including any combinations or modifications thereof.
  • the implant can be delivered through a lumen of the catheter.
  • a catheter 610 can be provided that comprises a lumen 612 configured to receive the implant 620 therein.
  • the implant 620 can comprise a support component 622 and a cover component 624 .
  • FIG. 13 illustrates the implant 620 in a collapsed, elongated configuration, which enables the implant 620 to be moved within the catheter lumen 612 .
  • the support component 622 and the cover component 624 can be attached to each other or be separated and freely movable relative to each other. Whether attached or separated, the support and cover components 622 , 624 can be configured to be advanced through the catheter lumen 612 together, as a single unit.
  • FIG. 13 also illustrates that, according to some embodiments, the support component 620 can be at least partially enclosed, enveloped, or covered by the cover component 624 such that the support component 622 and the cover component 624 can be attached to each other and delivered together (and as shown in FIG. 14A , released into the vessel together).
  • the support and cover component 622 , 624 can be separated from each other and moved through the catheter lumen 612 independently of each other.
  • the implant 620 can also be configured such that the support component 622 is deployed into the cover component 624 after the cover component 624 has been positioned within the vessel.
  • FIG. 14A illustrates that the implant 620 can be expanded from the collapsed configuration to an expanded configuration.
  • the support component 622 of the implant 620 can increase in its diameter, expanding within the cover component 624 .
  • the support component 622 can press the cover component 624 against a side wall of the lumen and thereby fix the cover component 624 (and the implant 620 ) within the lumen.
  • the cover component 624 can comprise a valve component 626 and a sheath portion 628 .
  • the valve component 626 and the sheath portion 628 can form a substantially continuous sleeve or layer (e.g., having a seal between the valve component 626 and the sheath portion 628 such that fluid passes only through an aperture or opening of the valve component 626 ) into which the support component 622 can expand.
  • the aperture or opening can have a size between about 100 microns and about 3,000 microns, about 500 microns and about 2,800 microns, or about 1,000 microns and about 2,500 microns.
  • the sheath portion 628 can be porous, nonporous, and/or comprise one or more portions that are nonporous, such as impermeable graft or other such sections.
  • the support component 622 having dual wire loop features can be held in a generally linear or straight configuration within a lumen 612 of a catheter 610 .
  • the loops 630 (shown in the expanded configuration illustrated in FIG. 14A ) of the support component 622 can be pulled or longitudinally stretched to create tension between open loops 630 to allow the support component 622 , when deployed, to spring back to or return to an expanded shape consisting of various expanded loops 630 , as illustrated in FIG. 14A , as the support component 622 exits from a distal end 632 of the catheter 610 .
  • the support component 622 of the implant 620 can be configured as illustrated in FIGS. 13-16B , and as shown and described in co-pending U.S. Application No. 61/835,406, filed Jun. 14, 2013, titled Implantable Luminal Devices and Methods (086538-0032), the entirety of which is incorporated herein by reference. Further, various other configurations can be used, such as those disclosed in co-pending U.S. Application No. 61/904,376, filed Nov. 14, 2013, titled Implantable Luminal Devices and Methods (086538-0041). Accordingly, support component can comprise separate wires that are preset into shapes that are generally mirror images of each other along a longitudinal center plane (extending through the central axis) of the support component, as illustrated in FIGS. 13-14A . The wires extend from a first end to a second and of the support component and can be joined or connected together, either mechanically or chemically, to form the support component.
  • FIGS. 12-16B illustrate embodiments of implants having a support component and a valve component, which can be delivered by advancing the implant within the lumen of the catheter as opposed to being supported, engaged, or restrained along an exterior surface of the catheter.
  • FIGS. 14B-14C illustrate an implant 650 having a support component 652 , a valve component 654 a , and a cover component 656 .
  • the support component 652 can be configured as illustrated and described above with respect to the support component 622 shown in FIGS. 13-14B .
  • the valve component 654 a can comprise a movable component 660 that can be attached to a first end 662 of the support component 652 .
  • the movable component 660 can be movable between an open position 670 and a closed position 672 .
  • the movable component 660 can be spaced apart from the first end 662 of the support component 652 such that fluid can flow between the first end 662 and an outer perimeter 674 of the movable component 660 .
  • the valve component 654 a can serve to prevent retrograde (and in some embodiments, anterograde flow) through the valve component 654 a .
  • Such embodiments can be useful to prevent displacement of embolic material outside of the target region, such as into upstream portions of the vessel, or undesired dilution of the embolic material in the target region.
  • the movable component 660 can be moved relative to the first end 662 in response to pressure or a longitudinal force exerted against the movable component 660 .
  • the movable component 660 can move away from the support component 652 (e.g., from the closed position 672 toward the open position 674 shown in FIG. 14B ).
  • the movable component 660 can be biased toward the closed position 672 such that the movable component 660 returns to the closed position 672 after being urged toward the open position 674 .
  • the movable component 660 can prevent retrograde flow through the valve component 654 a.
  • the movable component 660 may move toward and away from the nonmovable component 682 . With blood flow entering the opening 684 in the nonmovable component 682 , the smaller, movable component 660 can separate from the nonmovable component 682 , thus creating a space for blood to pass.
  • a pressure less than a normal systolic pressure e.g., less than about 120 mm Hg, less than about 110 mm Hg, less than about 100 mm Hg, less than about 90 mm Hg, or less than about 80 mm Hg
  • the movable component 660 can return or fall back against at least the nonmovable component 682 , thus at least partially closing the opening 684 or sealing against retrograde or backflow through the vessel.
  • the movable component 660 can be coupled relative to the first end 662 .
  • the movable component 660 can be attached using at least one fastener 680 .
  • the fastener 680 can be elastic, resilient, flexible, or inelastic.
  • the fastener 680 can comprise at least one hinge-type fastener, a strap-type fastener, and/or material having one or more apertures extending therethrough such that fluid or material can pass out of the first end 662 of the implant 650 past the movable component 660 when the movable component 660 is in the open position 670 .
  • the movable component 660 can be attached using a plurality of fasteners 680 (shown as flexible strap-type fasteners) that permit anterograde flow out of the implant 650 past the movable component 660 .
  • the movable and/or nonmovable components 660 , 682 can be connected by bands, strips, or ribbons so that the movable component 660 may move to and from the nonmovable component 682 freely.
  • the valve component 654 a can also comprise a nonmovable component 682 .
  • the nonmovable component 682 can be attached to the support component 652 .
  • the nonmovable component 682 can comprise a material formed separately from and later attached to the support component 652 .
  • the nonmovable component 682 can comprise a plate, three-dimensional structure, a wire, or other feature that is attached to, dried onto, or otherwise coupled to the support component 652 .
  • the nonmovable component 682 can be coupled to the distal end 662 of the support component 652 such that the nonmovable component 682 does not move longitudinally relative to the support component 652 .
  • the nonmovable component 682 can be fixed relative to the support component 652 .
  • the nonmovable component 682 can comprise at least one opening 684 through which fluid or material passing through the lumen of the implant 650 can flow and exit the lumen of the implant 650 .
  • the opening 684 can comprise one or more apertures that are formed in the nonmovable component 682 .
  • the movable component 660 can have a size greater than the size of the opening 684 such that when positioned over the opening 684 , the movable component 660 can block flow through the opening 684 .
  • the nonmovable component 682 and the movable component 660 can be configured to nest, mate, or be positioned flush against each other when the valve component 654 a is in the closed position.
  • the nested, mated, or flush positioning of the nonmovable and movable components 682 , 660 can allow the valve component 654 a to at least partially obstruct or fully block flow through the valve component 654 a when in the closed position.
  • the nonmovable component 682 and the movable component 660 can each have shapes that correspond to each other and permit the valve component to at least partially obstruct or fully block flow therethrough.
  • the nonmovable component 682 can have a substantially flat or planar shape and the movable component 660 can also have a substantially flat or planar shape.
  • FIGS. 14B-14C where in the closed position of FIG. 14C , backflow against the valve component 654 a would cause the movable component 662 be positioned flush against the nonmovable component 682 , thus preventing flow through the opening 684 .
  • the nonmovable component 682 can have a curved or arcuate shape and the movable component 660 can also have a curved or arcuate shape. As illustrated in FIGS. 14A-14C , the movable component 660 can comprise a substantially conical shape. In some embodiments, for example, the nonmovable component 682 can also comprise a substantially conical shape such that the movable and nonmovable components 660 , 682 can self-center when in contact with each other or have a self-centering function.
  • the shape of the nonmovable and movable components 682 , 660 can comprise mating components such that the nonmovable and movable components 682 , 660 assume a substantially fixed rotational orientation relative to each other when the valve component 654 a is in the closed position (e.g., when the nonmovable and movable components 682 , 660 are nested or mated against each other).
  • the movable and/or nonmovable components 660 , 682 can be formed from a film layer, such as a fabric or other polymer (e.g., ePTFE) film that is attached to one or more of the loops of the support component 652 .
  • a film layer such as a fabric or other polymer (e.g., ePTFE) film that is attached to one or more of the loops of the support component 652 .
  • the nonmovable component 682 can comprise an annular or doughnut-shaped component
  • the movable component 660 can comprise a solid round panel that is oversized relative to the opening 684 in the nonmovable component 682 .
  • a valve component 654 b can be used with the support component 652 and the cover component 656 of the implant 650 .
  • the valve component 654 b can function to allow anterograde flow while substantially preventing retrograde flow through the implant 650 .
  • the valve component 654 b can be configured as a plurality of movable panels 690 that can fold, bend, deflect, or otherwise move from a closed position 692 ( FIG. 15A ) to an open position 694 ( FIG. 15B ).
  • the valve component 654 b can comprise a single layer or sheet of material having at least one cut to form at least two moving edges that can be displaced relative to each other in order to form an aperture or opening 696 between the edges.
  • the edges are formed by four intersecting cuts (e.g., intersecting generally perpendicularly), thus forming sixteen movable edges and eight movable panels 690 .
  • the valve component 654 b can be configured to have two, three, four, five, six, seven, or more panels.
  • the valve component 654 b can comprise an elastic, flexible, or deflectable material that can be biased to maintain the closed position 692 unless a threshold level of pressure is met, such as pressure exceeding a normal systolic pressure (e.g., about 120 mm Hg). Further, the valve component 654 b can move toward the closed position 692 when the pressure is below a normal systolic pressure (e.g., less than about 120 mm Hg, less than about 110 mm Hg, less than about 100 mm Hg, less than about 90 mm Hg, or less than about 80 mm Hg).
  • a normal systolic pressure e.g., less than about 120 mm Hg, less than about 110 mm Hg, less than about 100 mm Hg, less than about 90 mm Hg, or less than about 80 mm Hg.
  • a valve component 654 c can also be provided in which the single layer or sheet of material has a three-dimensional shape, such as a dome, cone, pyramid, wedge, or other shapes.
  • the material of the valve component 654 c has a single cut forming opposing edges 700 that can move relative to each other in order to open or close an aperture 702 of the valve component 654 c in open or closed positions 710 , 712 . Multiple cuts can also be made in three-dimensionally shaped valve components.
  • valve component 654 c can be formed from separate hemispherical components that are aligned and attached to the support component 652 in order to permit relative movement between the hemispherical components to open or close the aperture 702 in response to pressure fluctuations.
  • Such components can be deflectable or rigid.
  • the edges 700 of the aperture 702 can comprise a frame element. Both of the edges 700 can have a frame element extending therealong.
  • the frame element can function to maintain an arcuate shape of the edges 700 such that the edges 700 can reliably meet and avoid gapping or spaces therebetween when the edges 700 meet in the closed position (as shown in FIG. 16A ).
  • the frame element(s) can be a section of the support component 652 that extends from the loop of the first end 662 of the support component 652 .
  • the frame element(s) can aid, support, or provide the biasing force to urge the opposing edges 700 toward the closed position 710 .
  • the valve component 654 c can also comprise an elastic, flexible, or deflectable material that can be biased to maintain the closed position 710 unless a threshold level of pressure is met, such as pressure exceeding a normal systolic pressure (e.g., about 120 mm Hg). Further, the valve component 654 c can move toward the closed position 710 when the pressure is below a normal systolic pressure (e.g., less than about 120 mm Hg, less than about 110 mm Hg, less than about 100 mm Hg, less than about 90 mm Hg, or less than about 80 mm Hg).
  • a normal systolic pressure e.g., less than about 120 mm Hg, less than about 110 mm Hg, less than about 100 mm Hg, less than about 90 mm Hg, or less than about 80 mm Hg.
  • an implant can be deployed into a body lumen in order to deliver a material (e.g., embolic material, contrast agents, or drugs) to a target body region.
  • a material e.g., embolic material, contrast agents, or drugs
  • the procedure can be performed such that one or more implants is fully expanded into contact with the lumen and released thereat in order to at least partially occlude flow through the lumen. Thereafter, the material can be injected through an aperture or valve of the implant into the lumen at a location downstream of the implant.
  • the implant can be left in place to at least partially occlude the lumen after the material has been delivered. In some instances, the implant can fully or at least substantially occlude the lumen immediately after its release into the lumen. In order to do so, the aperture or valve of the implant is closed.
  • the valve component of the implant can be configured to become at least partially closed once the catheter carrying the implant is withdrawn and the implant is fully released into the lumen.
  • the valve component can be at least partially closed or sealed to at least a frame of the implant, thereby at least partially closing or sealing the implant distal portion.
  • the valve component can be closed or sealed using embolic material, adhesives, or other such materials.
  • a portion of the catheter can be configured to move beyond or through the distal portion of the implant or have a close fit with the implant in order to precisely deliver a material into the lumen downstream of the implant and avoid dispersion or diffusion of the material upstream of the implant.
  • the implant proximal portion can be maintained engaged with the catheter while the implant distal portion is allowed to expand into contact with the vessel wall (see e.g., FIGS. 17A-17D, 19A-19C, and 20A-20D ).
  • the expansion of the implant distal portion can cause the implant to foreshorten and thus cause the distal portion of the catheter to move beyond or through the distal portion of the implant.
  • the catheter may not move beyond or through the distal portion of the implant, but the implant distal portion can be open thereby permitting free flow of material from the catheter distal tip (see e.g., the implant illustrated in FIGS. 7A-7D ). Thereafter, material can be injected into the lumen, thus avoiding dispersion or diffusion of the material upstream of the implant.
  • the implant distal portion can be maintained engaged with the catheter while the implant proximal portion is allowed to expand into contact with the vessel wall (see e.g., FIGS. 18A-18D ), whereafter material can be injected into the lumen, thus avoiding dispersion or diffusion of the material upstream of the implant.
  • Reflux of material against the implant can cause at least a portion of the implant to become closed (see e.g., FIGS. 7C-7D ).
  • the implant can use a polytetrafluoroethylene (“PTFE”) or expanded polytetrafluoroethylene (“ePTFE”) cover member that has a plurality of ribbons extending distally and around an aperture in the distal portion of the implant.
  • PTFE polytetrafluoroethylene
  • ePTFE expanded polytetrafluoroethylene
  • valve component can be closed mechanically, such as by being biased toward a closed position. Mechanical biasing can cause the valve component to be released and move toward its closed position once the implant is released and disengaged from by the catheter.
  • a clinician can use an embodiment of the implant disclosed herein (illustrated as the implant shown in FIGS. 7A-7D ) to deposit embolic particles into a target body region.
  • a guide catheter 760 can be advanced to a target region of a lumen 752 of a blood vessel 750 .
  • the vessel 750 can be an artery.
  • the guide catheter 760 can be advanced to the target region over a guidewire.
  • Guidewires used in accordance with any of the embodiments disclosed herein can have a size of between about 0.005 inches and about 0.030 inches, between about 0.008 inches and about 0.024 inches, or between about 0.010 inches and about 0.018 inches, such as 0.010 inches, 0.014 inches, or 0.018 inches.
  • An implant carrier assembly 762 can be advanced to the target region.
  • the implant carrier assembly 762 can be advanced through the catheter 760 toward a distal portion of the catheter 760 , as shown in FIGS. 17A, 18A, and 20A .
  • the catheter 760 can also be omitted and the implant carrier assembly 762 can be advanced to the target region over a guidewire, such as that mentioned above.
  • FIGS. 19A-19C illustrate that methods or procedures disclosed herein can also omit the guide catheter 760 .
  • the implant carrier assembly 762 can be advanced along a guidewire 767 until reaching the target region.
  • a supporting catheter 764 of the carrier assembly 762 can comprise a lumen that is configured to receive the guidewire 767 to facilitate distal advancement without a guide catheter or other member.
  • the supporting catheter 764 and an implant 766 carried thereon can reach much smaller vessels or arteries than in embodiments that require a guide catheter 760 .
  • the implant 766 can be placed in vessels or arteries ranging in size from about 1.2 mm to about 6.5 mm, from about 1.4 mm to about 6.0 mm, and about 1.7 mm to about 3.0 mm.
  • the implant 766 and the supporting catheter 764 can have a passing profile or outer diameter of between about 3 Fr and about 8 Fr, or that can be compatible with a guide catheter having a size of between about 3 Fr and about 12 Fr.
  • the guidewire 767 can have a size of between about 0.005 inches and about 0.030 inches, between about 0.008 inches and about 0.024 inches, or between about 0.010 inches and about 0.018 inches, such as 0.010 inches, 0.014 inches, or 0.018 inches.
  • the guide catheter 760 can be proximally withdrawn from the vessel 750 , as shown in FIGS. 17B, 18B, and 20B .
  • the implant carrier assembly 762 can be positioned at the target region whether by use of a catheter 760 or not, as shown in FIGS. 17B, 18B, 19A, and 20B .
  • the clinician can expand a first or second portion (or both) of the implant 766 in order to at least partially or fully occlude flow past the implant 766 into a downstream section 770 of the lumen 752 .
  • the deployment handle can be configured such as those disclosed herein and/or in co-pending U.S. patent application Ser. No. 14/044,794, filed Oct. 2, 2013, the entirety of which is incorporated herein by reference. This blockage of downstream flow through the vessel can make possible a highly targeted and concentrated delivery of material to a target region, avoiding dilution of the material in the downstream section 770 or reflux of the material 768 into an upstream region 772 of the vessel 750 .
  • the clinician can expand a distal portion 780 of the implant 766 while maintaining a proximal portion 782 of the implant 766 in a closed state.
  • the distal portion 780 can expand into apposition with a wall of the vessel 750 , thereby occluding, substantially or fully, flow through the vessel to the downstream section 770 of the lumen 752 .
  • the downstream section 770 of the lumen 752 can be isolated from the upstream section 772 of the lumen 752 .
  • This occlusion or isolation can enable the clinician to provide a more targeted delivery of material 768 to a target region and avoid dilution of the material 768 in the downstream section 770 or reflux of the material 768 into an upstream region 772 of the vessel 750 .
  • the clinician can expand the proximal portion 782 of the implant 766 while maintaining the distal portion 780 of the implant 766 in a closed state.
  • the proximal portion 782 can expand into apposition with a wall of the vessel 750 , thereby occluding, substantially or fully, flow through the vessel to the downstream section 770 of the lumen 752 .
  • a flushing port such as that illustrated in the embodiments of FIGS. 1 and 2 , can be used to inject fluid into the proximal portion 782 in order to facilitate expansion thereof.
  • the downstream section 770 of the lumen 752 can be isolated from the upstream section 772 of the lumen 752 .
  • This occlusion or isolation can enable the clinician to provide a more targeted delivery of material 768 to a target region and avoid dilution of the material 768 in the downstream section 770 or reflux of the material 768 into an upstream region 772 of the vessel 750 .
  • FIGS. 17C, 18C, 19B, and 20C illustrate that the clinician can release a desired material 768 into the downstream section 770 of the lumen 752 .
  • the desired material 768 can comprise an embolic material, such as NBCA glue, liquid embolic agents, a radiopaque material, a radioactive material, drugs or other therapeutic materials.
  • the release of such material 768 into the downstream section 770 of the lumen 752 can be performed until a desired amount or concentration of such material 768 is achieved in the downstream section 770 .
  • material immediately adjacent to the valve component of the implant can function to at least partially close or seal the valve component.
  • an adhesive material can be released at the end of the process in order to allow the implant to self-seal.
  • the material especially glues or other adhesive-type materials
  • the material can facilitate the creation of an at least partially closed or sealed valve that no longer permit flow through and out of the implant to the downstream section of the vessel.
  • the material can tend to facilitate thrombosis or coagulation of blood to further occlude the lumen (see e.g., FIGS. 8A-8B ).
  • the remaining portion of the implant 766 is expanded or released and the catheter 764 can be removed from the vessel 750 , as shown in FIGS. 17D, 18D, and 19C .
  • the implant 766 and the catheter 764 can be removed from the vessel 750 .
  • FIGS. 20C-20D illustrate that the guide catheter 760 can be maintained adjacent to the implant 766 such that after material has been deployed from the assembly 762 , the assembly 762 can be proximally withdrawn into the guide catheter 760 .
  • the guide catheter 760 can be distally advanced over the assembly 762 such that the implant 766 is not moved relative to the blood vessel 750 .
  • implants can be deployed in lumens having dimensions of between about 2 mm and about 20 mm.
  • the target delivery profile can be about 6 Fr or smaller.
  • the implant assembly can be compatible with a guide catheter having a size of between about 3 Fr and about 12 Fr.
  • implants disclosed herein can have a fibrous membrane feature can be used in various clinical applications, as discussed above.
  • implants disclosed herein having a fibrous membrane feature can have an expanded diameter of between about 3 mm and about 22 mm.
  • FIGS. 17A-20D can be implemented in accordance with further aspect shown in FIGS. 21-24B .
  • the procedure For procedures that deliver an embolic agent comprising radioactive particles for additional radiological treatment of a tumor, the procedure must precisely deliver the material the target region. Such delivery must be well-controlled delivery and calibrated in order to protect a patient from the unnecessary additional risks that may occur should the material being improperly distributed within other areas of the downstream vasculature.
  • FIG. 21 illustrates an embodiment of a procedure in which a first implant 800 is deployed into a vessel 802 adjacent to a target structure, vasculature, or lesion 804 .
  • the target structure 804 can be fed by a series of arteries 806 .
  • an implant assembly 810 can be advanced to a location within the vessel 802 that is proximal to the target arteries 806 and the first implant 800 .
  • the implant assembly 810 and the first implant 800 can be spaced apart in close proximity to each other to allow flow to only those target arteries 806 and to shield flow to other unintended areas.
  • the implant assembly 810 and the first implant 800 can be spaced apart in a range of from about 0.1 inches to about 5 inches, about 0.5 inches to about 3 inches, about 0.8 inches to about 2 inches, about 1 inches to about 1.5 inches, or about 1.2 inches to about 1.4 inches.
  • Various ranges of spacing between the implant 800 and the assembly 810 can be achieved to precisely target a region of the vessel 802 and/or select arteries 806 .
  • a distal portion of a second implant 820 is expanded into apposition with the walls of the vessel 802 in order to at least partially block anterograde flow to the arteries 806 .
  • a material 822 can then be released into the space between the first and second implants 800 , 820 .
  • the material can thus be concentrated toward the arteries 806 , thereby enhancing the efficacy of the delivery.
  • additional steps or procedures can be performed, such as imaging, in order to further treat the vessel 802 or target structure 804 .
  • first and/or second implants 800 , 820 can be released and left in the vessel 802 in order to provide occlusion of the vessel.
  • one or both of the first or second implants 800 , 820 can be removed from the vessel 802 after the material has been delivered to the arteries 806 and target structure 804 .
  • procedures can be provided that allow temporary occlusion of a blood vessel in order to treat a target structure while thereafter being able to restore blood flow through the previously occluded artery.
  • FIG. 22 illustrates the delivery of a material 822 toward arteries 806 and a target structure 804 .
  • an implant assembly 810 has been advanced to a location adjacent to the target structure 804 .
  • the implant 820 is expanded into apposition with the walls of the blood vessel 802 .
  • the material 822 can then be released into the downstream areas of the vessel 802 and arteries 806 .
  • the implant 820 can be expanded and released, such that blood flow to the target structure 804 is restricted or eliminated, thus inducing infarction of the target structure 804 .
  • Such embodiments advantageously mitigate any upstream migration of the material 822 toward an upstream section 832 of the vessel, and can tend to enhance or increase the concentration of material delivered to the arteries 806 and target structure 804 .
  • the procedure can also mitigate any downstream migration of the material 822 toward a downstream section 830 of the vessel.
  • such a dual-implant system or procedure can also mitigate any upstream migration of the material 822 toward an upstream section 832 of the vessel 802 .
  • Embodiments of this technique allow confident and precise application of material in any of a variety of situations, such as those mentioned above.
  • various treatment procedures can be performed for a target body region, such as tumor devascularization, reducing traumatic bleeding or hemorrhage, high-flow vascular malformations, vascular or airway volume reduction procedures, treatment of a target lesion, treatment and embolization of incompetent venous systems in low extremities (e.g., legs and lower abdominal area), treatment varicose veins in the leg (e.g., great saphenous vein and spider veins in deeper system), attending to other indications such as AVM, pelvic varices, etc.
  • a single treatment may not be sufficient to fully devascularize, heal, or otherwise treat the target body region.
  • a second procedure can be performed to remove and/or modify the first occlusive implant using the catheter and/or a second occlusive implant.
  • a second procedure can be undertaken in which the first occlusive implant can be removed and/or modified.
  • the second procedure can be performed after one, two, three, four, five or six months, or longer, and depends on the health of the patient and need for such a procedure.
  • the second procedure can be performed by removing the first implant and/or modifying the first implant, such as by restoring flow through a valve of the first implant.
  • the first option for the second procedure comprises removing the first implant from the vessel using a removal device. After removal, the first implant can be replaced by a new, second implant.
  • Another option for the second procedure comprises modifying the first occlusive implant, such as by restoring flow through the first implant, physically altering the first implant 970 (see FIGS. 23A-23B ), injecting additional material toward the target region, and/or inserting a second implant 980 into the first implant 970 (see FIGS. 24A-24B ) so as to change the effect or degree of the occlusion or permit additional material to be deployed downstream of the first implant 970 .
  • the first implant 970 can be modified by penetrating or punching a hole or aperture in the cover member or otherwise removing a portion of the first implant 970 .
  • the punching can comprise disconnecting, opening, or otherwise tearing a valve component from the first implant distal portion.
  • the hole or aperture can be made in order to restore flow at least partially through the first implant 970 , thereby allowing revascularization of the target body region.
  • FIG. 23A illustrates that when the first occlusive implant 970 is left in the vessel 802 , the clinician can advance a catheter, wire, or other adjustment member 972 to the target body region where the first implant 970 is deployed.
  • the adjustment member 972 can be used to create a hole or aperture in the distal portion of the first implant 970 by advancing a distal tip of the adjustment member 972 through the membrane or cover member of the first implant 970 , as illustrated in FIG. 23B .
  • such revascularization can provide the final step to the procedure and no further occlusion may be necessary. However, as necessary, additional optional steps can be taken to occlude or otherwise treat the target region.
  • the first implant 970 has been modified, and flow has been restored, a further procedure may be performed. If the deposition of another material, such as an embolic material, contrast agent, or drug, is recommended for the target body region, such material can then be deposited toward the target region. For example, after revascularizing the vessel, the clinician can deposit additional material toward the target region without delivering an additional implant to at least partially occlude the vessel.
  • the injection of additional material can include using and/or placing a second implant in the vessel.
  • the second implant can comprise any of the implants disclosed herein or be operated using any of the methods disclosed herein, such as any of the methods or treatment procedures illustrated in FIGS. 17A-22 .
  • a second implant 980 can be placed proximally of the first implant within the lumen.
  • the second implant 980 can be configured to fit within the lumen of the first implant.
  • the piercing or opening of the distal portion of the first implant 970 can be performed by using the catheter 982 used to deliver the second implant 980 .
  • the distal end of the catheter 982 can be advanced distally through the distal portion of the first implant 970 , thus opening the first implant 970 in a manner similar to that discussed above with respect to FIGS. 23A-23B .
  • modification of the first implant 970 and the further treatment of the target body region can be performed by modifying, penetrating, or punching a hole or aperture into the first implant 970 in a central location of the distal portion of the first implant 970 , as noted above, and positioning a distal portion of the second implant 980 within the first implant 970 .
  • the valve component of the first implant 970 can be maintained interconnected with at least a portion of the first implant 970 , such as with the cover member or frame member.
  • the valve component can remain attached to the first implant 970 , thereby preventing release of the valve component into distal vasculature. Later use of embolic material, glue, or other such materials can allow the dislocated valve component to be more securely fixed or adhered relative to the first implant 970 .
  • the second implant 980 can be coupled to or attached to the first implant 970 when released into the lumen.
  • the second implant 980 can sit entirely within the first implant 970 .
  • a distal portion of the second implant 980 can be configured to extend distally beyond the distal portion of the first implant 970 to facilitate passage of a material therethrough.
  • the second implant 980 can then be used in a manner as discussed herein with respect to other embodiments, such as for providing a material to a downstream target region.
  • FIGS. 17A-24B illustrate embodiments in which the implant comprises a helical support component that can be coupled to a catheter (see e.g., FIGS. 3-12B ), such methods and procedures can also be implemented using an implant that has a deflectable support component that can be at advanced within a catheter (see e.g., FIGS. 13-16B ).
  • any of the valve components disclosed herein can be used with a helical support component that can be coupled to a catheter (as shown in FIGS. 3-12B ) or a deflectable support component that can be at advanced within a catheter (as shown in FIGS. 13-16B ), including any combinations or modifications thereof.
  • implants disclosed herein may be used for various applications for reducing or stopping flow through a luminal structure in a patient and inducing infarction of a target tissue.
  • Implants of the subject technology may be used for rapid, well-controlled, and reliable occlusion of luminal structures.
  • the luminal structure may comprise at least one of a blood vessel, a body organ, a lung, an airway, a Fallopian tube, a cervical canal, a vagina, a cervix, a vas deferens, a bronchus, a ureter, a colon, a rectum, an anus, a bio duct, a pancreatic duct, or other suitable tubular structures known to those of ordinary skill in the art.
  • implants of the present disclosure may be used for temporary occlusion in cases of lung disease, or for temporary occlusion of female reproductive organs for contraceptive purposes.
  • implants of the present disclosure may be removed, or flow may be restored through the luminal structure to restore original organ functions.
  • some embodiments of the implants of the present disclosure may be used for various endoluminal occlusion procedures, including procedures for the lungs (e.g., selective endobronchial occlusion for lung reduction, occlusion of bronchopleural or bronchocutaneous fistulas, endovascular occlusion of pulmonary AVMs and fistulas or aortopulmonary anastomoses) and procedures for reproductive organs (e.g., endoluminal occlusion of vas deferens or Fallopian tubes for minimally-invasive contraceptive intervention, endovascular occlusion of varicocele in males and low abdominal gonadal veins for reducing or completely eliminating chronic pelvic pain syndrome in females).
  • procedures for the lungs e.g., selective endobronchial occlusion for lung reduction, occlusion of bronchopleural or bronchocutaneous fistulas, endovascular occlusion of pulmonary AVMs and fistulas or
  • implants of the present disclosure may be used for stopping blood loss from a damaged blood vessel, closing an abnormal blood vessel or a blood vessel supplying a vascular anamaly, or interrupting blood supply to an organ or part of an organ for permanent devascularization (e.g., closure of splenic artery in spleen laceration, devascularization of tissues involved by neoplastic process, either pre-operatively or as a palliative measure).
  • implants of the present disclosure may be used for various endovascular (e.g., neural and peripheral) procedures, head and neck AVFs, dissecting intracranial and extracranial vessels, traumatic and non-traumatic vessel injury or rupture (e.g., pelvic hemorrhages in trauma patients, carotid blow-out in patients with head and neck cancers, hemorrhage induced by a neoplasia, etc.), and devascularization prior to (or as an alternative to) surgical resection of various organs or tumors.
  • endovascular e.g., neural and peripheral
  • implants of the present disclosure may be used for various organs, including for example, the spleen (e.g., endovascular occlusion as a preoperative intervention or as an alternative to surgical resection with indications including traumatic hemorrhage, hypersplenism, bleeding secondary to portal hypertension or splenic vein thrombosis, and various disorders such as thalassemia major, thrombocytopenia, idiopathic thrombocytopenic purpura, Gaucher disease, and Hodgkin disease), the liver (e.g., occlusion of portal veins collaterals as adjunct to transjugular intrahepatic portosystemic shunt (“TIPS”), occlusion of the TIPS itself in cases of encephalopathy, occlusion of intrahepatic arterioportal fistulas), the kidney (e.g., endoluminal ureteral occlusion for intractable lower urinary tract fistula with urine leakage, or for the treatment of
  • TIPS trans
  • a cover component of an implant may be used to occlude, partially or completely, luminal structure in which a respective implant is deployed.
  • occlusion may refer to either partial or complete occlusion.
  • cover components can comprise at least one of a polyurethane, a polyan alloye, PTFE, ePTFE, silicone, and other suitable materials known to those of ordinary skill in the art.
  • cover components may be elastic.
  • cover components may be permeable or non-permeable.
  • an average thickness of a cover component can be between about 0.0005 inches and about 0.006 inches. In some aspects, the average thickness of a cover component may be less than about 0.0005 inches or greater than about 0.006 inches. In certain embodiments, an average thickness of a distal portion of a cover component is greater than an average thickness of a proximal portion of a cover component. Such a configuration may ensure that more flow may be reduced at the distal portion of a cover component. In some embodiments, the average thickness of the distal portion of a cover component is between about 0.002 inches and about 0.012 inches. In some embodiments, the average thickness of the distal portion of a cover component may be less than about 0.002 inches or greater than about 0.012 inches.
  • the average thickness of the proximal portion of a cover component is between about 0.0005 inches and about 0.006 inches. In some embodiments, the average thickness of the proximal portion of a cover component may be less than about 0.0005 inches or greater than about 0.006 inches.
  • Some embodiments of the implant described herein can incorporate one or more features of implants and/or implant deployment systems
  • the phrase “at least one of” preceding a series of items, with the term “and” or “or” to separate any of the items, modifies the list as a whole, rather than each member of the list (i.e., each item).
  • the phrase “at least one of” does not require selection of at least one of each item listed; rather, the phrase allows a meaning that includes at least one of any one of the items, and/or at least one of any combination of the items, and/or at least one of each of the items.
  • phrases “at least one of A, B, and C” or “at least one of A, B, or C” each refer to only A, only B, or only C; any combination of A, B, and C; and/or at least one of each of A, B, and C.
  • top should be understood as referring to an arbitrary frame of reference, rather than to the ordinary gravitational frame of reference.
  • a top surface, a bottom surface, a front surface, and a rear surface may extend upwardly, downwardly, diagonally, or horizontally in a gravitational frame of reference.

Abstract

An implant can include a support component, a cover component, and a valve component. The valve component can be operable to permit flow through the implant. The implant can be delivered on a catheter, with one of the ends of the implant being selectively expanded to permit temporary occlusion of a vessel while delivering a material through the valve component to a downstream target region. The other end of the implant can thereafter be released such that the implant occludes the vessel, or the implant can be removed from the vessel entirely.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application claims the priority benefit of U.S. Provisional Application Nos. 61/835,406, filed Jun. 14, 2013, 61/835,461, filed Jun. 14, 2013, and 61/900,321, filed Nov. 5, 2013, the entirety of each of which is incorporated herein by reference.
  • BACKGROUND
  • 1. Field of the Inventions
  • The present disclosure is related to endovascular apparatuses and methods, and more specifically, to apparatuses and methods for delivering a material to a target region of a body lumen and regulating blood flow therethrough.
  • 2. Description of the Related Art
  • Blood vessels can be accessed to deploy embolic agents, contrast agents, and medications to target regions of the body. Some target regions include the blood vessels themselves, as well as organs or other tissue being fed by blood vessels.
  • For example, through embolization, blood flow can be reduced to encourage atrophy or infarction of a target region of the body. Such target regions can include tumors, fibroids, and vascular malformations, such as arteriovenous malformations (“AVM”) or arteriovenous fistulas (“AVF”). Further, embolization of blood vessels can also be achieved to slow or stop bleeding in emergency situations.
  • Embolic agents can be used to treat cancer. For example, embolics can be used to occlude the vasculature feeding a tumor. Drug-loaded embolics, such as drug-loaded microspheres, can be used to deliver chemotherapeutic agents and/or therapeutic agents designed to treat inflamed or diseased tissue. In addition, clinicians have administered chemotherapeutic agents in combination with embolic polyvinyl alcohol (“PVA”) particles. This type of targeted therapy can localize treatment at the site of the tumor and minimize the systemic dose while maximizing the therapeutic dose delivered locally to the target lesion, reducing potential side effects and damage to healthy tissue.
  • SUMMARY
  • Various embodiments of medical methods and apparatus disclosed herein enable a clinician to provide a targeted delivery of a material, such as an embolic material, contrast agent, or drug, to a select body region. Some embodiments relate to vessel occlusion and tissue ablation or infarction by delivery of radially expandable implant frames that can be used to deliver a material to a downstream target area, such as a blood vessels or tissue. In some embodiments, the implant can be positioned to achieve immediate total occlusion of blood flow to ensure high material concentration in the target area, precise or calibrated control of delivered material, and specific targeting of certain structures and protection of others, which is especially useful for smaller target vessels and tissues. Some embodiments also provide for secondary procedures to be performed after an initial implant and material has been deployed at a target region. Furthermore, some embodiments of the present system can help close a bodily lumen or vessel rapidly and with confidence. These various advantages and benefits can provide improved health and quality of life for millions of people.
  • In accordance with some embodiments, various frame configurations, expected delivered and expanded dimensions, and a description of target anatomy of some embodiments are provided. Aspects of implants and delivery devices that can be utilized in combination with the implants and features disclosed herein are disclosed in applicant's co-pending U.S. patent application Ser. No. 14/044,794, filed on Oct. 2, 2013; U.S. Patent Application No. 61/904,376, filed Nov. 14, 2013, titled Implantable Luminal Devices and Methods (086538-0041); U.S. Patent Application No. 61/904,379, filed on Nov. 14, 2013, titled Torque Resistant Distal Catheter Tip (086538-0043); U.S. patent application Ser. No. ______, filed on ______, (Titled: Occlusive Anchoring Devices, Atty Ref: 086538-0044); U.S. patent application Ser. No. 12/906,993, filed on Oct. 18, 2010; and U.S. patent application Ser. No. 13/828,974, filed on Mar. 14, 2013, U.S. Patent Application No. 61/835,406, filed on Jun. 14, 2013, and U.S. Patent Application No. 61/835,461, filed on Jun. 14, 2013, the entireties of which are incorporated herein by reference.
  • Some embodiments can provide vascular implantation for vessels that are from about 2 mm to about 16 mm, from about 5 mm to about 13 mm, and in some embodiments, from about 7 mm to about 11 mm. The target delivery profile can be from about 2 Fr to about 8 Fr, about 3 Fr to about 7 Fr, from about 4 Fr to about 6 Fr, or in some embodiments, about 5 Fr. Additionally, expansion of the implant can provide sufficient radial force against the inside wall of a vein. Some embodiments can comprise features or means configured to minimize backflow of blood or minimize venous insufficiency. For example, treatment applications for embodiments of the implant can include ilio-femoral venous obstruction and chronic iliac venous outflow obstruction as a result of venous disease.
  • Further, in some embodiments, the implant can provide enhanced control of the delivery of a material or agent. For example, in accordance with an aspect of some embodiments is the realization that the delivery and distribution of a material can depend exclusively upon distal flow patterns. Some embodiments disclosed herein can enable control of material delivery, prevent reflux of the material, and permit calibrated delivery of the material, which can often be limited by early reflux along a delivery platform. The material can comprise liquid embolic agents such as N-butyl cyanoacrylate (“NBCA”), Onyx, or other liquid agents, radioembolization particles, and microspheres, such as microspheres filled with the radioactive isotope Yttrium Y-90.
  • The subject technology is illustrated, for example, according to various aspects described below. Various examples of aspects of the subject technology are described as numbered clauses (1, 2, 3, etc.) for convenience. These are provided as examples and do not limit the subject technology. It is noted that any of the dependent clauses may be combined in any combination, and placed into a respective independent clause, e.g., clause 1 or clause 5. The other clauses can be presented in a similar manner.
  • Clause 1. A material delivery device, comprising: an expandable support member having a lumen and an outflow end, the support member being configured to expand from a collapsed configuration to an expanded configuration for placement in a body lumen; a cover component, extending along the support member, defining an aperture; and a valve component coupled to the cover component and disposed at the outflow end, the valve component permitting outflow of a material through the aperture and restricting backflow of the material into the aperture.
  • Clause 2. The device of Clause 1, wherein the cover component comprises a tubular membrane coupled to the support member and the valve component comprises a free end of the tubular membrane extending away from the support member at the outflow end, the free end of the tubular membrane being configured to permit outflow of the material through the outflow end and to invert or fold onto itself to restrict backflow of the material into the outflow end.
  • Clause 3. The device of any one of Clauses 1 to 2, wherein the tubular membrane comprises inner and outer portions that extend along respective interior and exterior surfaces of the support member.
  • Clause 4. The device of Clause 3, wherein the free end of the tubular membrane extends from the outer portion, and the inner portion comprises a second free end.
  • Clause 5. The device of Clause 4, wherein the free end is coupled to the second free end.
  • Clause 6. The device of any one of Clauses 1 to 5, wherein the cover component comprises a tubular membrane coupled to the support member and the valve component comprises a free end of the tubular membrane extending away from the support member at the outflow end, wherein the tubular membrane comprises a tubular outer portion extending along a support member exterior and a segmented inner portion, comprising a plurality of strips, extending along a support member interior.
  • Clause 7. The device of Clause 6, wherein the free end is coupled to at least one of the plurality of strips.
  • Clause 8. The device of Clause 7, wherein the coupling comprises a suture.
  • Clause 9. The device of any one of Clauses 1 to 8, wherein the valve component is movable between open and closed positions, the valve component permitting flow of the material through the outflow end when in the open position and restricting backflow of the material through the outflow end when in the closed position.
  • Clause 10. The device of Clause 9, wherein in the open position, at least a portion of the valve component is spaced apart from the aperture to permit flow through the aperture.
  • Clause 11. The device of Clause 9, wherein in the closed position, the valve component has a sealing relationship with at least one of the support member or cover component to close the aperture at least partially and restrict flow through the device.
  • Clause 12. The device of any one of Clauses 1 to 11, wherein the valve component comprises a mesh material.
  • Clause 13. The device of Clause 12, wherein the mesh material is coupled to an outer surface of the cover component adjacent to the outflow end.
  • Clause 14. The device of any one of Clauses 1 to 13, wherein the valve component comprises a flap structure coupled to the cover component adjacent the outflow end, the flap structure being movable away from the aperture to permit flow therethrough.
  • Clause 15. The device of any one of Clauses 1 to 14, wherein the valve component comprises a plurality of deflectable panels.
  • Clause 16. The device of any one of Clauses 1 to 15, wherein the valve component comprises a split dome.
  • Clause 17. The device of any one of Clauses 1 to 16, wherein the support member comprises a helical body.
  • Clause 18. The device of any one of Clauses 1 to 17, wherein the support member comprises a deflectable frame configured to expand from a substantially linear collapsed configuration to the expanded configuration.
  • Clause 19. A method of delivering a material to a target region of a body lumen, comprising: advancing an implant to the target region, the implant having first and second sections engaged with a catheter at respective first and second engagement points; releasing the implant first section from engagement with the catheter at the first engagement point; permitting the implant first section to expand against a lumen wall at the target region such that the lumen becomes at least substantially occluded; and injecting a material through a portion of the implant.
  • Clause 20. The method of Clause 19, wherein the implant first section comprises an implant distal section, and wherein the releasing comprises disengaging a first engagement member from the distal section.
  • Clause 21. The method of Clause 20, wherein the portion of the implant comprises a valve component and the permitting comprises causing the valve component to contact a distal end of the catheter such that the catheter distal end moves the valve component to an open position.
  • Clause 22. The method of Clause 21, wherein the injecting comprises advancing the material out through the valve component after the valve component is in the open position.
  • Clause 23. The method of any one of Clauses 19 to 22, further comprising, after the material is injected into the lumen, releasing the implant second section and moving the catheter proximally relative to the implant such that the valve component moves to a closed position.
  • Clause 24. The method of Clause 23, wherein the moving the catheter relative to the implant comprises proximally withdrawing the catheter within the lumen.
  • Clause 25. The method of any one of Clauses 19 to 24, wherein the implant first section comprises a proximal section, and wherein the releasing comprises disengaging a first engagement member from the proximal section.
  • Clause 26. The method of Clause 25, wherein the permitting further comprises flushing the implant with a fluid to facilitate expansion of the proximal section.
  • Clause 27. The method of any one of Clauses 19 to 26, further comprising releasing the implant second section into apposition with the lumen wall such that the implant is disengaged from the catheter.
  • Clause 28. The method of any one of Clauses 19 to 27, further comprising proximally withdrawing the assembly from the lumen.
  • Clause 29. The method of Clause 28, wherein the withdrawing comprises withdrawing the assembly into a guide catheter such that expanded first section collapses within the guide catheter.
  • Clause 30. The method of any one of Clauses 19 to 29, further comprising, prior to releasing the implant first section, releasing a blocking implant into contact against the lumen wall downstream of the target region, the blocking implant occluding flow through the lumen beyond the target region.
  • Clause 31. The method of Clause 30, further comprising, after injecting a material, allowing the material to flow into the target region, and removing the blocking implant from the lumen.
  • Clause 32. A method of delivering a material to a target region of a body lumen, comprising:
  • removing an occlusion at a distal end of an implant, deployed within the lumen upstream of the target region, thereby restoring flow through the lumen to the target region; and
  • after removing the occlusion from the implant, injecting a material into the lumen such that the material passes through the implant to the target region.
  • Clause 33. The method of Clause 32, wherein contacting the implant comprises advancing an adjustment member through the implant to pierce a cover component of the implant.
  • Clause 34. The method of Clause 33, wherein the adjustment member comprises a catheter and the advancing comprises advancing the catheter through the implant to pierce a cover component of the implant.
  • Clause 35. The method of any one of Clauses 32 to 34, wherein the implant is a first implant, and the method further comprises: after contacting the first implant, advancing a second implant to the target region, the second implant having first and second sections engaged with a catheter at respective first and second engagement points; releasing the first section from engagement with the catheter at the first engagement point; and before injecting a material, permitting the implant first section to expand against a lumen wall at the target region such that the lumen becomes at least substantially occluded.
  • Clause 36. The method of Clause 35, further comprising releasing the second implant adjacent to the first implant.
  • Clause 37. The method of Clause 35, further comprising releasing the second implant within the first implant.
  • Clause 38. The method of any one of Clauses 32 to 37, wherein contacting the first implant comprises contacting a mesh component of the first implant with a material to dissolve coagulated material on the mesh component, thereby restoring flow through the mesh component.
  • Clause 39. A delivery assembly, for delivering an expandable member to a body lumen or luminal structure of a patient, comprising: a carrier member, positionable in a luminal structure of a patient, comprising a lumen having a cross-sectional area comprising a first portion and a second portion that are separated by a line segment intersecting a circumference of the carrier member, the carrier member comprising a slot extending through the carrier member into the lumen and bounded by the line segment and the circumference, within the first portion; an elongate member extending through the carrier lumen and across the slot; and an expandable member configured to expand within and engage the luminal structure, the expandable member comprising a coupling portion that fits within the slot, the coupling portion comprising an aperture configured to receive the elongate member therethrough when the coupling portion is positioned within the slot; wherein the elongate member is configured to move axially through the carrier lumen to be removed from the aperture and permit release of the coupling portion from the slot.
  • Clause 40. The assembly of Clause 39, wherein the carrier lumen extends to and is open at a distal end of the carrier member.
  • Clause 41. The assembly of any one of Clauses 39 to 40, wherein the carrier member comprises a second slot, distal to the slot, configured to receive a distal coupling portion of the expandable member.
  • Clause 42. The assembly of Clause 41, wherein the distal coupling portion comprises an aperture configured to receive an elongate member therethrough when the distal coupling portion is positioned within the second slot.
  • Clause 43. The assembly of any one of Clauses 39 to 42, wherein the elongate member is configured to be refracted by an operator such that the elongate member permits the release of the first portion.
  • Clause 44. The assembly of any one of Clauses 39 to 43, wherein the slot comprises a slot depth of between about ⅓ and about ⅔ of a carrier member diameter.
  • Clause 45. The assembly of any one of Clauses 39 to 44, wherein the slot comprises a slot depth of about ½ of a carrier member diameter.
  • Clause 46. The assembly of any one of Clauses 39 to 45, further comprising a cover member extending at least partially over the expandable member.
  • Clause 47. The assembly of any one of Clauses 39 to 46, wherein the slot comprises distal and proximal faces that extend in substantially parallel planes, the slot defining a slot width between the distal and proximal faces.
  • Clause 48. The assembly of Clause 47, wherein the distal and proximal faces extend substantially perpendicularly relative to a longitudinal axis of the carrier member.
  • Clause 49. The assembly of Clause 47, wherein the distal and proximal faces are obliquely oriented relative to a longitudinal axis of the carrier member.
  • Clause 50. The assembly of any one of Clauses 39 to 49, wherein the coupling portion comprises a flat cross-sectional shape.
  • Clause 51. The assembly of any one of Clauses 39 to 50, wherein the slot width is less than twice a thickness of the coupling portion.
  • Clause 52. An expandable implant, for placement in a body lumen or luminal structure of a patient via a carrier member, comprising: an expandable member configured to expand within and engage the body lumen, the expandable member comprising proximal and distal end portions, the proximal end portion comprising an aperture configured to receive an elongate member therethrough for coupling the proximal end portion relative to a carrier member for delivery to the body lumen; and a cover member extending at least partially over the proximal and distal end portions, the cover member comprising an open end for permitting fluid flow therethrough.
  • Clause 53. The implant of Clause 52, wherein the expandable member comprises a coil.
  • Clause 54. The implant of any one of Clauses 52 to 53, wherein the expandable member comprises a flat coil.
  • Clause 55. The implant of any one of Clauses 52 to 54, wherein the expandable member comprises a flat coil and the aperture extends radially through the proximal end portion of the flat coil.
  • Clause 56. The implant of Clause 55, wherein the proximal end portion comprises a substantially planar portion, the aperture extending through a center of the proximal end portion.
  • Clause 57. The implant of any one of Clauses 52 to 56, wherein the proximal end portion defines an average width that is approximately equal to an average width of the expandable member between the proximal and distal end portions.
  • Clause 58. The implant of any one of Clauses 52 to 57, wherein the distal end portion comprises a second aperture configured to receive an elongate member therethrough for coupling the distal end portion relative to the carrier member for delivery to the body lumen.
  • Clause 59. The implant of Clause 58, wherein the distal end portion comprises a substantially planar portion, the second aperture extending through a center of the distal end portion.
  • Clause 60. A method of delivering an expandable member to a luminal structure of a patient, comprising: advancing a carrier member through a luminal structure of a patient to a target area, the carrier member being coupled to an expandable member via an elongate member, the elongate member extending through a lumen of the carrier member to engage an end portion of the expandable member within a slot of the carrier member; proximally retracting the elongate member from an aperture of the end portion to release the end portion; and permitting release of the expandable member against the luminal structure.
  • Clause 61. The method of Clause 60, further comprising proximally retracting an elongate member from a second aperture of a second end portion of the expandable member.
  • Clause 62. The method of any one of Clauses 60 to 61, wherein the proximally retracting comprises proximally retracting a second elongate member from a second aperture of a second end portion of the expandable member.
  • Clause 63. The method of any one of Clauses 60 to 62, performed in combination with the method of any one of Clauses 19 to 38.
  • Clause 64. The method of any one of Clauses 60 to 63, performed using the implant of any one of Clauses 1 to 18 or Clauses 52 to 59.
  • Clause 65. The method of any one of Clauses 59 to 63, performed using the assembly of any one of Clauses 39 to 51.
  • Clause 66. A method of manufacturing an expandable member for delivery into a luminal structure of a patient via a carrier member, comprising: positioning an expandable member onto a carrier member; placing an end portion of the expandable member into a slot of the carrier member; and inserting an elongate member into an aperture of the end portion to engage the end portion within the slot.
  • Clause 67. The method of Clause 66, wherein the end portion comprises a flat cross-sectional shape, and the placing the end portion comprises twisting the end portion such that the flat shape is aligned with the slot, in a side, cross-sectional view.
  • Clause 68. The method of Clause 67, wherein the slot comprises distal and proximal faces extending in a substantially parallel planes.
  • Clause 69. The method of Clause 68, wherein the substantially parallel planes are oriented substantially perpendicular relative to a longitudinal axis of the carrier member.
  • Clause 70. The method of Clause 68, wherein the substantially parallel planes are obliquely oriented relative to a longitudinal axis of the carrier member.
  • Clause 71. The method of any one of Clauses 66 to 70, further comprising: placing a second end portion of the expandable member into a second slot of the carrier member; and inserting a second elongate member into a second aperture of the second end portion to engage the second end portion within the slot.
  • Clause 72. The method of any one of Clauses 66 to 71, performed using the implant of any one of Clauses 1 to 18 or Clauses 52 to 59.
  • Clause 73. The method of any one of Clauses 66 to 72, performed using the assembly of any one of Clauses 39 to 51.
  • Clause 74. The implants, assemblies, or methods of any of the preceding Clauses, wherein a slot width, slot depth, catheter lumen inner diameter, catheter lumen inner diameter, engagement component diameter, aperture diameter, proximal end portion width, or proximal end portion thickness is within any of the corresponding ranges disclosed herein.
  • Additional features and advantages of the subject technology will be set forth in the description below, and in part will be apparent from the description, or may be learned by practice of the subject technology. The advantages of the subject technology will be realized and attained by the structure particularly pointed out in the written description and embodiments hereof as well as the appended drawings.
  • It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory and are intended to provide further explanation of the subject technology.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • The accompanying drawings, which are included to provide further understanding of the subject technology and are incorporated in and constitute a part of this specification, illustrate aspects of the subject technology and together with the description serve to explain the principles of the subject technology.
  • FIG. 1 is a perspective view of an implant carrier assembly, according to some embodiments.
  • FIG. 2 illustrates a perspective view of another implant carrier assembly, according to some embodiments.
  • FIG. 3 is a perspective view of an implant having a valve component, according to some embodiments.
  • FIG. 4 is a perspective view of the implant of FIG. 3, illustrating a support component thereof, according to some embodiments.
  • FIG. 5A is a perspective view of a support frame mounted on a catheter, according to some embodiments.
  • FIG. 5B is an end view of the catheter and support frame of FIG. 5A, according to some embodiments.
  • FIG. 6A is a perspective view of a support frame mounted on a catheter, according to some embodiments.
  • FIG. 6B is an end view of the catheter and support frame of FIG. 6A, according to some embodiments.
  • FIGS. 6C-6E are side, cross-sectional views of an aperture that extends through the catheter and engagement of an end of the support frame therein, according to some embodiments.
  • FIGS. 7A-7B are side, cross-sectional views of positions of an implant assembly having a valve component, according to some embodiments.
  • FIGS. 7C-7D are side, cross-sectional views of the implant assembly of FIGS. 6A-6B subsequent to deployment and illustrating the closure thereof, according to some embodiments.
  • FIGS. 8A-8D are side, cross-sectional views of positions of an implant assembly having a mesh-type valve component, according to some embodiments.
  • FIGS. 9A-9B are side, cross-sectional views of positions of an implant assembly having a valve component, according to some embodiments.
  • FIGS. 10A-10B are side, cross-sectional views of positions of an implant assembly having a valve component, according to some embodiments.
  • FIGS. 11A-11B are side, cross-sectional views of positions of an implant assembly having a valve component, according to some embodiments.
  • FIGS. 12A-12B are side, cross-sectional views of positions of an implant assembly having a valve component, according to some embodiments.
  • FIG. 13 shows a perspective view of a frame in a compressed state within a deliver catheter, according to some embodiments.
  • FIG. 14A shows a perspective view of a frame partially expanded from a delivery catheter, according to some embodiments.
  • FIGS. 14B-14C are perspective views of an implant having a valve component, according to some embodiments.
  • FIGS. 15A-15B are perspective views of an implant having a valve component, according to some embodiments.
  • FIGS. 16A-16B are perspective views of an implant having a valve component, according to some embodiments.
  • FIGS. 17A-17D are cross-sectional schematic views illustrating processes of depositing embolic particles into a target vessel region, according to some embodiments.
  • FIGS. 18A-18D are cross-sectional schematic views illustrating another process of depositing embolic particles into a target vessel region, according to some embodiments.
  • FIGS. 19A-19C are cross-sectional schematic views illustrating another process of depositing embolic particles into a target vessel region, according to some embodiments.
  • FIGS. 20A-20D are cross-sectional schematic views illustrating another process of depositing embolic particles into a target vessel region, according to some embodiments.
  • FIG. 21 is a cross-sectional schematic view illustrating deposition of embolic particles into a target vessel region, according to some embodiments.
  • FIG. 22 is a cross-sectional schematic view illustrating deposition of embolic particles into a target vessel region, according to some embodiments.
  • FIGS. 23A-23B illustrate schematic views illustrating alteration of an implanted occlusive device, according to some embodiments.
  • FIGS. 24A-24B illustrate schematic views illustrating alteration of an implanted first occlusive device and the insertion of a second device into the first device, according to some embodiments.
  • DETAILED DESCRIPTION
  • In the following detailed description, numerous specific details are set forth to provide a full understanding of the subject technology. It should be understood that the subject technology may be practiced without some of these specific details. In other instances, well-known structures and techniques have not been shown in detail so as not to obscure the subject technology.
  • While the present description sets forth specific details of various embodiments, it will be appreciated that the description is illustrative only and should not be construed in any way as limiting. It is contemplated that although particular embodiments of the present inventions may be disclosed or shown in particular contexts, such embodiments can be used in a variety of endoluminal applications. Various applications of such embodiments and modifications thereto, which may occur to those who are skilled in the art, are also encompassed by the general concepts described herein.
  • Some embodiments of the procedure, technique, and implant disclosed herein can enable a clinician, in one or a several clinical procedures, to occlude, dynamically control the flow through, or deploy a material through an implant. For example, according to some embodiments disclosed herein, procedures, techniques, and implants are provided by which an implant can be deployed into a body lumen in order to provide targeted delivery of a material, such as an embolic material, contrast agent, or drug. It shall be noted that even though some of the embodiments disclosed herein may refer to the use of an embolic material, such embodiments can employ one or more materials, such as embolic materials, contrast agents, or drugs, including those disclosed herein and other acceptable materials.
  • Additionally, in some embodiments, methods and implants are provided in which a clinician can deposit embolic material into a target area downstream of an implanted shunt while preventing upstream flow or backflow of the particles away from the target area.
  • In some embodiments, an implant can be expanded into apposition with a luminal wall to at least partially occlude flow through the lumen, and embolic material can be released through an aperture or valve component of the implant, thereby isolating the flow of embolic material into the target region. The valve component can comprise a one-way valve. Such procedures, techniques, and implants can be used to induce infarction of tumors, arteries, or other target body regions.
  • Further, in accordance with some embodiments, a clinician can place one or more implants into the vasculature and use of an implant to facilitate the delivery of a material, such as an embolic material, to a target region within the body.
  • For example, a clinician can advance an implant to a location upstream of specific arteries and/or a target structure fed by the arteries. At least a portion of the implant can be expanded into apposition with the vessel wall, thereby reducing and/or eliminating any anterograde blood flow past the implant. Thereafter, a material can be passed through a valve component or aperture of the implant in order to pass the material toward the target region. Such embodiments advantageously enhance or increase the concentration of material delivered to the arteries and target structure. Further, in some embodiments, a distal implant can be released at a location immediately distal to the target region such that the distal implant prevents or mitigates any downstream migration of the material toward a downstream section of the vessel.
  • Some embodiments of the flow regulating implant can comprise a generally tubular member. In some embodiments, the tubular member can further comprise a graft, cover, or other material attached to a frame. Some implants that can be used in some embodiments are disclosed in applicant's co-pending U.S. patent application Ser. No. 12/906,933, filed on Oct. 18, 2010, Ser. No. 13/828,974, filed on Mar. 14, 2013, and 61/835,406, filed on Jun. 14, 2013, titled “Implantable Luminal Devices and Methods,” the entireties of which are incorporated herein by reference.
  • FIGS. 1 and 2 illustrate embodiments of an implant carrier assembly. As shown in FIGS. 1 and 2, the implant carrier assembly 500, 500′ can comprise a catheter 510 having a lumen that extends between a proximal portion 512 and a distal portion 514 of the catheter. The catheter 510 can also comprise an engagement section 516, which can be located along a distal portion of the catheter 510, configured to engage and/or restrain an implant positioned therealong. Thus, the implant can be supported, engaged, or restrained along an exterior surface of the catheter. The catheter 510 can define a length from about 50 cm to about 200 cm, from about 70 cm to about 160 cm, or in some embodiments, about 120 cm, with a working length of from about 85 cm to about 140 cm, from about 95 cm to about 130 cm. In accordance with some embodiments, the total length of the implant carrier assembly (with handle) can be about 117 cm, with a working length of 97 cm.
  • The catheter 510 can be configured to move within a guide sheath when advancing the assembly 500, 500′ into a patient for treatment. The proximal portion 512 of the catheter 510 can be configured to be relatively stiff in order to enhance the pushability of the catheter 510 through the guide sheath. Further, the distal portion 514 can be relatively flexible in order to improve the maneuverability and trackability of the catheter 510 as it is advanced through the guide sheath.
  • The assembly 500, 500′ can also comprise an implant or device 520 loaded on the engagement section 516. The implant 520 can be supported on the engagement section 516 of the catheter 510. Further, the assembly 500, 500′ can also comprise a deployment handle assembly 530, 530′ attached to the catheter proximal portion 512. The deployment handle 530 shown in FIG. 1 includes two pull members 532, whereas the deployment handle 530′ shown in FIG. 1 includes a single pull member 532′. As discussed further herein and in co-pending U.S. patent application Ser. No. 14/044,794, filed Oct. 2, 2013, the entirety of which is incorporated herein by reference, the pull members 532, 532′ can be used to release the implant 520 from engagement with the engagement section 516 of the catheter 510. In some embodiments, both deployment handles 530, 530′ can be used to release distal and proximal portions of the implant 520. However, the deployment handle 530 can be configured to provide dedicated pull members 532 for releasing each of the distal and proximal portions of the implant 520. In contrast, the deployment handle 530′ can be configured to provide a single pull member 532′ that can be, for example, moved a first distance to release the distal portion of the implant 520 and pulled a second distance to release the proximal portion of the implant 520. Either embodiment can be used in performing the methods and procedures disclosed herein.
  • Other features and characteristics of the assembly 500, 500′ can be provided such as those disclosed in co-pending U.S. patent application Ser. No. 14/044,794, filed Oct. 2, 2013, the entirety of which is incorporated herein by reference.
  • As shown in FIGS. 3-4, the implant 520 can be supported on the engagement section 516 of the catheter 510. The implant 520 can comprise one or more apertures or valve components that can be actuated to permit flow of a material, such as an embolic material, contrast agent, or drug, through the implant 520. The implant 520 can comprise a plurality of components, such as one or more support components 540, a valve component 542, and/or a cover member 544. The cover member 544 can comprise an aperture through which a material can be passed. In embodiments using a valve component 542, the valve component 542 can be coupled to the support component 540 and/or cover member 544 and can permit flow of a material therethrough.
  • FIGS. 5A-5B illustrate aspects of an engagement system between the catheter 510, the support component 540, and at least one engagement component 546 a, 546 b. As noted above, when using a single pull member 532′, a single engagement component 546 can be used to engage and release proximal and distal portions 534, 536 of the support component 540. Further, when using to pull members 532, two engagement components 546 a, 546 b can be used to engage and release the proximal and distal portions 534, 536 of the support component 540. Various aspects of such embodiments are disclosed in co-pending U.S. patent application Ser. No. 14/044,794, filed Oct. 2, 2013, the entirety of which is incorporated herein by reference. Thus, the implant 520 can be delivered using various embodiments of the carrier assembly 500, 500′.
  • In accordance with some embodiments, the engagement system can be configured such that the support component comprises one or more apertures that extend through one or more portions thereof to facilitate engagement with at least one engagement component when the support component is coupled to the catheter. For example, the engagement component can extend through the lumen of the catheter adjacent an aperture, notch, or slot of the catheter and pass through an aperture of a distal end portion of the support component in order to engage the distal end portion and secure the distal end portion relative to the aperture, notch, or slot of the catheter. The aperture can extend through the support component at an end portion or other location between the end portions, such as a midportion thereof.
  • Further, the support component can be coupled to the catheter with the engaged portion of the support component extending through the aperture, notch, or slot of the catheter. Advantageously, the engagement between the support component and the engagement component within the catheter lumen can reduce the profile of the carrier assembly, thereby permitting the assembly to be compatible with small gauge catheters, such as sizes between about 3 Fr and about 8 Fr, about 4 Fr and about 7 Fr, or about 5 Fr and about 6 Fr. However, in some embodiments, the engagement component can extend radially external to or outwardly from the catheter lumen to engage the portion of the support component outside of the catheter lumen and still provide compatibility with small gauge catheters.
  • In accordance with some embodiments, the implant carrier assembly can be configured to comprise at least one engagement member that extends at least partially through the catheter lumen. The engagement member can engage at least a portion of, and in some embodiments, one or both the proximal and distal sections of the support component. The engagement member can comprise a wire. However, in some embodiments, the engagement member can comprise a plug or other structure that can interact with one or both of the proximal or distal sections of the support component.
  • In some embodiments, the engagement member can be actuatable or controllable using a handle assembly, as discussed further below.
  • For example, an engagement section of the catheter can be configured to facilitate engagement between the support component and the engagement member extending from the handle assembly. In some embodiments, the engagement member can be selectively actuated or withdrawn in order to release engagement between the support component and the engagement member. The movement of the engagement member can be configured to be a proximal withdrawal of the engagement member. However, the engagement member can also be configured such that disengagement occurs when the engagement member is distally advanced (such as when a proximally oriented hook or segment of the engagement member engages with the support component). Indeed, the engagement member can be moved a first distance (whether proximally or distally) in order to release or disengage with one of the proximal or distal sections of the support component. Further, the engagement member can be moved a second distance, greater than the first distance (whether proximally or distally) in order to release or disengage with the other one of the proximal or distal sections of the support component.
  • Further, in some embodiments, the engagement section of the catheter can facilitate engagement between the implant and two or more engagement members extending from the handle assembly. Although the engagement member is illustrated as extending between the proximal and distal sections of the support component, the engagement member can engage one of the proximal or distal sections while a second engagement member can be used to engage the other of the proximal or distal sections.
  • For example, the catheter can comprise an engagement section and a lumen. The assembly can comprise an implant or support component supported on the engagement section. Further, the assembly can comprise a first engagement member and a second engagement member 546 a, 546 b configured to engage with the support component, as shown in FIG. 5B. As shown in FIG. 5A, a distal portion of the engagement member 546 b can engage a proximal portion of support component and a distal portion of the engagement member 546 a can engage with a distal portion of the support component.
  • Accordingly, in embodiments that comprise two engagement members, the engagement members can be actuated independently of each other in order to control the release of the respective proximal or distal sections of the support component or implant.
  • Additionally, some embodiments can be configured such that an engagement member extends through the catheter lumen and between at least one of the proximal or distal sections of the support component and the wall of the catheter. For example, the engagement member can be disposed radially between the proximal or distal section of the support component and the wall of the catheter.
  • For example, FIG. 5B illustrates the configuration of the catheter and the aperture, notch, or slot in relation to the engagement member and the proximal section of the support component. As shown, the proximal section can sit within the aperture and provide enough clearance between the proximal section and wall or the inner surface of the wall such that the engagement member can be positioned intermediate the wall and the proximal section. As also shown, the proximal section can extend across the entire diameter of the lumen in a transverse direction. However, the proximal and/or distal sections can also be configured to extend across the lumen less than a diameter of the lumen (whether in the transverse direction or in a radial direction).
  • Accordingly, the engagement member can secure the proximal section within the aperture to prevent movement of the proximal section in an axial direction (shown in FIG. 5A) and/or a radial direction (shown in FIG. 5B). In some embodiments, the support component can be a resilient or self-expanding support component, such that the proximal section will tend to expand or move out of the aperture without the presence of the engagement member. Thus, when the engagement member is in place between the proximal section and the wall of the catheter, the proximal section can be retained or engaged within the aperture. However, when the engagement member is removed from between the catheter and the proximal section of the support component, the proximal section of the support component will no longer be constrained and can therefore expand out of the aperture, notch, or slot.
  • The engagement between the proximal section, the engagement member, and the aperture can also be present at the distal end of the support component, although it will not be discussed further herein. However, as noted, some embodiments can be implemented in which a single end of the support component is retained within an aperture or otherwise engaged by the engagement member.
  • In addition to FIGS. 5A-5B, FIGS. 6A-6E illustrate additional aspects of some embodiments of an engagement system. FIG. 6A illustrates a support component 540′ having a proximal end region 541 that comprises an aperture 543 extending therethrough. The aperture 543 can be configured to receive at least one engagement component therethrough. For example, in FIG. 6A, the engagement component 546 b passes through the aperture 543 of the proximal end region 541, thus securing the proximal end region 541 relative to the aperture, the notch, or slot 539 of the catheter 510. In this manner, the proximal end region 541 can be radially secured (such that the proximal end region 541 does not radially expand out of the slot 539) and circumferentially or laterally secured (such that the proximal end region 541 does not slide out of the slot 539) relative to the catheter 510.
  • The proximal end region 541 can comprise a flattened portion, as illustrated in the cross-sectional view of FIG. 6B. However, the proximal end region 541 can also extend along an arcuate path without having a discrete flattened portion.
  • FIG. 6B (and as generally shown in the embodiment of FIGS. 5A-5B) also illustrates that the slot 539 formed in the catheter 510 can, in some embodiments, be defined by a line segment or chord 537 extending through the catheter lumen 517. The line segment or chord 537 can intersect with the circumference of the catheter 510. The line segment 537 can be a diameter of a circular cross-section, but need not be a diameter and can be a chord intersecting the circumference. The line segment 537 can define a base or bottom of the slot 539. The orientation or spacing of the line segment 537 from an outer circumference of the catheter 510 can define a slot depth. The slot depth can be measured as the distance from the line segment to the outermost point along the circumference of the catheter 510. As noted below, the slot can have a depth that extends between about ⅕ and about ⅔ of the catheter outer diameter, such as about ¼, ⅓, or ½ of the catheter outer diameter.
  • Referring still to FIG. 6B (and generally to FIG. 5B), the slot 539 can extend only partially into the catheter lumen 517, such that the lumen 517 provides sufficient space for material to pass therethrough. When viewed in cross-section, the line segment can divide the lumen 517 into first and second portions. For example, the engagement component 543 and the proximal end region 541 can be positioned within a first portion of the lumen 517. A second portion of the lumen 517 can be a clear-through portion that allows material to be urged therethrough.
  • Further, the proximal end region 541 can comprise at least one aperture extending therethrough. In some embodiments, the aperture can extend through the proximal end region in a direction transverse to a longitudinal axis of the support component. For example, in some embodiments, the proximal end region can be flat, and the aperture can extend through the flat proximal end region, as illustrated in FIGS. 6A-6E. However, the aperture can also extend through the proximal end region in a direction substantially parallel relative to a longitudinal axis of the support component. In such embodiments, the proximal end region can have a flat, square, rectangular, and/or twisted shape. According to some embodiments, the proximal end region 541 can be deflectable in order to facilitate placement of the proximal end region 541 into the slot 539 of the catheter 510.
  • The proximal end region 541 can define a width that is about equal to a width of the support component 540′. Thus, in some embodiments, the support component 540′ may not have a tapering width in the proximal end region 541. However, the support component 540′ can also taper toward a larger or smaller width in the proximal end region 541. For example, a larger width in the proximal end region 541 can facilitate the accommodation of the aperture 543 thereat. However, non-tapering or other tapering embodiments of the proximal end region 541 can define a width sufficient to accommodate the aperture 543 thereat.
  • In some embodiments, the width of the proximal end region 541 can be at least about two times the width, size, or diameter of the aperture 543. However, in other embodiments, the width of the proximal end region 541 can be three, four, five, or more times the width, size, or diameter of the aperture 543.
  • Some embodiments can also be configured such that the support component and the cover member cooperatively substantially seal the slot of the catheter lumen. FIGS. 6C-6E illustrate side, cross-sectional views of the embodiments of the catheter that can be used to couple the engagement component and the support component. According to some embodiments, the aperture, notch, or slot of the catheter can have a V-shape. However, the slot can comprise a slanted configuration and/or U-shaped configured to reduce and/or eliminate leakage of material from the slot when material is urged through the catheter lumen for deposition into the body lumen.
  • FIGS. 6C-6D illustrate slots 539 a, 539 b formed in the catheter 510, which are slanted or extend transversely relative to a plane that is perpendicular relative to the longitudinal axis of the catheter 510. FIG. 6E illustrate a slot 539 c formed in the catheter 510, which extends substantially within a plane that is perpendicular relative to the longitudinal axis of the catheter 510.
  • In accordance with some embodiments, the slots 539 a, 539 b, 539 c can have proximal and distal faces 513, 515. The proximal and distal faces 513, 515 can extend in respective planes. In some embodiments, the proximal and distal faces 513, 515 can be defined by edges of the catheter through which the slot is cut. The proximal and distal faces 513, 515 (or the planes through which they extend) can be substantially parallel relative to each other (whereas the slot 539 of FIG. 6A illustrates proximal and distal faces (or the planes through which they extend) that are oriented transverse relative to each other). The proximal and distal faces 513, 515 (or the planes through which they extend) can be oriented substantially perpendicular relative to a longitudinal axis of the catheter. Further, in some embodiments, the proximal and distal faces 513, 515 (or the planes through which they extend) can be obliquely oriented relative to a longitudinal axis of the catheter.
  • As illustrated in FIG. 6C, the slot 539 a can be configured such that the proximal and distal faces 513 a, 515 a have a forward slant or orientation. For example, the slot 539 a or the proximal and distal faces 513 a, 515 a can have a slope or taper that converges toward the longitudinal axis of the catheter 510 in a direction away from a supporting area 511 of the catheter 510. Thus, the proximal end portion 541 can be inserted into the slot 539 a at an angle relative to the longitudinal axis of the catheter 510 and, referring to the orientation illustrated in FIG. 6C, turned counterclockwise to an angled orientation in order to insert the proximal end portion 540 into the slot 539 a.
  • The slot 539 b of FIG. 6D can be configured such that the proximal and distal faces 513 b, 515 b have a reverse slant or orientation. For example, the slot 539 b or the proximal and distal faces 513 b, 515 b can have a slope or taper that converges toward the longitudinal axis of the catheter 510 in a direction toward or into a supporting area 511 of the catheter 510. Thus, the proximal end portion 541 can be inserted into the slot 539 b at an angle relative to the longitudinal axis of the catheter 510 and, referring to the orientation illustrated in FIG. 6D, turned clockwise to an angled orientation in order to insert the proximal end portion 540 into the slot 539 b.
  • Further, as illustrated in FIG. 6E, the slot 539 c or proximal and distal faces 513 c, 515 c can extend generally perpendicular relative to the longitudinal axis of the catheter 510. Thus, the proximal end portion 541 can be inserted into the slot 539 c at a substantially perpendicular angle relative to the longitudinal axis of the catheter 510 and, referring to the orientation illustrated in FIG. 6E, turned clockwise or counterclockwise to an angled orientation in order to insert the proximal end portion 540 into the slot 539 a.
  • Advantageously, the slots 539 a, 539 b, 539 c each are configured such that the proximal and distal faces of the slots 539 a, 539 b, 539 c closely approximate the thickness of the proximal end portion 541 and the membrane 520 wrapped around the proximal end portion 541 when inserted into the slot. Accordingly, in embodiments of the catheter that do not comprise a dedicated or separate lumen for passage of material, the material passing through the catheter lumen 517 will not tend to leak from or exit the slot of the catheter lumen 517.
  • For example, the slots 539 a, 539 b, 539 c can define a slot width, between the proximal and distal faces, that is between about 0.004 inches and about 0.012 inches. Further, the slot width can be between about 0.005 inches and about 0.010 inches. Furthermore, the slot width can be between about 0.006 inches and about 0.008 inches, or about 0.007 inches. As shown in FIG. 6A, the slot may be tapered (have a trapezoidal shape, when viewed in a side view along the longitudinal axis of the catheter) with a wider end positioned toward the outer contour of the catheter. Further, as shown in FIGS. 6C-6E, the slot may be straight (have a rectangular or square shape, when viewed in a side view along the longitudinal axis of the catheter).
  • In some embodiments, the thickness of the distal end portion 541 of the support component 540 can be between about 0.002 inches and about 0.008 inches. Further, the thickness of the distal end portion 541 can be between about 0.003 inches and about 0.006 inches. In some embodiments, the thickness of the distal end portion 541 can be about 0.004 inches.
  • Thus, with a cover member 520 having a thickness of between about 0.0005 inches and about 0.006 inches, the distal end portion 541 and cover member 520 can fit into the slot with high dimensional accuracy in order to reduce any gap in the slot wherethrough material can exit the catheter lumen.
  • Additionally, the slots 539 a, 539 b, 539 c can define a slot depth or dimension indicative of the diametric or radial extent of the slot into or through the catheter 510. The slot depth can be between about ⅕ and about ⅔ of the catheter outer diameter, such as about ¼, ⅓, or ½ of the catheter outer diameter. The slot depth can be at least ⅓, ½, ⅔, or ¾ of the width of the proximal end portion 541. For example, the slot depth can be between about 0.004 inches and about 0.110 inches. Further, the slot depth can be between about 0.008 inches and about 0.090 inches. The slot depth can be between about 0.010 inches and about 0.060 inches. Furthermore, the slot depth can be between about 0.014 inches and about 0.040 inches. The slot depth can be or between about 0.018 inches and about 0.030 inches. In some embodiments, the slot depth can be about 0.020 inches, about 0.024 inches, or about 0.028 inches.
  • Further, the engagement component can have a diameter of between about 0.001 inches and about 0.020 inches, between about 0.003 inches and about 0.010 inches, or between about 0.004 inches and about 0.007 inches, such as 0.005 inches.
  • The proximal end portion can define a width of between about 0.010 inches and about 0.030 inches, between about 0.012 inches and about 0.020 inches, between about 0.014 inches and about 0.018 inches, and in some embodiments, about 0.015 inches.
  • In some embodiments, the catheter lumen can have an inner diameter of between about 0.010 inches and about 0.080 inches, between about 0.015 inches and about 0.070 inches, between about 0.020 inches and about 0.060 inches, between about 0.025 inches and about 0.050 inches, or between about 0.030 inches and about 0.040 inches.
  • Further, the catheter can have an outer diameter of between about 0.020 inches and about 0.160 inches, between about 0.030 inches and about 0.140 inches, between about 0.040 inches and about 0.120 inches, between about 0.050 inches and about 0.100 inches, or between about 0.060 inches and about 0.080 inches. In some embodiments, the catheter outer diameter is about 3 Fr, 4 Fr, 5 Fr, 6 Fr, 7 Fr, 8 Fr, 9 Fr, 10 Fr, 11 Fr, or 12 Fr.
  • Thus, the slot depth can be configured such that the proximal end portion can be inserted into the slot and a sufficient width of the proximal end portion can be received within the slot to allow the aperture to be accessible to the engagement component extending within the catheter lumen.
  • Furthermore, although FIGS. 6C-6E illustrate embodiments of a single slot, the catheter can be configured to comprise two or more slots that can be used to couple the support component thereto. One or both of the two or more slots be configured such as the slots illustrated by elements 539, 539 a, 539 b, or 539 c. Thus, the two or more slots can be identical or different in size, shape, or orientation. Further, the catheter can comprise a single or dual lumen structure. According to some embodiments, the slot structures and embodiments illustrated in FIG. 6C-6E can be particularly advantageous for tending to reduce and/or eliminate leakage through the slots of a single lumen catheter structure.
  • For any embodiment of the assembly and/or implant disclosed herein, the slot width, slot depth, catheter lumen inner diameter, catheter lumen inner diameter, engagement component diameter, aperture diameter, proximal end portion width, and proximal end portion thickness can be configured within any of the ranges disclosed herein.
  • In some embodiments, a portion of the catheter can be configured to move beyond or through the distal portion of the implant in order to precisely deliver a material into the lumen downstream of the implant. The implant distal portion (e.g., a valve component of the implant) and the catheter distal tip can have a close fit, thus allowing material to be injected into the lumen while avoiding dispersion or diffusion of the material upstream of the implant. For example, in some embodiments, the implant proximal portion can be maintained engaged with the catheter while the implant distal portion is allowed to expand into contact with the vessel wall. The expansion of the implant distal portion can cause the implant to foreshorten and thus cause the distal portion of the catheter to move beyond or through the distal portion of the implant, whereafter material can be injected into the lumen, thus avoiding dispersion or diffusion of the material upstream of the implant.
  • However, in some embodiments, the implant distal portion can be maintained engaged with the catheter while the implant proximal portion is allowed to expand into contact with the vessel wall, whereafter material can be injected into the lumen, thus avoiding dispersion or diffusion of the material upstream of the implant.
  • According to some embodiments, while a proximal or distal portion of the implant is initially expanded with the other portion being maintained engaged with the catheter, or after both portions of the implant are expanded and released from the catheter, the catheter can be urged distally relative to the implant distal portion such that the catheter distal tip extends beyond or through the implant distal portion.
  • In any of such embodiments, the deployment handle and its pull member(s) can be interconnected with the engagement component(s) to allow desired actuation of the assembly and implant. When two pull members are used, the proximal pull member can be interconnected with the engagement component that controls release of either the distal or proximal implant portion. Accordingly, some embodiments disclosed herein can allow a clinician to target specific regions and precisely control the flow and dispersion of the material.
  • Referring now to FIGS. 7A-12B, various embodiments of the implant 520 are illustrated in which the implant 520 comprises different valve components.
  • FIGS. 7A-7B illustrate an implant 520 a having a valve component 542 a that comprises a flap structure 550 a. The flap structure 550 a can extend distally from the implant 520 a. The flap structure 550 a can comprise one or more sections of material of a cover member 544 a. In some embodiments, the flap structure 550 a can comprise at least an outer layer of the cover member 544 a. For example, the cover member 544 a can comprise inner and outer sections 545 a, 545 b. The inner and outer sections 545 a, 545 b can at least partially envelop, enclose, or cover the support component 540.
  • In some embodiments, the cover member 544 a can comprise a tubular membrane that is everted or inverted such that the outer section 545 b extends along an exterior of the support component 540 and the inner section 545 a extends along an interior of the support component 540. The cover member 544 a can be unitarily formed as an uncut, continuous tube or can comprise one or more longitudinal cuts or breaks such that the inner or outer sections 545 a, 545 b comprise one or more strips of material. The cover member 544 a and/or the implant 520 a can comprise additional features such as those disclosed in co-pending U.S. patent application Ser. No. 14/044,794, filed Oct. 2, 2013, the entirety of which is incorporated herein by reference.
  • As illustrated in FIG. 7A, in some embodiments, the inner section 545 a can comprise one or more strips of material that can be secured to the distal end portion of the outer section 545 b using a mechanical, thermal, or chemical coupling. For example, a suture, adhesive, or tie coupling 547 can be used to couple a strip of the inner section 545 a with the distal end portion of the outer section 545 b. In some embodiments, the flap structure 550 a can comprise the coupling 547; however, the coupling 547 can also be omitted from the flap structure 550 a and implant 520 a.
  • In some embodiments, such as that illustrated in FIGS. 7A-7B, the coupling 547 can secure only a portion of the inner or outer sections 545 a, 545 b to each other. However, in some embodiments, the entire inner section 545 a can be secured to the entire outer section 545 b. As shown in FIG. 7B, a distal portion 548 a of the implant 520 a can be released (using the engagement component 546 a) while a proximal portion 549 a is maintained in engagement (using the engagement component 546 b). As the distal portion 548 a expands and the implant 520 a foreshortens, the coupling 547 can be drawn proximally. At this point, in some embodiments of the methods or procedures disclosed herein, a material (e.g., embolic material, contrast agents, or drugs) can be passed through a delivery lumen 570 of the catheter 510 (shown by arrows 571) into downstream vasculature 559 of the vessel 561 (see FIGS. 7C-7D). However, the material can also be delivered after the proximal portion 549 a has been released. For example, the distal tip 564 of the catheter 510 can then move distally beyond the distal portion 548 a of the implant 520 a to provide a clear outflow pathway for material injected through the catheter 510.
  • The catheter can comprise a single or dual lumen structure in combination with any of the embodiments disclosed herein. FIGS. 7A-7B and 8A-8C illustrate a single lumen structure while FIGS. 9A-10B illustrate a dual lumen structure.
  • FIGS. 7C-7D illustrate the release, closing, and sealing of the valve component 542 a in a lumen 561. These figures illustrate that the distal portions of the inner and outer sections 545 a, 545 b can be coupled together or closed on top of each other. For example, in some embodiments, the inner and outer sections 545 a, 545 b can be closed using an adhesive material, which can be injected through the delivery lumen 570 of the catheter 510. Applicant has found that such embodiments can advantageously provide a simple construction and at least a partially or fully complete seal to be achieved by adhering the inner and outer sections 545 a, 545 b to each other. FIG. 7C illustrates an initial reflux or vacillation of the distal portions of the inner and outer sections 545 a, 545 b. During the back-and-forth movement represented in FIG. 7C, the distal portions can tend to adhere to each other until being coupled to each other to close the lumen 561, thereby preventing flow therethrough, as shown in FIG. 7D. Thereafter, the implant 520 a can at least partially or fully occlude the lumen 561.
  • In some embodiments, the procedure for expanding the cover component and support component of the implant can be modified such that the cover component expands into contact with the body lumen wall before the support component begins expanding. For example, the cover component can be inflated by flushing the cover component with saline or other material prior to releasing or permitting expansion of an end of the support component. This inflating step can be performed in operating any of the implants that have a substantially closed end prior to expansion of the support component, which can permit an increase in fluid pressure within the cover component sufficient to inflate the cover component (see e.g., FIGS. 9A, 10A, 11A, and 12A that have valve components in a substantially closed position prior to support component expansion; but see e.g., FIG. 7A that has an open end formed by loose ends of the cover component). Further, as the cover component is inflated, the valve component of the cover component can draw closer to the distal end of the catheter, which can provide various advantages and permit operation of the valve component using the distal end of the catheter, according to some embodiments.
  • Further, in some embodiments, the valve component can satisfy to seemingly opposite goals: (1) to provide eventual occlusion of the vessel and prevent or reduce reflux of material into a proximal portion of the vessel, and (2) to provide a secondary opportunity to return at a later time to provide a further treatment of the vessel without removing, destroying, or otherwise damaging the valve component.
  • For example, in some embodiments, the valve component can comprise a mesh or fibrous material. FIGS. 8A-8D illustrate an implant 520 b in a collapsed and expanded configurations. In FIG. 8A, the implant 520 b comprises a cover member 544 b that at least partially encloses, envelops, or covers the support frame 540. The implant 520 b can comprise distal and proximal portions 548 b, 549 b. The implant 520 b can also comprise a mesh portion 550 b that is coupled to the distal portion 548 b of the implant 520 b.
  • The mesh portion 550 b can comprise a plurality of filaments, woven ePTFE strips or sutures, or other porous, biocompatible materials. The mesh portion 550 b can be coupled to the distal portion 548 b, such as by being coupled to the distal portion of the cover member 544 b. As illustrated in FIGS. 8A-8D, the mesh portion 550 b can comprise a layer of material that is coupled to an outer surface of the cover member 544 b along a distal portion of the cover member 544 b. The mesh portion 550 b can be secured relative to the cover member 544 b using mechanical, thermal, or chemical bonding, such as adhesives. In some embodiments, a frictional engagement can secure the mesh structure 550 b relative to the cover member 544 b. For example, when the implant 520 b is expanded into contact with the vessel wall, the mesh portion 550 b can be secured relative to the implant 520 b and support structure 540 by virtue of radial compressive force and frictional engagement against the vessel wall and the outer surface of the cover member 544 b.
  • The mesh portion 550 b can also be formed with the cover member 544 b from a single, continuous piece of material. For example, in some embodiments, the mesh portion 550 b can be formed as a tubular body having an open end and a closed end, opposite the open end, that comprises a plurality of pores, cells, apertures, perforations, incisions, windows, or other cuts to provide a substantially mesh-type closed end.
  • Thus, in some embodiments, the cover member 544 b can also be configured as a material having a closed mesh end. In order to manufacture some embodiments of an implant, the tubular mesh body can be moved onto the distal portion of the catheter 510, with the catheter 510 entering the open end of the tubular body. The support component 540 can then be positioned over a distal section of the tubular body and coupled relative to the catheter 510. Further, a proximal section of the tubular body, extending proximally of the support component 540, can thereafter be everted over the support component 540 to at least partially cover the support component 540. In some embodiments, the proximal section can be at least partially coupled to a corresponding portion of the distal section of the tubular body or mesh portion. Further, in some embodiments, the proximal section of the tubular body can extend fully distally of the support component 540.
  • In use, the mesh portion 550 b can effectively protect against or tend to block proximal migration or reflux of material ejected into the downstream vasculature 559 of the vessel 561. For example, although the mesh portion 550 b can be sufficiently porous (e.g., have an average pore size) that is greater than the size of particles of a material passing therethrough, thrombosis and/or the use of materials, such as glues, can tend to close the size of the pores of the mesh portion 550 b. Accordingly, after the particles of the material have passed through the mesh portion 550 b, the mesh portion 550 b can tend to prevent proximal migration or reflux. The mesh portion 550 b can thereby provide at least partial or full occlusion of the vessel 561.
  • Additionally, as similarly discussed further below with regard to FIGS. 23A-24B, the embodiment shown in FIGS. 8A-8D can allow a secondary operation to be performed, such as to deposit additional material into the downstream vasculature 559, by dissolving the clotted material on the mesh portion 550 b. The mesh portion 550 b can be cleared such that additional material can be passed therethrough during the second operation. For example, after the implant has been placed and has occluded the vessel, the mesh portion 550 b can be cleared and flow through the implant can be restored by injecting a material, fluid, or saline through the mesh portion 550 b. A catheter can be advanced until a distal end of the catheter is positioned adjacent to the mesh portion 550 b. Thereafter, a material, fluid, or saline can be ejected from the distal end of the catheter against the mesh portion 550 b. This ejection can serve to clear the thrombosed material mesh portion 550 b.
  • Accordingly, in some embodiments, the clinician can clear or unblock the mesh portion 550 b to deposit further material in the target region in a second procedure without puncturing, piercing, or otherwise damaging the implant 520 b. After clearing the mesh portion 550 b, the clinician can inject additional material to the target region.
  • Additionally, in some embodiments, the clinician may elect to place a second implant at the site of the first implant (see e.g., FIGS. 24A-24B) without puncturing, piercing, or otherwise damaging the implant 520 b.
  • Referring now to FIGS. 8B-8C, the cover member 544 b of the implant 520 b can be initially expanded by introducing fluid or material 571 through the catheter lumen 570 into an interior chamber 573 formed between a layer of the cover member 544 b positioned against the catheter 510 and a layer of the cover member 544 b surrounding the support component 540. Accordingly, the cover component 544 b can be inflated by flushing the cover component 544 b prior to releasing or permitting expansion of the support component 540. The substantially closed end formed by the mesh portion 550 b can allow an increase in fluid pressure within the interior chamber 573 sufficient to inflate the cover component 544 b until the cover component 544 b comes in contact with a vessel wall 561.
  • According to some embodiments, the mesh portion 550 b can be configured to block or restrict flow therethrough when the fluid pressure is less than 240 mm Hg or 5 pounds per square inch (“psi”). However, for fluid pressures above 5 psi, the mesh portion 550 b can expand or deflect such that the plurality of pores, cells, apertures, perforations, incisions, windows, or other cuts opens to permit flow through the mesh portion 550 b.
  • For example, in some embodiments, a fluid or material 571 can be injected through the catheter lumen 570 and into the interior chamber 573 such that the fluid or material 571 in the interior chamber 573 is at a pressure greater than 5 psi, such as between about 10 psi and about 200 psi, between about 40 psi and about 180 psi, or between about 70 psi and about 140 psi. The delivery pressure can be varied by using certain delivery mechanisms. For example, using a 5 mL syringe, the fluid or material can be delivered at between about 80 psi and about 100 psi. Further, using a 3 mL syringe, the fluid or material can be delivered at between about 120 psi and about 140 psi. Furthermore, using a 1 mL syringe, the fluid or material can be delivered at about 200 psi.
  • At such high fluid delivery pressures, the mesh portion 550 b can permit passage of the material 571 (shown in FIGS. 8B-8D as an embolic material) to the downstream portion 559 of the vessel when injected through the catheter lumen 570. However, in some embodiments, after the implant 520 b is released into the vessel 561 (see e.g., FIG. 8D), even under severely elevated systolic pressure (e.g., above 240 mm Hg or about 4.6 psi), the mesh portion 550 b can be configured to block or restrict flow through the mesh portion 550 b. Further, in some embodiments, a glue or embolic material can be injected and can tend to occlude the pores, cells, apertures, perforations, incisions, windows, or other cuts of the mesh portion 550 b, thus sealing the mesh portion 550 b. The “seal” of the mesh portion 550 b can be reversible, as discussed above.
  • In some embodiments, the mesh portion 550 b can also be configured such that the pores, cells, apertures, perforations, incisions, windows, or other cuts of the mesh portion 550 b define an open configuration and a closed configuration. The open configuration can be achieved when the cover member 544 b is in a generally unexpanded configuration, as illustrated in FIG. 8A. When in the unexpanded configuration, material 571 can be passed through the mesh portion 550 b. However, when a sufficient amount of material 571 has been deposited into the downstream vasculature 559 through the mesh portion 550 b, the support component 540 can be expanded, thus causing expansion of the mesh portion 550 b and, in some embodiments, shrinking of the pores, cells, apertures, perforations, incisions, windows, or other cuts of the mesh portion 550 b. Thereafter, when a glue or embolic material is used, the glue or embolic material can act to further close or seal the pores, cells, apertures, perforations, incisions, windows, or other cuts of the mesh portion 550 b. The “seal” of the mesh portion 550 b can be reversible, as discussed above.
  • FIG. 9A-10B illustrate embodiments of an implant 520 c being delivered using different catheters, which can provide unique benefits and advantages. FIGS. 9A and 10A, illustrate an implant 520 c having a valve component 542 c that comprises a flap structure 550 c. The flap structure 550 c can comprise a flat plate that is attached to a distal end 560 of the cover member 544 c or to a distal end of the support component 540. The flap structure 550 c can be resiliently biased toward a closed position (as shown in FIGS. 9A and 10A) in which the flap structure 550 c covers an aperture 562 of the implant 520 c.
  • However, upon expansion of the implant 520 c (illustrated as expansion of a distal portion 548 c of the implant 520 c in FIGS. 9B and 10B), proximal foreshortening of the implant 520 c can cause a distal tip 564 of the catheter 510, 510′ to be advanced distally relative to the implant distal portion 548 c, thus contacting against the flap structure 550 c. When the distal tip 564 presses against the flap structure 550 c, the flap structure 550 c will tend to deflect from the closed position, thus opening the lumen of the implant 520 c such that it is in fluid communication with the lumen of the vessel into which the implant 520 c is being deployed. The distal tip 564, 564′ of the catheter 510, 510′ can then move distally beyond the distal portion 548 c of the implant 520 c, and as shown, have a clear outflow pathway for material injected through the catheter 510, 510′.
  • Further, the catheter 510, 510′ can comprise a material delivery lumen 570 through which material can be passed toward the target region. The catheter 510 can also comprise a distal port 572, 572′ in communication with the lumen 570. As noted above, when the catheter distal tip 564, 564′ moves distally beyond the distal portion 548 c of the implant 520 c, the port 572, 572′ will provide a clear outflow pathway for material injected through the lumen 570. The port 572, 572′ can therefore be moved into a position in which it is in unobstructed, fluid communication with the target region, as illustrated in FIGS. 9B and 10B. Accordingly, material can then be delivered through the lumen 570 and out through the port 572, 572′ into the target region. The lumen 570 can also be used to flush the implant or pass other fluids through the implant or toward a downstream section of the blood vessel.
  • FIGS. 9A-9B illustrate that the distal tip 564 of the catheter 510 can comprise a generally flat face that is oriented substantially orthogonal relative to the longitudinal axis of the catheter 510. In such embodiments, the distal tip 564 can be moved relative to the distal portion 548 c of the implant 520 c until the flap structure 550 c is moved away from the closed position shown in FIG. 9A toward the open position shown in FIG. 9B, thereby allowing the port 572 to have a clear outflow pathway for material to be ejected from the lumen 570.
  • FIGS. 10A-10B illustrate an embodiment of the distal tip 564 in which the port 572′ is facing generally downward or radially outward relative to the longitudinal axis of the catheter 510′. Such embodiments can provide an advantageous beveled or angled configuration, which may need to move the flap structure 550 c only a short length or make a single point of contact in order to achieve a clear outflow pathway for the material to be ejected from the lumen 570. According to some embodiments, the bevel of the catheter 510′ can be modified such that the catheter 510′ defines a generally conical tip or the bevel can be removed entirely such that the distal tip 564 is generally flat, as illustrated in FIGS. 7A-7B, 9A-9B, and 11A-12B.
  • After the desired saturation or amount of embolic material been released, the implant 520 c can be entirely removed from the vessel or implanted at the target region. For example, a proximal portion 549 c of the implant 520 c can be released and allowed to expand into apposition with the vessel wall. Thus, in accordance with some procedures, material can be released into the target region and flow through the vessel can be occluded using the implant 520 c, thereby inducing infarction of the target region.
  • FIGS. 11A-12B illustrate additional embodiments of an implant 520 c having a valve component 542 d and movement of the catheter distal end 564 distally beyond the implant distal end. For example, FIGS. 11A-11B illustrate a dome-shaped valve component 542 d. The dome-shaped valve component 542 d can comprise a pair of opposing, flexible half-dome structures 580 that can be biased toward each other such that a slit or gap between the structures 580 is in a substantially closed position.
  • Similar to the discussion above regarding the embodiment in FIG. 9A-9B, the distal end 564 of the catheter 510 can be urged or moved through the aperture 562 of the implant 520 d, thus contacting the structures 580 and causing separation thereof, such that the gap or slit between the structures 580 is opened and the lumen 570 of the catheter 510 is placed in fluid communication with the target region, as shown in FIG. 11B.
  • Additionally, FIGS. 12A-12B illustrate an embodiment of an implant 520 e having a valve component 542 e, in the form of an iris diaphragm-type valve structure. The valve component 542 e can comprise a plurality of flexible leaflets or structures 590 that can be biased toward each other such that an aperture 592 between the structures 590 is in a substantially closed position.
  • Similar to the discussion above regarding the embodiment in FIG. 9A-11B, the distal end 564 of the catheter 510 can be urged or moved through the aperture 562 of the implant 520 d, thus contacting the structures 590 and causing separation thereof, such that the aperture 592 between the structures 590 is opened and the lumen 570 of the catheter 510 is placed in fluid communication with the target region, as shown in FIG. 12B.
  • In addition to the embodiments discussed above, which can be carried on a distal engagement section of the catheter, other embodiments can be provided in which the implant is delivered by distally advancing the implant through a lumen of the catheter. Thus, instead of engaging the implant externally to the catheter, the implant can be advanced internally to the catheter, such as by pushing or pulling the implant through the lumen. In some embodiments, support and valve components of the implant can be collapsed into an elongate position and released into an expanded position within the vessel. Features and aspects of the implants, including the support component and the valve component, are also disclosed in co-pending U.S. Application No. 61/904,376, filed Nov. 14, 2013, titled Implantable Luminal Devices and Methods (086538-0041), the entirety of which is incorporated herein by reference. Further, any of the valve components disclosed herein (see e.g., FIGS. 7A-16B) can be used with a helical support component that can be coupled to a catheter (as shown in FIGS. 3-12B) or a deflectable support component that can be at advanced within a catheter (as shown in FIGS. 13-16B), including any combinations or modifications thereof.
  • For example, referring to FIGS. 13-14A, the implant can be delivered through a lumen of the catheter. As shown, a catheter 610 can be provided that comprises a lumen 612 configured to receive the implant 620 therein. The implant 620 can comprise a support component 622 and a cover component 624. FIG. 13 illustrates the implant 620 in a collapsed, elongated configuration, which enables the implant 620 to be moved within the catheter lumen 612.
  • The support component 622 and the cover component 624 can be attached to each other or be separated and freely movable relative to each other. Whether attached or separated, the support and cover components 622, 624 can be configured to be advanced through the catheter lumen 612 together, as a single unit. For example, FIG. 13 also illustrates that, according to some embodiments, the support component 620 can be at least partially enclosed, enveloped, or covered by the cover component 624 such that the support component 622 and the cover component 624 can be attached to each other and delivered together (and as shown in FIG. 14A, released into the vessel together).
  • However, according to some embodiments, the support and cover component 622, 624 can be separated from each other and moved through the catheter lumen 612 independently of each other. For example, the implant 620 can also be configured such that the support component 622 is deployed into the cover component 624 after the cover component 624 has been positioned within the vessel.
  • Once the implant 620 reaches the target area, FIG. 14A illustrates that the implant 620 can be expanded from the collapsed configuration to an expanded configuration. In the expanded configuration, the support component 622 of the implant 620 can increase in its diameter, expanding within the cover component 624. In either embodiment, whether the support component 622 and the cover component 624 are attached to each other or separated and freely movable relative to each other, when the support component 622 expands, the support component 622 can press the cover component 624 against a side wall of the lumen and thereby fix the cover component 624 (and the implant 620) within the lumen.
  • The cover component 624 can comprise a valve component 626 and a sheath portion 628. The valve component 626 and the sheath portion 628 can form a substantially continuous sleeve or layer (e.g., having a seal between the valve component 626 and the sheath portion 628 such that fluid passes only through an aperture or opening of the valve component 626) into which the support component 622 can expand. The aperture or opening can have a size between about 100 microns and about 3,000 microns, about 500 microns and about 2,800 microns, or about 1,000 microns and about 2,500 microns. The sheath portion 628 can be porous, nonporous, and/or comprise one or more portions that are nonporous, such as impermeable graft or other such sections.
  • Additionally, as illustrated above and in FIG. 13, as with various embodiments discussed herein, the support component 622 having dual wire loop features can be held in a generally linear or straight configuration within a lumen 612 of a catheter 610. The loops 630 (shown in the expanded configuration illustrated in FIG. 14A) of the support component 622 can be pulled or longitudinally stretched to create tension between open loops 630 to allow the support component 622, when deployed, to spring back to or return to an expanded shape consisting of various expanded loops 630, as illustrated in FIG. 14A, as the support component 622 exits from a distal end 632 of the catheter 610.
  • The support component 622 of the implant 620 can be configured as illustrated in FIGS. 13-16B, and as shown and described in co-pending U.S. Application No. 61/835,406, filed Jun. 14, 2013, titled Implantable Luminal Devices and Methods (086538-0032), the entirety of which is incorporated herein by reference. Further, various other configurations can be used, such as those disclosed in co-pending U.S. Application No. 61/904,376, filed Nov. 14, 2013, titled Implantable Luminal Devices and Methods (086538-0041). Accordingly, support component can comprise separate wires that are preset into shapes that are generally mirror images of each other along a longitudinal center plane (extending through the central axis) of the support component, as illustrated in FIGS. 13-14A. The wires extend from a first end to a second and of the support component and can be joined or connected together, either mechanically or chemically, to form the support component.
  • FIGS. 12-16B illustrate embodiments of implants having a support component and a valve component, which can be delivered by advancing the implant within the lumen of the catheter as opposed to being supported, engaged, or restrained along an exterior surface of the catheter.
  • FIGS. 14B-14C illustrate an implant 650 having a support component 652, a valve component 654 a, and a cover component 656. The support component 652 can be configured as illustrated and described above with respect to the support component 622 shown in FIGS. 13-14B. The valve component 654 a can comprise a movable component 660 that can be attached to a first end 662 of the support component 652. The movable component 660 can be movable between an open position 670 and a closed position 672. In the open position 670, the movable component 660 can be spaced apart from the first end 662 of the support component 652 such that fluid can flow between the first end 662 and an outer perimeter 674 of the movable component 660. In the closed position 672, the valve component 654 a can serve to prevent retrograde (and in some embodiments, anterograde flow) through the valve component 654 a. Such embodiments can be useful to prevent displacement of embolic material outside of the target region, such as into upstream portions of the vessel, or undesired dilution of the embolic material in the target region.
  • In accordance with some embodiments, the movable component 660 can be moved relative to the first end 662 in response to pressure or a longitudinal force exerted against the movable component 660. For example, the movable component 660 can move away from the support component 652 (e.g., from the closed position 672 toward the open position 674 shown in FIG. 14B). The movable component 660 can be biased toward the closed position 672 such that the movable component 660 returns to the closed position 672 after being urged toward the open position 674. In the closed position 672, the movable component 660 can prevent retrograde flow through the valve component 654 a.
  • For example, the movable component 660 may move toward and away from the nonmovable component 682. With blood flow entering the opening 684 in the nonmovable component 682, the smaller, movable component 660 can separate from the nonmovable component 682, thus creating a space for blood to pass. At a pressure less than a normal systolic pressure (e.g., less than about 120 mm Hg, less than about 110 mm Hg, less than about 100 mm Hg, less than about 90 mm Hg, or less than about 80 mm Hg), the movable component 660 can return or fall back against at least the nonmovable component 682, thus at least partially closing the opening 684 or sealing against retrograde or backflow through the vessel.
  • The movable component 660 can be coupled relative to the first end 662. For example, the movable component 660 can be attached using at least one fastener 680. The fastener 680 can be elastic, resilient, flexible, or inelastic. The fastener 680 can comprise at least one hinge-type fastener, a strap-type fastener, and/or material having one or more apertures extending therethrough such that fluid or material can pass out of the first end 662 of the implant 650 past the movable component 660 when the movable component 660 is in the open position 670. Thus, as illustrated in FIG. 14B, the movable component 660 can be attached using a plurality of fasteners 680 (shown as flexible strap-type fasteners) that permit anterograde flow out of the implant 650 past the movable component 660. The movable and/or nonmovable components 660, 682 can be connected by bands, strips, or ribbons so that the movable component 660 may move to and from the nonmovable component 682 freely.
  • According to some embodiments, the valve component 654 a can also comprise a nonmovable component 682. The nonmovable component 682 can be attached to the support component 652. The nonmovable component 682 can comprise a material formed separately from and later attached to the support component 652. The nonmovable component 682 can comprise a plate, three-dimensional structure, a wire, or other feature that is attached to, dried onto, or otherwise coupled to the support component 652. For example, the nonmovable component 682 can be coupled to the distal end 662 of the support component 652 such that the nonmovable component 682 does not move longitudinally relative to the support component 652. In some embodiments, the nonmovable component 682 can be fixed relative to the support component 652.
  • The nonmovable component 682 can comprise at least one opening 684 through which fluid or material passing through the lumen of the implant 650 can flow and exit the lumen of the implant 650. The opening 684 can comprise one or more apertures that are formed in the nonmovable component 682. The movable component 660 can have a size greater than the size of the opening 684 such that when positioned over the opening 684, the movable component 660 can block flow through the opening 684.
  • In some embodiments, the nonmovable component 682 and the movable component 660 can be configured to nest, mate, or be positioned flush against each other when the valve component 654 a is in the closed position. In such embodiments, the nested, mated, or flush positioning of the nonmovable and movable components 682, 660 can allow the valve component 654 a to at least partially obstruct or fully block flow through the valve component 654 a when in the closed position.
  • For example, the nonmovable component 682 and the movable component 660 can each have shapes that correspond to each other and permit the valve component to at least partially obstruct or fully block flow therethrough. In some embodiments, the nonmovable component 682 can have a substantially flat or planar shape and the movable component 660 can also have a substantially flat or planar shape. Such an embodiment as illustrated in FIGS. 14B-14C, where in the closed position of FIG. 14C, backflow against the valve component 654 a would cause the movable component 662 be positioned flush against the nonmovable component 682, thus preventing flow through the opening 684.
  • Further, in some embodiments, the nonmovable component 682 can have a curved or arcuate shape and the movable component 660 can also have a curved or arcuate shape. As illustrated in FIGS. 14A-14C, the movable component 660 can comprise a substantially conical shape. In some embodiments, for example, the nonmovable component 682 can also comprise a substantially conical shape such that the movable and nonmovable components 660, 682 can self-center when in contact with each other or have a self-centering function. Furthermore, in some embodiments, the shape of the nonmovable and movable components 682, 660 can comprise mating components such that the nonmovable and movable components 682, 660 assume a substantially fixed rotational orientation relative to each other when the valve component 654 a is in the closed position (e.g., when the nonmovable and movable components 682, 660 are nested or mated against each other).
  • In some embodiments, the movable and/or nonmovable components 660, 682 can be formed from a film layer, such as a fabric or other polymer (e.g., ePTFE) film that is attached to one or more of the loops of the support component 652. As shown, the nonmovable component 682 can comprise an annular or doughnut-shaped component, and the movable component 660 can comprise a solid round panel that is oversized relative to the opening 684 in the nonmovable component 682.
  • Referring now to FIGS. 15A-15B, another embodiment of a valve component is shown. In this embodiment, a valve component 654 b can be used with the support component 652 and the cover component 656 of the implant 650. As discussed above similarly with regard to the valve component 654 a, the valve component 654 b can function to allow anterograde flow while substantially preventing retrograde flow through the implant 650.
  • In the embodiment illustrated in FIGS. 15A-15B, the valve component 654 b can be configured as a plurality of movable panels 690 that can fold, bend, deflect, or otherwise move from a closed position 692 (FIG. 15A) to an open position 694 (FIG. 15B). For example, the valve component 654 b can comprise a single layer or sheet of material having at least one cut to form at least two moving edges that can be displaced relative to each other in order to form an aperture or opening 696 between the edges. In FIG. 15B, the edges are formed by four intersecting cuts (e.g., intersecting generally perpendicularly), thus forming sixteen movable edges and eight movable panels 690. However, the valve component 654 b can be configured to have two, three, four, five, six, seven, or more panels.
  • The valve component 654 b can comprise an elastic, flexible, or deflectable material that can be biased to maintain the closed position 692 unless a threshold level of pressure is met, such as pressure exceeding a normal systolic pressure (e.g., about 120 mm Hg). Further, the valve component 654 b can move toward the closed position 692 when the pressure is below a normal systolic pressure (e.g., less than about 120 mm Hg, less than about 110 mm Hg, less than about 100 mm Hg, less than about 90 mm Hg, or less than about 80 mm Hg).
  • Further, as shown in FIGS. 16A-16B, a valve component 654 c can also be provided in which the single layer or sheet of material has a three-dimensional shape, such as a dome, cone, pyramid, wedge, or other shapes. In FIGS. 16A-16B, the material of the valve component 654 c has a single cut forming opposing edges 700 that can move relative to each other in order to open or close an aperture 702 of the valve component 654 c in open or closed positions 710, 712. Multiple cuts can also be made in three-dimensionally shaped valve components. Alternatively, the valve component 654 c can be formed from separate hemispherical components that are aligned and attached to the support component 652 in order to permit relative movement between the hemispherical components to open or close the aperture 702 in response to pressure fluctuations. Such components can be deflectable or rigid.
  • In some embodiments, the edges 700 of the aperture 702 can comprise a frame element. Both of the edges 700 can have a frame element extending therealong. The frame element can function to maintain an arcuate shape of the edges 700 such that the edges 700 can reliably meet and avoid gapping or spaces therebetween when the edges 700 meet in the closed position (as shown in FIG. 16A). In some embodiments, the frame element(s) can be a section of the support component 652 that extends from the loop of the first end 662 of the support component 652. Thus, in accordance with some embodiments, the frame element(s) can aid, support, or provide the biasing force to urge the opposing edges 700 toward the closed position 710.
  • As noted above with respect to the valve components 654 a, 654 b, the valve component 654 c can also comprise an elastic, flexible, or deflectable material that can be biased to maintain the closed position 710 unless a threshold level of pressure is met, such as pressure exceeding a normal systolic pressure (e.g., about 120 mm Hg). Further, the valve component 654 c can move toward the closed position 710 when the pressure is below a normal systolic pressure (e.g., less than about 120 mm Hg, less than about 110 mm Hg, less than about 100 mm Hg, less than about 90 mm Hg, or less than about 80 mm Hg).
  • Methods of Material Delivery
  • According to some embodiments disclosed herein, procedures, techniques, and implants are provided by which an implant can be deployed into a body lumen in order to deliver a material (e.g., embolic material, contrast agents, or drugs) to a target body region.
  • In some embodiments, the procedure can be performed such that one or more implants is fully expanded into contact with the lumen and released thereat in order to at least partially occlude flow through the lumen. Thereafter, the material can be injected through an aperture or valve of the implant into the lumen at a location downstream of the implant.
  • In addition, the implant can be left in place to at least partially occlude the lumen after the material has been delivered. In some instances, the implant can fully or at least substantially occlude the lumen immediately after its release into the lumen. In order to do so, the aperture or valve of the implant is closed.
  • The valve component of the implant can be configured to become at least partially closed once the catheter carrying the implant is withdrawn and the implant is fully released into the lumen. For example, the valve component can be at least partially closed or sealed to at least a frame of the implant, thereby at least partially closing or sealing the implant distal portion. The valve component can be closed or sealed using embolic material, adhesives, or other such materials.
  • In some embodiments, as discussed above, a portion of the catheter can be configured to move beyond or through the distal portion of the implant or have a close fit with the implant in order to precisely deliver a material into the lumen downstream of the implant and avoid dispersion or diffusion of the material upstream of the implant.
  • For example, the implant proximal portion can be maintained engaged with the catheter while the implant distal portion is allowed to expand into contact with the vessel wall (see e.g., FIGS. 17A-17D, 19A-19C, and 20A-20D). In some embodiments, the expansion of the implant distal portion can cause the implant to foreshorten and thus cause the distal portion of the catheter to move beyond or through the distal portion of the implant. Further, in some embodiments, the catheter may not move beyond or through the distal portion of the implant, but the implant distal portion can be open thereby permitting free flow of material from the catheter distal tip (see e.g., the implant illustrated in FIGS. 7A-7D). Thereafter, material can be injected into the lumen, thus avoiding dispersion or diffusion of the material upstream of the implant.
  • However, in some embodiments, the implant distal portion can be maintained engaged with the catheter while the implant proximal portion is allowed to expand into contact with the vessel wall (see e.g., FIGS. 18A-18D), whereafter material can be injected into the lumen, thus avoiding dispersion or diffusion of the material upstream of the implant.
  • Reflux of material against the implant (e.g., embolic or adhesive material) can cause at least a portion of the implant to become closed (see e.g., FIGS. 7C-7D). The implant can use a polytetrafluoroethylene (“PTFE”) or expanded polytetrafluoroethylene (“ePTFE”) cover member that has a plurality of ribbons extending distally and around an aperture in the distal portion of the implant. Although the ribbons will not tend to block anterograde flow through the aperture, reflux or retrograde flow of the embolic material can cause the ribbons to contact each other, adhere to one another, and become joined together as a mass that clogs and blocks the distal aperture of the implant, thereby closing or sealing the implant, as shown in FIG. 7D, for example. Such an implant configuration is discussed in co-pending U.S. patent application Ser. No. 14/044,794, filed Oct. 2, 2013, the entirety of which is incorporated herein by reference.
  • Further, the valve component can be closed mechanically, such as by being biased toward a closed position. Mechanical biasing can cause the valve component to be released and move toward its closed position once the implant is released and disengaged from by the catheter.
  • Referring initially to FIGS. 17A-20D, a clinician can use an embodiment of the implant disclosed herein (illustrated as the implant shown in FIGS. 7A-7D) to deposit embolic particles into a target body region. As shown in FIGS. 17A, 18A, and 20A, a guide catheter 760 can be advanced to a target region of a lumen 752 of a blood vessel 750. The vessel 750 can be an artery. Optionally, the guide catheter 760 can be advanced to the target region over a guidewire. Guidewires used in accordance with any of the embodiments disclosed herein can have a size of between about 0.005 inches and about 0.030 inches, between about 0.008 inches and about 0.024 inches, or between about 0.010 inches and about 0.018 inches, such as 0.010 inches, 0.014 inches, or 0.018 inches.
  • An implant carrier assembly 762 can be advanced to the target region. In some embodiments, the implant carrier assembly 762 can be advanced through the catheter 760 toward a distal portion of the catheter 760, as shown in FIGS. 17A, 18A, and 20A. However, in some embodiments, the catheter 760 can also be omitted and the implant carrier assembly 762 can be advanced to the target region over a guidewire, such as that mentioned above.
  • For example, FIGS. 19A-19C illustrate that methods or procedures disclosed herein can also omit the guide catheter 760. As shown, the implant carrier assembly 762 can be advanced along a guidewire 767 until reaching the target region. A supporting catheter 764 of the carrier assembly 762 can comprise a lumen that is configured to receive the guidewire 767 to facilitate distal advancement without a guide catheter or other member. Thus, in such embodiments, the supporting catheter 764 and an implant 766 carried thereon can reach much smaller vessels or arteries than in embodiments that require a guide catheter 760.
  • Thus, in some embodiments, including that illustrated in FIGS. 19A-19C, the implant 766 can be placed in vessels or arteries ranging in size from about 1.2 mm to about 6.5 mm, from about 1.4 mm to about 6.0 mm, and about 1.7 mm to about 3.0 mm.
  • The implant 766 and the supporting catheter 764 can have a passing profile or outer diameter of between about 3 Fr and about 8 Fr, or that can be compatible with a guide catheter having a size of between about 3 Fr and about 12 Fr. Further, as similarly noted above, the guidewire 767 can have a size of between about 0.005 inches and about 0.030 inches, between about 0.008 inches and about 0.024 inches, or between about 0.010 inches and about 0.018 inches, such as 0.010 inches, 0.014 inches, or 0.018 inches.
  • When used, as shown in FIGS. 17A, 18A, and 20A, the guide catheter 760 can be proximally withdrawn from the vessel 750, as shown in FIGS. 17B, 18B, and 20B. Thus, the implant carrier assembly 762 can be positioned at the target region whether by use of a catheter 760 or not, as shown in FIGS. 17B, 18B, 19A, and 20B.
  • Next, referring to FIGS. 17C, 18C, 19B, and 20C, using the deployment handle or actuation mechanism, the clinician can expand a first or second portion (or both) of the implant 766 in order to at least partially or fully occlude flow past the implant 766 into a downstream section 770 of the lumen 752. The deployment handle can be configured such as those disclosed herein and/or in co-pending U.S. patent application Ser. No. 14/044,794, filed Oct. 2, 2013, the entirety of which is incorporated herein by reference. This blockage of downstream flow through the vessel can make possible a highly targeted and concentrated delivery of material to a target region, avoiding dilution of the material in the downstream section 770 or reflux of the material 768 into an upstream region 772 of the vessel 750.
  • For example, in some embodiments, such as that illustrated in FIG. 17C, 18B, and 19C, the clinician can expand a distal portion 780 of the implant 766 while maintaining a proximal portion 782 of the implant 766 in a closed state. Thus, the distal portion 780 can expand into apposition with a wall of the vessel 750, thereby occluding, substantially or fully, flow through the vessel to the downstream section 770 of the lumen 752. Accordingly, the downstream section 770 of the lumen 752 can be isolated from the upstream section 772 of the lumen 752. This occlusion or isolation can enable the clinician to provide a more targeted delivery of material 768 to a target region and avoid dilution of the material 768 in the downstream section 770 or reflux of the material 768 into an upstream region 772 of the vessel 750.
  • Further, in some embodiments, such as that illustrated in FIG. 18C, the clinician can expand the proximal portion 782 of the implant 766 while maintaining the distal portion 780 of the implant 766 in a closed state. Thus, the proximal portion 782 can expand into apposition with a wall of the vessel 750, thereby occluding, substantially or fully, flow through the vessel to the downstream section 770 of the lumen 752. A flushing port, such as that illustrated in the embodiments of FIGS. 1 and 2, can be used to inject fluid into the proximal portion 782 in order to facilitate expansion thereof. Once expanded, as with the embodiment illustrated in FIG. 17C, the downstream section 770 of the lumen 752 can be isolated from the upstream section 772 of the lumen 752. This occlusion or isolation can enable the clinician to provide a more targeted delivery of material 768 to a target region and avoid dilution of the material 768 in the downstream section 770 or reflux of the material 768 into an upstream region 772 of the vessel 750.
  • After flow has been at least partially occluded, FIGS. 17C, 18C, 19B, and 20C illustrate that the clinician can release a desired material 768 into the downstream section 770 of the lumen 752. The desired material 768 can comprise an embolic material, such as NBCA glue, liquid embolic agents, a radiopaque material, a radioactive material, drugs or other therapeutic materials. The release of such material 768 into the downstream section 770 of the lumen 752 can be performed until a desired amount or concentration of such material 768 is achieved in the downstream section 770.
  • In some embodiments, after desired material has been delivered and if the implant is to remain in place within the lumen, material immediately adjacent to the valve component of the implant can function to at least partially close or seal the valve component. For example, in embodiments such as those that use the implant illustrated above in FIGS. 7A-7D, an adhesive material can be released at the end of the process in order to allow the implant to self-seal. Further, in embodiments in which the implant is biased toward a closed position (see e.g., the valve component in FIGS. 9A-12B), the material (especially glues or other adhesive-type materials) can facilitate the creation of an at least partially closed or sealed valve that no longer permit flow through and out of the implant to the downstream section of the vessel. Further, the material can tend to facilitate thrombosis or coagulation of blood to further occlude the lumen (see e.g., FIGS. 8A-8B).
  • In some embodiments, the remaining portion of the implant 766 is expanded or released and the catheter 764 can be removed from the vessel 750, as shown in FIGS. 17D, 18D, and 19C. However, in some embodiments, the implant 766 and the catheter 764 can be removed from the vessel 750. For example, FIGS. 20C-20D illustrate that the guide catheter 760 can be maintained adjacent to the implant 766 such that after material has been deployed from the assembly 762, the assembly 762 can be proximally withdrawn into the guide catheter 760. In some embodiments, the guide catheter 760 can be distally advanced over the assembly 762 such that the implant 766 is not moved relative to the blood vessel 750.
  • According to some embodiments, implants can be deployed in lumens having dimensions of between about 2 mm and about 20 mm. The target delivery profile can be about 6 Fr or smaller. For example, the implant assembly can be compatible with a guide catheter having a size of between about 3 Fr and about 12 Fr.
  • According to some embodiments, implants disclosed herein can have a fibrous membrane feature can be used in various clinical applications, as discussed above. According to some embodiments, implants disclosed herein having a fibrous membrane feature can have an expanded diameter of between about 3 mm and about 22 mm.
  • In addition, the methods and procedures discussed above with respect to FIGS. 17A-20D can be implemented in accordance with further aspect shown in FIGS. 21-24B. For procedures that deliver an embolic agent comprising radioactive particles for additional radiological treatment of a tumor, the procedure must precisely deliver the material the target region. Such delivery must be well-controlled delivery and calibrated in order to protect a patient from the unnecessary additional risks that may occur should the material being improperly distributed within other areas of the downstream vasculature.
  • For example, FIG. 21 illustrates an embodiment of a procedure in which a first implant 800 is deployed into a vessel 802 adjacent to a target structure, vasculature, or lesion 804. The target structure 804 can be fed by a series of arteries 806. After placing the first implant 800 in a location downstream of the arteries 806 to prevent flow of a delivered material (e.g., embolic material) to downstream vasculature, an implant assembly 810 can be advanced to a location within the vessel 802 that is proximal to the target arteries 806 and the first implant 800. The implant assembly 810 and the first implant 800 can be spaced apart in close proximity to each other to allow flow to only those target arteries 806 and to shield flow to other unintended areas. For example, the implant assembly 810 and the first implant 800 can be spaced apart in a range of from about 0.1 inches to about 5 inches, about 0.5 inches to about 3 inches, about 0.8 inches to about 2 inches, about 1 inches to about 1.5 inches, or about 1.2 inches to about 1.4 inches. Various ranges of spacing between the implant 800 and the assembly 810 can be achieved to precisely target a region of the vessel 802 and/or select arteries 806.
  • In the illustrated embodiment of FIG. 21, a distal portion of a second implant 820 is expanded into apposition with the walls of the vessel 802 in order to at least partially block anterograde flow to the arteries 806. A material 822 can then be released into the space between the first and second implants 800, 820. The material can thus be concentrated toward the arteries 806, thereby enhancing the efficacy of the delivery. Thereafter, additional steps or procedures can be performed, such as imaging, in order to further treat the vessel 802 or target structure 804.
  • As noted above, the first and/or second implants 800, 820 can be released and left in the vessel 802 in order to provide occlusion of the vessel. However, according to some embodiments, one or both of the first or second implants 800, 820 can be removed from the vessel 802 after the material has been delivered to the arteries 806 and target structure 804. Thus, procedures can be provided that allow temporary occlusion of a blood vessel in order to treat a target structure while thereafter being able to restore blood flow through the previously occluded artery.
  • FIG. 22 illustrates the delivery of a material 822 toward arteries 806 and a target structure 804. In this embodiment, an implant assembly 810 has been advanced to a location adjacent to the target structure 804. Thereafter, the implant 820 is expanded into apposition with the walls of the blood vessel 802. The material 822 can then be released into the downstream areas of the vessel 802 and arteries 806. Thus, the material 822 can be advanced downstream toward the target structure 804. Thereafter, the implant 820 can be expanded and released, such that blood flow to the target structure 804 is restricted or eliminated, thus inducing infarction of the target structure 804.
  • Such embodiments advantageously mitigate any upstream migration of the material 822 toward an upstream section 832 of the vessel, and can tend to enhance or increase the concentration of material delivered to the arteries 806 and target structure 804. In some embodiments, the procedure can also mitigate any downstream migration of the material 822 toward a downstream section 830 of the vessel. Further, such a dual-implant system or procedure can also mitigate any upstream migration of the material 822 toward an upstream section 832 of the vessel 802. Embodiments of this technique allow confident and precise application of material in any of a variety of situations, such as those mentioned above.
  • As discussed herein and as illustrated with respect to FIGS. 17A-22, various treatment procedures can be performed for a target body region, such as tumor devascularization, reducing traumatic bleeding or hemorrhage, high-flow vascular malformations, vascular or airway volume reduction procedures, treatment of a target lesion, treatment and embolization of incompetent venous systems in low extremities (e.g., legs and lower abdominal area), treatment varicose veins in the leg (e.g., great saphenous vein and spider veins in deeper system), attending to other indications such as AVM, pelvic varices, etc. In some situations, a single treatment may not be sufficient to fully devascularize, heal, or otherwise treat the target body region.
  • Therefore, according to some embodiments, after a first treatment or procedure in which a first occlusive implant has been released into a vessel or artery and remained thereat, at least partially occluding the vessel for a given period of time, a second procedure can be performed to remove and/or modify the first occlusive implant using the catheter and/or a second occlusive implant.
  • For example, depending on the therapeutic strategy, if a clinician believes that the target body region may benefit from a second treatment or procedure, a second procedure can be undertaken in which the first occlusive implant can be removed and/or modified. The second procedure can be performed after one, two, three, four, five or six months, or longer, and depends on the health of the patient and need for such a procedure.
  • The second procedure can be performed by removing the first implant and/or modifying the first implant, such as by restoring flow through a valve of the first implant. The first option for the second procedure comprises removing the first implant from the vessel using a removal device. After removal, the first implant can be replaced by a new, second implant.
  • Another option for the second procedure comprises modifying the first occlusive implant, such as by restoring flow through the first implant, physically altering the first implant 970 (see FIGS. 23A-23B), injecting additional material toward the target region, and/or inserting a second implant 980 into the first implant 970 (see FIGS. 24A-24B) so as to change the effect or degree of the occlusion or permit additional material to be deployed downstream of the first implant 970.
  • In some embodiments, the first implant 970 can be modified by penetrating or punching a hole or aperture in the cover member or otherwise removing a portion of the first implant 970. The punching can comprise disconnecting, opening, or otherwise tearing a valve component from the first implant distal portion. The hole or aperture can be made in order to restore flow at least partially through the first implant 970, thereby allowing revascularization of the target body region.
  • For example, FIG. 23A illustrates that when the first occlusive implant 970 is left in the vessel 802, the clinician can advance a catheter, wire, or other adjustment member 972 to the target body region where the first implant 970 is deployed. When the adjustment member 972 is positioned adjacent to the first implant 970, the adjustment member 972 can be used to create a hole or aperture in the distal portion of the first implant 970 by advancing a distal tip of the adjustment member 972 through the membrane or cover member of the first implant 970, as illustrated in FIG. 23B.
  • Thus, if determined appropriate, such revascularization can provide the final step to the procedure and no further occlusion may be necessary. However, as necessary, additional optional steps can be taken to occlude or otherwise treat the target region.
  • Once the first implant 970 has been modified, and flow has been restored, a further procedure may be performed. If the deposition of another material, such as an embolic material, contrast agent, or drug, is recommended for the target body region, such material can then be deposited toward the target region. For example, after revascularizing the vessel, the clinician can deposit additional material toward the target region without delivering an additional implant to at least partially occlude the vessel. However, in some embodiments, the injection of additional material can include using and/or placing a second implant in the vessel. The second implant can comprise any of the implants disclosed herein or be operated using any of the methods disclosed herein, such as any of the methods or treatment procedures illustrated in FIGS. 17A-22.
  • Referring to FIGS. 24A-24B, whether or not a further material is injected into the lumen, a second implant 980 can be placed proximally of the first implant within the lumen. In some embodiments, the second implant 980 can be configured to fit within the lumen of the first implant. Further, in some embodiments, such as that illustrated in FIG. 24A, the piercing or opening of the distal portion of the first implant 970 can be performed by using the catheter 982 used to deliver the second implant 980. For example, the distal end of the catheter 982 can be advanced distally through the distal portion of the first implant 970, thus opening the first implant 970 in a manner similar to that discussed above with respect to FIGS. 23A-23B.
  • In the embodiment shown in FIG. 24A, modification of the first implant 970 and the further treatment of the target body region can be performed by modifying, penetrating, or punching a hole or aperture into the first implant 970 in a central location of the distal portion of the first implant 970, as noted above, and positioning a distal portion of the second implant 980 within the first implant 970. However, the valve component of the first implant 970 can be maintained interconnected with at least a portion of the first implant 970, such as with the cover member or frame member. Thus, after being dislocated relative to the first implant, the valve component can remain attached to the first implant 970, thereby preventing release of the valve component into distal vasculature. Later use of embolic material, glue, or other such materials can allow the dislocated valve component to be more securely fixed or adhered relative to the first implant 970.
  • In some embodiments, the second implant 980 can be coupled to or attached to the first implant 970 when released into the lumen. For example, the second implant 980 can sit entirely within the first implant 970. However, a distal portion of the second implant 980 can be configured to extend distally beyond the distal portion of the first implant 970 to facilitate passage of a material therethrough.
  • The second implant 980 can then be used in a manner as discussed herein with respect to other embodiments, such as for providing a material to a downstream target region.
  • Additionally, although the illustrated methods and procedures shown and described with respect to FIGS. 17A-24B illustrate embodiments in which the implant comprises a helical support component that can be coupled to a catheter (see e.g., FIGS. 3-12B), such methods and procedures can also be implemented using an implant that has a deflectable support component that can be at advanced within a catheter (see e.g., FIGS. 13-16B). Further, any of the valve components disclosed herein (see e.g., FIGS. 7A-16B) can be used with a helical support component that can be coupled to a catheter (as shown in FIGS. 3-12B) or a deflectable support component that can be at advanced within a catheter (as shown in FIGS. 13-16B), including any combinations or modifications thereof.
  • According to various aspects of the subject technology, implants disclosed herein may be used for various applications for reducing or stopping flow through a luminal structure in a patient and inducing infarction of a target tissue. Implants of the subject technology may be used for rapid, well-controlled, and reliable occlusion of luminal structures. For example, the luminal structure may comprise at least one of a blood vessel, a body organ, a lung, an airway, a Fallopian tube, a cervical canal, a vagina, a cervix, a vas deferens, a bronchus, a ureter, a colon, a rectum, an anus, a bio duct, a pancreatic duct, or other suitable tubular structures known to those of ordinary skill in the art. In some embodiments, implants of the present disclosure may be used for temporary occlusion in cases of lung disease, or for temporary occlusion of female reproductive organs for contraceptive purposes. In some embodiments, implants of the present disclosure may be removed, or flow may be restored through the luminal structure to restore original organ functions.
  • In addition to the applications mentioned above, some embodiments of the implants of the present disclosure may be used for various endoluminal occlusion procedures, including procedures for the lungs (e.g., selective endobronchial occlusion for lung reduction, occlusion of bronchopleural or bronchocutaneous fistulas, endovascular occlusion of pulmonary AVMs and fistulas or aortopulmonary anastomoses) and procedures for reproductive organs (e.g., endoluminal occlusion of vas deferens or Fallopian tubes for minimally-invasive contraceptive intervention, endovascular occlusion of varicocele in males and low abdominal gonadal veins for reducing or completely eliminating chronic pelvic pain syndrome in females). In some embodiments, implants of the present disclosure may be used for stopping blood loss from a damaged blood vessel, closing an abnormal blood vessel or a blood vessel supplying a vascular anamaly, or interrupting blood supply to an organ or part of an organ for permanent devascularization (e.g., closure of splenic artery in spleen laceration, devascularization of tissues involved by neoplastic process, either pre-operatively or as a palliative measure). In some embodiments, implants of the present disclosure may be used for various endovascular (e.g., neural and peripheral) procedures, head and neck AVFs, dissecting intracranial and extracranial vessels, traumatic and non-traumatic vessel injury or rupture (e.g., pelvic hemorrhages in trauma patients, carotid blow-out in patients with head and neck cancers, hemorrhage induced by a neoplasia, etc.), and devascularization prior to (or as an alternative to) surgical resection of various organs or tumors.
  • In certain embodiments, implants of the present disclosure may be used for various organs, including for example, the spleen (e.g., endovascular occlusion as a preoperative intervention or as an alternative to surgical resection with indications including traumatic hemorrhage, hypersplenism, bleeding secondary to portal hypertension or splenic vein thrombosis, and various disorders such as thalassemia major, thrombocytopenia, idiopathic thrombocytopenic purpura, Gaucher disease, and Hodgkin disease), the liver (e.g., occlusion of portal veins collaterals as adjunct to transjugular intrahepatic portosystemic shunt (“TIPS”), occlusion of the TIPS itself in cases of encephalopathy, occlusion of intrahepatic arterioportal fistulas), the kidney (e.g., endoluminal ureteral occlusion for intractable lower urinary tract fistula with urine leakage, or for the treatment of uretero-arterial fistulae, endovascular occlusion as an alternative to surgical resection for end-stage renal disease or renovascular hypertension requiring unilateral or bilateral nephrectomy and renal transplant with native kidneys in situ), and the heart (e.g., occlusion of coronary AVFs, transarterial embolization of Blalock-Taussig shunts). The application of implants of the present disclosure is not limited to applications for human patients, but may also include veterinary applications.
  • According to various embodiments of the subject technology, a cover component of an implant may be used to occlude, partially or completely, luminal structure in which a respective implant is deployed. In some embodiments as used herein, occlusion may refer to either partial or complete occlusion. In some embodiments, cover components can comprise at least one of a polyurethane, a polyanhidrate, PTFE, ePTFE, silicone, and other suitable materials known to those of ordinary skill in the art. In some embodiments, cover components may be elastic. In some embodiments, cover components may be permeable or non-permeable.
  • In some embodiments, an average thickness of a cover component can be between about 0.0005 inches and about 0.006 inches. In some aspects, the average thickness of a cover component may be less than about 0.0005 inches or greater than about 0.006 inches. In certain embodiments, an average thickness of a distal portion of a cover component is greater than an average thickness of a proximal portion of a cover component. Such a configuration may ensure that more flow may be reduced at the distal portion of a cover component. In some embodiments, the average thickness of the distal portion of a cover component is between about 0.002 inches and about 0.012 inches. In some embodiments, the average thickness of the distal portion of a cover component may be less than about 0.002 inches or greater than about 0.012 inches. In some embodiments, the average thickness of the proximal portion of a cover component is between about 0.0005 inches and about 0.006 inches. In some embodiments, the average thickness of the proximal portion of a cover component may be less than about 0.0005 inches or greater than about 0.006 inches.
  • Some embodiments of the implant described herein can incorporate one or more features of implants and/or implant deployment systems
  • The foregoing description is provided to enable a person skilled in the art to practice the various configurations described herein. While the subject technology has been particularly described with reference to the various figures and configurations, it should be understood that these are for illustration purposes only and should not be taken as limiting the scope of the subject technology.
  • There may be many other ways to implement the subject technology. Various functions and elements described herein may be partitioned differently from those shown without departing from the scope of the subject technology. Various modifications to these configurations will be readily apparent to those skilled in the art, and generic principles defined herein may be applied to other configurations. Thus, many changes and modifications may be made to the subject technology, by one having ordinary skill in the art, without departing from the scope of the subject technology.
  • It is understood that the specific order or hierarchy of steps in the processes disclosed is an illustration of exemplary approaches. Based upon design preferences, it is understood that the specific order or hierarchy of steps in the processes may be rearranged. Some of the steps may be performed simultaneously. The accompanying method claims present elements of the various steps in a sample order, and are not meant to be limited to the specific order or hierarchy presented.
  • As used herein, the phrase “at least one of” preceding a series of items, with the term “and” or “or” to separate any of the items, modifies the list as a whole, rather than each member of the list (i.e., each item). The phrase “at least one of” does not require selection of at least one of each item listed; rather, the phrase allows a meaning that includes at least one of any one of the items, and/or at least one of any combination of the items, and/or at least one of each of the items. By way of example, the phrases “at least one of A, B, and C” or “at least one of A, B, or C” each refer to only A, only B, or only C; any combination of A, B, and C; and/or at least one of each of A, B, and C.
  • Terms such as “top,” “bottom,” “front,” “rear” and the like as used in this disclosure should be understood as referring to an arbitrary frame of reference, rather than to the ordinary gravitational frame of reference. Thus, a top surface, a bottom surface, a front surface, and a rear surface may extend upwardly, downwardly, diagonally, or horizontally in a gravitational frame of reference.
  • Furthermore, to the extent that the term “include,” “have,” or the like is used in the description or the claims, such term is intended to be inclusive in a manner similar to the term “comprise” as “comprise” is interpreted when employed as a transitional word in a claim.
  • The word “exemplary” is used herein to mean “serving as an example, instance, or illustration.” Any embodiment described herein as “exemplary” is not necessarily to be construed as preferred or advantageous over other embodiments.
  • A reference to an element in the singular is not intended to mean “one and only one” unless specifically stated, but rather “one or more.” Pronouns in the masculine (e.g., his) include the feminine and neuter gender (e.g., her and its) and vice versa. The term “some” refers to one or more. Underlined and/or italicized headings and subheadings are used for convenience only, do not limit the subject technology, and are not referred to in connection with the interpretation of the description of the subject technology. All structural and functional equivalents to the elements of the various configurations described throughout this disclosure that are known or later come to be known to those of ordinary skill in the art are expressly incorporated herein by reference and intended to be encompassed by the subject technology. Moreover, nothing disclosed herein is intended to be dedicated to the public regardless of whether such disclosure is explicitly recited in the above description.
  • While certain aspects and embodiments of the inventions have been described, these have been presented by way of example only, and are not intended to limit the scope of the inventions. Indeed, the novel methods and systems described herein may be embodied in a variety of other forms without departing from the spirit thereof. The accompanying claims and their equivalents are intended to cover such forms or modifications as would fall within the scope and spirit of the inventions.

Claims (26)

What is claimed is:
1. A material delivery device, comprising:
an expandable support member having a lumen and an outflow end, the support member being configured to expand from a collapsed configuration to an expanded configuration for placement in a body lumen;
a cover component, extending along the support member, defining an aperture; and
a valve component coupled to the cover component and disposed at the outflow end, the valve component permitting outflow of a material through the aperture and restricting backflow of the material into the aperture.
2. The device of claim 1, wherein the cover component comprises a tubular membrane coupled to the support member and the valve component comprises a free end of the tubular membrane extending away from the support member at the outflow end, the free end of the tubular membrane being configured to permit outflow of the material through the outflow end and to invert or fold onto itself to restrict backflow of the material into the outflow end.
3. The device of claim 2, wherein the tubular membrane comprises inner and outer portions that extend along respective interior and exterior surfaces of the support member.
4. The device of claim 3, wherein the free end of the tubular membrane extends from the outer portion, and the inner portion comprises a second free end.
5. The device of claim 4, wherein the free end is coupled to the second free end.
6. The device of claim 1, wherein the cover component comprises a tubular membrane coupled to the support member and the valve component comprises a free end of the tubular membrane extending away from the support member at the outflow end, wherein the tubular membrane comprises a tubular outer portion extending along a support member exterior and a segmented inner portion, comprising a plurality of strips, extending along a support member interior.
7. The device of claim 6, wherein the free end is coupled to at least one of the plurality of strips.
8. The device of claim 1, wherein the valve component is movable between open and closed positions, the valve component permitting flow of the material through the outflow end when in the open position and restricting backflow of the material through the outflow end when in the closed position.
9. The device of claim 1, wherein the valve component comprises a mesh material.
10. The device of claim 9, wherein the mesh material is coupled to an outer surface of the cover component adjacent to the outflow end.
11. The device of claim 1, wherein the valve component comprises a flap structure coupled to the cover component adjacent the outflow end, the flap structure being movable away from the aperture to permit flow therethrough.
12. A method of delivering a material to a target region of a body lumen, comprising:
advancing an implant to the target region, the implant having first and second sections engaged with a catheter at respective first and second engagement points;
releasing the implant first section from engagement with the catheter at the first engagement point;
permitting the implant first section to expand against a lumen wall at the target region such that the lumen becomes at least substantially occluded; and
injecting a material through a portion of the implant.
13. The method of claim 12, wherein the implant first section comprises an implant distal section, and wherein the releasing comprises disengaging a first engagement member from the distal section.
14. The method of claim 13, wherein the portion of the implant comprises a valve component and the permitting comprises causing the valve component to contact a distal end of the catheter such that the catheter distal end moves the valve component to an open position.
15. The method of claim 14, further comprising, after the material is injected into the lumen, releasing the implant second section and moving the catheter proximally relative to the implant such that the valve component moves to a closed position.
16. The method of claim 15, wherein the moving the catheter relative to the implant comprises proximally withdrawing the catheter within the lumen.
17. The method of claim 12, further comprising releasing the implant second section into apposition with the lumen wall such that the implant is disengaged from the catheter.
18. The method of claim 12, further comprising proximally withdrawing the assembly from the lumen.
19. The method of claim 12, further comprising, prior to releasing the implant first section, releasing a blocking implant into contact against the lumen wall downstream of the target region, the blocking implant occluding flow through the lumen beyond the target region.
20. The method of claim 19, further comprising, after injecting the material, allowing the material to flow into the target region, and removing the blocking implant from the lumen.
21. A method of delivering a material to a target region of a body lumen, comprising:
contacting a first occlusive implant, deployed within the lumen upstream of the target region, to remove the occlusion and permit flow through the first implant, thereby restoring flow through the lumen to the target region; and
after contacting the first implant, injecting a material into the lumen such that the material passes through the first implant to the target region.
22. The method of claim 21, wherein contacting the first implant comprises advancing an adjustment member through the first implant to pierce a cover component of the first implant.
23. The method of claim 21, further comprising:
after contacting the first implant, advancing a second implant to the target region, the second implant having first and second sections engaged with a catheter at respective first and second engagement points;
releasing the first section from engagement with the catheter at the first engagement point; and
before injecting a material, permitting the implant first section to expand against a lumen wall at the target region such that the lumen becomes at least substantially occluded.
24. The method of claim 23, further comprising releasing the second implant adjacent to the first implant.
25. The method of claim 23, further comprising releasing the second implant within the first implant.
26. The method of claim 21, wherein contacting the first implant comprises contacting a mesh component of the first implant with a material to dissolve coagulated material on the mesh component, thereby restoring flow through the mesh component.
US14/101,171 2013-06-14 2013-12-09 Catheter-assisted tumor treatment Active 2035-12-12 US9737308B2 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
US14/101,171 US9737308B2 (en) 2013-06-14 2013-12-09 Catheter-assisted tumor treatment
AU2013392058A AU2013392058B2 (en) 2013-06-14 2013-12-20 Catheter-assisted tumor treatment
PCT/US2013/076964 WO2014200563A1 (en) 2013-06-14 2013-12-20 Catheter-assisted tumor treatment
CA2915267A CA2915267A1 (en) 2013-06-14 2013-12-20 Catheter-assisted tumor treatment
ES13886735T ES2957207T3 (en) 2013-06-14 2013-12-20 Catheter-assisted tumor treatment
EP13886735.3A EP3007756B1 (en) 2013-06-14 2013-12-20 Catheter-assisted tumor treatment
US14/304,868 US9737306B2 (en) 2013-06-14 2014-06-13 Implantable luminal devices
EP14810987.9A EP3007656A2 (en) 2013-06-14 2014-06-13 Implantable luminal devices
CA2915223A CA2915223A1 (en) 2013-06-14 2014-06-13 Implantable luminal devices
US14/304,869 US9636116B2 (en) 2013-06-14 2014-06-13 Implantable luminal devices
AU2014277882A AU2014277882A1 (en) 2013-06-14 2014-06-13 Implantable luminal devices
PCT/US2014/042427 WO2014201434A2 (en) 2013-06-14 2014-06-13 Implantable luminal devices
US14/622,729 US20150157329A1 (en) 2013-06-14 2015-02-13 Luminal device delivery system
US14/973,414 US10149968B2 (en) 2013-06-14 2015-12-17 Catheter-assisted tumor treatment
US15/583,956 US10441290B2 (en) 2013-06-14 2017-05-01 Implantable luminal devices

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361835461P 2013-06-14 2013-06-14
US201361835406P 2013-06-14 2013-06-14
US201361900321P 2013-11-05 2013-11-05
US14/101,171 US9737308B2 (en) 2013-06-14 2013-12-09 Catheter-assisted tumor treatment

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US14/304,869 Continuation-In-Part US9636116B2 (en) 2013-06-14 2014-06-13 Implantable luminal devices
US14/304,868 Continuation-In-Part US9737306B2 (en) 2013-06-14 2014-06-13 Implantable luminal devices
US14/973,414 Continuation-In-Part US10149968B2 (en) 2013-06-14 2015-12-17 Catheter-assisted tumor treatment

Publications (3)

Publication Number Publication Date
US20140371716A1 US20140371716A1 (en) 2014-12-18
US20170128076A9 true US20170128076A9 (en) 2017-05-11
US9737308B2 US9737308B2 (en) 2017-08-22

Family

ID=52022640

Family Applications (1)

Application Number Title Priority Date Filing Date
US14/101,171 Active 2035-12-12 US9737308B2 (en) 2013-06-14 2013-12-09 Catheter-assisted tumor treatment

Country Status (6)

Country Link
US (1) US9737308B2 (en)
EP (1) EP3007756B1 (en)
AU (1) AU2013392058B2 (en)
CA (1) CA2915267A1 (en)
ES (1) ES2957207T3 (en)
WO (1) WO2014200563A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012002944A1 (en) 2010-06-29 2012-01-05 Artventive Medical Group, Inc. Reducing flow through a tubular structure
US8984733B2 (en) 2013-02-05 2015-03-24 Artventive Medical Group, Inc. Bodily lumen occlusion
US9095344B2 (en) 2013-02-05 2015-08-04 Artventive Medical Group, Inc. Methods and apparatuses for blood vessel occlusion
US10149968B2 (en) 2013-06-14 2018-12-11 Artventive Medical Group, Inc. Catheter-assisted tumor treatment
US9636116B2 (en) 2013-06-14 2017-05-02 Artventive Medical Group, Inc. Implantable luminal devices
US10363043B2 (en) 2014-05-01 2019-07-30 Artventive Medical Group, Inc. Treatment of incompetent vessels
GB2528808B (en) * 2014-06-05 2016-12-07 Cook Medical Technologies Llc Apparatus for delivering filamentary material into a patient
US10813644B2 (en) 2016-04-01 2020-10-27 Artventive Medical Group, Inc. Occlusive implant and delivery system
CN111150933B (en) * 2019-09-02 2022-08-09 杭州神络医疗科技有限公司 Catheter electrode and in vivo implanted nerve stimulation device

Family Cites Families (386)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3868956A (en) 1972-06-05 1975-03-04 Ralph J Alfidi Vessel implantable appliance and method of implanting it
US3805767A (en) 1973-02-26 1974-04-23 Erb Rene Method and apparatus for non-surgical, reversible sterilization of females
US3918431A (en) 1974-01-11 1975-11-11 Manfred Sinnreich Fallopian tube obturating device
US4013063A (en) 1974-10-09 1977-03-22 Louis Bucalo Implant for reversibly preventing conception
US4245623A (en) 1978-06-06 1981-01-20 Erb Robert A Method and apparatus for the hysteroscopic non-surgical sterilization of females
CA1204643A (en) 1981-09-16 1986-05-20 Hans I. Wallsten Device for application in blood vessels or other difficulty accessible locations and its use
US5693083A (en) 1983-12-09 1997-12-02 Endovascular Technologies, Inc. Thoracic graft and delivery catheter
US4682592A (en) 1985-01-28 1987-07-28 Thorsgard Knute E Method and device for achieving reversible male sterilization
US4706671A (en) 1985-05-02 1987-11-17 Weinrib Harry P Catheter with coiled tip
US4705517A (en) 1985-09-03 1987-11-10 Becton, Dickinson And Company Percutaneously deliverable intravascular occlusion prosthesis
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5102417A (en) 1985-11-07 1992-04-07 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4649922A (en) 1986-01-23 1987-03-17 Wiktor Donimik M Catheter arrangement having a variable diameter tip and spring prosthesis
EP0257091B1 (en) 1986-02-24 1993-07-28 Robert E. Fischell An intravascular stent and percutaneous insertion system
US4800882A (en) 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
JPS63238872A (en) 1987-03-25 1988-10-04 テルモ株式会社 Instrument for securing inner diameter of cavity of tubular organ and catheter equipped therewith
JPH088933B2 (en) 1987-07-10 1996-01-31 日本ゼオン株式会社 Catheter
JPS6446477A (en) 1987-08-13 1989-02-20 Terumo Corp Catheter
US5242451A (en) 1987-09-24 1993-09-07 Terumo Kabushiki Kaisha Instrument for retaining inner diameter of tubular organ lumen
US4827946A (en) 1988-01-06 1989-05-09 Steven Kaali Electrified vaginal ring
DE68922497T2 (en) 1988-08-24 1995-09-14 Marvin J Slepian ENDOLUMINAL SEAL WITH BISDEGRADABLE POLYMERS.
US4913141A (en) 1988-10-25 1990-04-03 Cordis Corporation Apparatus and method for placement of a stent within a subject vessel
US5065751A (en) 1990-01-03 1991-11-19 Wolf Gerald L Method and apparatus for reversibly occluding a biological tube
DE4104702C2 (en) 1991-02-15 1996-01-18 Malte Neuss Implants for organ pathways in spiral form
US5147370A (en) 1991-06-12 1992-09-15 Mcnamara Thomas O Nitinol stent for hollow body conduits
US5474089A (en) 1991-06-26 1995-12-12 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method and device for reversible sterilization
US5242452A (en) 1991-10-11 1993-09-07 Kanji Inoue Device for collapsing an appliance collapsible for insertion into human organs
CA2079417C (en) 1991-10-28 2003-01-07 Lilip Lau Expandable stents and method of making same
US5290310A (en) 1991-10-30 1994-03-01 Howmedica, Inc. Hemostatic implant introducer
US5372600A (en) 1991-10-31 1994-12-13 Instent Inc. Stent delivery systems
US5234437A (en) 1991-12-12 1993-08-10 Target Therapeutics, Inc. Detachable pusher-vasoocclusion coil assembly with threaded coupling
US6059825A (en) 1992-03-05 2000-05-09 Angiodynamics, Inc. Clot filter
US5772668A (en) 1992-06-18 1998-06-30 American Biomed, Inc. Apparatus for placing an endoprosthesis
US5342387A (en) 1992-06-18 1994-08-30 American Biomed, Inc. Artificial support for a blood vessel
US6336938B1 (en) 1992-08-06 2002-01-08 William Cook Europe A/S Implantable self expanding prosthetic device
US5382261A (en) 1992-09-01 1995-01-17 Expandable Grafts Partnership Method and apparatus for occluding vessels
US5304198A (en) 1992-11-13 1994-04-19 Target Therapeutics Single-lumen balloon catheter having a directional valve
IL108455A (en) 1993-01-27 1997-04-15 Instent Inc Vascular and coronary stents
DE69432145T2 (en) 1993-03-11 2004-01-15 Medinol Ltd STENT
US6090115A (en) 1995-06-07 2000-07-18 Intratherapeutics, Inc. Temporary stent system
US5334210A (en) 1993-04-09 1994-08-02 Cook Incorporated Vascular occlusion assembly
IL105828A (en) 1993-05-28 1999-06-20 Medinol Ltd Medical stent
JPH07405A (en) 1993-06-14 1995-01-06 Toshio Saeki Thrombus migration preventing filter
JPH0718501A (en) 1993-06-30 1995-01-20 Naohisa Ashida Package structure of trunks
US5476505A (en) 1993-11-18 1995-12-19 Advanced Cardiovascular Systems, Inc. Coiled stent and delivery system
US5417708A (en) 1994-03-09 1995-05-23 Cook Incorporated Intravascular treatment system and percutaneous release mechanism therefor
AU705305B2 (en) 1994-03-18 1999-05-20 Cook Medical Technologies Llc Helical embolization coil
US6117157A (en) 1994-03-18 2000-09-12 Cook Incorporated Helical embolization coil
US5824044A (en) 1994-05-12 1998-10-20 Endovascular Technologies, Inc. Bifurcated multicapsule intraluminal grafting system
US5499995C1 (en) 1994-05-25 2002-03-12 Paul S Teirstein Body passageway closure apparatus and method of use
US5725552A (en) 1994-07-08 1998-03-10 Aga Medical Corporation Percutaneous catheter directed intravascular occlusion devices
US6123715A (en) 1994-07-08 2000-09-26 Amplatz; Curtis Method of forming medical devices; intravascular occlusion devices
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US5891108A (en) 1994-09-12 1999-04-06 Cordis Corporation Drug delivery stent
US5702419A (en) 1994-09-21 1997-12-30 Wake Forest University Expandable, intraluminal stents
US5814062A (en) 1994-12-22 1998-09-29 Target Therapeutics, Inc. Implant delivery assembly with expandable coupling/decoupling mechanism
CH688400A5 (en) 1995-01-17 1997-09-15 Donata Gianesi Carrying device for golf utensils.
US6350266B1 (en) 1995-02-02 2002-02-26 Scimed Life Systems, Inc. Hybrid stone retrieval device
US6440097B1 (en) 1995-10-06 2002-08-27 Target Therapeutics, Inc. Balloon catheter with delivery side holes
US5830222A (en) 1995-10-13 1998-11-03 Transvascular, Inc. Device, system and method for intersititial transvascular intervention
US6283951B1 (en) 1996-10-11 2001-09-04 Transvascular, Inc. Systems and methods for delivering drugs to selected locations within the body
US6302875B1 (en) 1996-10-11 2001-10-16 Transvascular, Inc. Catheters and related devices for forming passageways between blood vessels or other anatomical structures
IL151563A0 (en) 1995-10-13 2003-04-10 Transvascular Inc A longitudinal compression apparatus for compressing tissue
US6616675B1 (en) 1996-02-02 2003-09-09 Transvascular, Inc. Methods and apparatus for connecting openings formed in adjacent blood vessels or other anatomical structures
US6283983B1 (en) 1995-10-13 2001-09-04 Transvascular, Inc. Percutaneous in-situ coronary bypass method and apparatus
GB9522332D0 (en) 1995-11-01 1996-01-03 Biocompatibles Ltd Braided stent
US6168622B1 (en) 1996-01-24 2001-01-02 Microvena Corporation Method and apparatus for occluding aneurysms
EP1707233A3 (en) 1996-02-02 2006-12-20 Medtronic Vascular, Inc. Apparatus for blocking flow through blood vessels
ATE247429T1 (en) 1996-02-02 2003-09-15 Transvascular Inc SYSTEM FOR INTERSTITIAL TRANSVASCULAR SURGICAL PROCEDURES
WO1997027893A1 (en) 1996-02-02 1997-08-07 Transvascular, Inc. Methods and apparatus for blocking flow through blood vessels
US20030229366A1 (en) 1996-02-02 2003-12-11 Transvascular, Inc. Implantable lumen occluding devices and methods
US5733294A (en) 1996-02-28 1998-03-31 B. Braun Medical, Inc. Self expanding cardiovascular occlusion device, method of using and method of making the same
US6533805B1 (en) 1996-04-01 2003-03-18 General Surgical Innovations, Inc. Prosthesis and method for deployment within a body lumen
US6629981B2 (en) 2000-07-06 2003-10-07 Endocare, Inc. Stent delivery system
US6702846B2 (en) 1996-04-09 2004-03-09 Endocare, Inc. Urological stent therapy system and method
AR001590A1 (en) 1996-04-10 1997-11-26 Jorge Alberto Baccaro Abnormal vascular communications occluder device and applicator cartridge of said device
US20050245894A1 (en) 1996-05-20 2005-11-03 Medtronic Vascular, Inc. Methods and apparatuses for drug delivery to an intravascular occlusion
US6007544A (en) 1996-06-14 1999-12-28 Beth Israel Deaconess Medical Center Catheter apparatus having an improved shape-memory alloy cuff and inflatable on-demand balloon for creating a bypass graft in-vivo
US5797952A (en) 1996-06-21 1998-08-25 Localmed, Inc. System and method for delivering helical stents
GB9614950D0 (en) 1996-07-16 1996-09-04 Anson Medical Ltd A ductus stent and delivery catheter
JP2001500401A (en) 1996-08-26 2001-01-16 トランスバスキュラー インコーポレイテッド Method and apparatus for transmyocardial direct cardiovascular regeneration
US6432127B1 (en) 1996-10-11 2002-08-13 Transvascular, Inc. Devices for forming and/or maintaining connections between adjacent anatomical conduits
US6258119B1 (en) 1996-11-07 2001-07-10 Myocardial Stents, Inc. Implant device for trans myocardial revascularization
US5925074A (en) 1996-12-03 1999-07-20 Atrium Medical Corporation Vascular endoprosthesis and method
US7073504B2 (en) 1996-12-18 2006-07-11 Ams Research Corporation Contraceptive system and method of use
US5868782A (en) 1996-12-24 1999-02-09 Global Therapeutics, Inc. Radially expandable axially non-contracting surgical stent
US5733329A (en) 1996-12-30 1998-03-31 Target Therapeutics, Inc. Vaso-occlusive coil with conical end
WO1998031308A1 (en) 1997-01-21 1998-07-23 The Penn State Research Foundation Transcervical contraceptive platinum microcoil
DE19703482A1 (en) 1997-01-31 1998-08-06 Ernst Peter Prof Dr M Strecker Stent
US5782860A (en) 1997-02-11 1998-07-21 Biointerventional Corporation Closure device for percutaneous occlusion of puncture sites and tracts in the human body and method
US6464712B1 (en) 1997-02-11 2002-10-15 Biointerventional Corporation Expansile device for use in blood vessels and tracts in the body and method
US6056770A (en) 1997-02-11 2000-05-02 Biointerventional Corporation Expansile device for use in blood vessels and tracts in the body and method
US8323305B2 (en) 1997-02-11 2012-12-04 Cardiva Medical, Inc. Expansile device for use in blood vessels and tracts in the body and method
US6152946A (en) 1998-03-05 2000-11-28 Scimed Life Systems, Inc. Distal protection device and method
AU744343B2 (en) 1997-04-11 2002-02-21 Transvascular, Inc. Methods and apparatus for transmyocardial direct coronary revascularization
US5957929A (en) 1997-05-02 1999-09-28 Micro Therapeutics, Inc. Expandable stent apparatus and method
US5980554A (en) 1997-05-05 1999-11-09 Micro Therapeutics, Inc. Wire frame partial flow obstruction for aneurysm treatment
US5928260A (en) 1997-07-10 1999-07-27 Scimed Life Systems, Inc. Removable occlusion system for aneurysm neck
WO1999012484A1 (en) 1997-09-05 1999-03-18 Neurovasx, Inc. Vessel occlusion device
US5954766A (en) 1997-09-16 1999-09-21 Zadno-Azizi; Gholam-Reza Body fluid flow control device
US5925063A (en) 1997-09-26 1999-07-20 Khosravi; Farhad Coiled sheet valve, filter or occlusive device and methods of use
US6395014B1 (en) 1997-09-26 2002-05-28 John A. Macoviak Cerebral embolic protection assembly and associated methods
CA2307764A1 (en) 1997-11-07 1999-05-20 Salviac Limited Implantable occluder devices for medical use
DE69838952T2 (en) 1997-11-07 2009-01-02 Salviac Ltd. EMBOLISM PROTECTION DEVICE
US6330884B1 (en) 1997-11-14 2001-12-18 Transvascular, Inc. Deformable scaffolding multicellular stent
US6533807B2 (en) 1998-02-05 2003-03-18 Medtronic, Inc. Radially-expandable stent and delivery system
US5944738A (en) 1998-02-06 1999-08-31 Aga Medical Corporation Percutaneous catheter directed constricting occlusion device
ATE392858T1 (en) 1998-03-31 2008-05-15 Medtronic Vascular Inc CATHETER AND SYSTEMS FOR A PERCUTANE INSITU ARTERIO-VENOUS BYPASS
US6063111A (en) 1998-03-31 2000-05-16 Cordis Corporation Stent aneurysm treatment system and method
US6165194A (en) 1998-07-24 2000-12-26 Micrus Corporation Intravascular flow modifier and reinforcement device
US6152943A (en) 1998-08-14 2000-11-28 Incept Llc Methods and apparatus for intraluminal deposition of hydrogels
US6605294B2 (en) 1998-08-14 2003-08-12 Incept Llc Methods of using in situ hydration of hydrogel articles for sealing or augmentation of tissue or vessels
US6210338B1 (en) 1998-08-21 2001-04-03 Aga Medical Corp. Sizing catheter for measuring cardiovascular structures
US6241678B1 (en) 1998-08-21 2001-06-05 Aga Medical Corporation Sizing catheter for measuring septal defects
US20080086214A1 (en) 1998-08-31 2008-04-10 Wilson-Cook Medical Inc. Medical device having a sleeve valve with bioactive agent
AU6384699A (en) 1998-09-10 2000-04-03 Percardia, Inc. Tmr shunt
US6641610B2 (en) 1998-09-10 2003-11-04 Percardia, Inc. Valve designs for left ventricular conduits
US6328755B1 (en) 1998-09-24 2001-12-11 Scimed Life Systems, Inc. Filter delivery device
US6019779A (en) 1998-10-09 2000-02-01 Intratherapeutics Inc. Multi-filar coil medical stent
US5979446A (en) 1998-10-22 1999-11-09 Synergyn Technologies, Inc. Removable fallopian tube plug and associated methods
US7044134B2 (en) 1999-11-08 2006-05-16 Ev3 Sunnyvale, Inc Method of implanting a device in the left atrial appendage
US6214042B1 (en) 1998-11-10 2001-04-10 Precision Vascular Systems, Inc. Micro-machined stent for vessels, body ducts and the like
US20060178727A1 (en) 1998-12-03 2006-08-10 Jacob Richter Hybrid amorphous metal alloy stent
US8382821B2 (en) 1998-12-03 2013-02-26 Medinol Ltd. Helical hybrid stent
GB9828696D0 (en) 1998-12-29 1999-02-17 Houston J G Blood-flow tubing
AU774924B2 (en) 1999-01-22 2004-07-15 W.L. Gore & Associates, Inc. Covered endoprosthesis and delivery system
US6248122B1 (en) 1999-02-26 2001-06-19 Vascular Architects, Inc. Catheter with controlled release endoluminal prosthesis
US7226467B2 (en) 1999-04-09 2007-06-05 Evalve, Inc. Fixation device delivery catheter, systems and methods of use
US6899730B1 (en) 1999-04-15 2005-05-31 Scimed Life Systems, Inc. Catheter-stent device
EP1173110B1 (en) 1999-04-15 2009-07-08 Smart Therapeutics, Inc. Intravascular stent for treating neurovascular vessel lesion
AU3844799A (en) 1999-05-07 2000-11-21 Salviac Limited A filter element with retractable guidewire tip
US6241758B1 (en) 1999-05-28 2001-06-05 Advanced Cardiovascular Systems, Inc. Self-expanding stent delivery system and method of use
FR2797761B1 (en) 1999-08-24 2002-03-22 Novatech Inc DEVICE FOR PROVIDING RELEASE IN A HUMAN OR ANIMAL CONDUIT OF AN OBJECT, IN PARTICULAR A PROSTHESIS, AND IMPLANTATION SYSTEM COMPRISING A CATHETER AND SUCH A DEVICE
US6425909B1 (en) 1999-11-04 2002-07-30 Concentric Medical, Inc. Methods and devices for filtering fluid flow through a body structure
US6790218B2 (en) 1999-12-23 2004-09-14 Swaminathan Jayaraman Occlusive coil manufacture and delivery
US6391037B1 (en) 2000-03-02 2002-05-21 Prodesco, Inc. Bag for use in the intravascular treatment of saccular aneurysms
US20030070683A1 (en) * 2000-03-04 2003-04-17 Deem Mark E. Methods and devices for use in performing pulmonary procedures
CA2427543A1 (en) 2000-03-15 2004-11-02 Yu-Ling Cheng Thermally reversible implant and filler
US6468301B1 (en) 2000-03-27 2002-10-22 Aga Medical Corporation Repositionable and recapturable vascular stent/graft
US20010031981A1 (en) 2000-03-31 2001-10-18 Evans Michael A. Method and device for locating guidewire and treating chronic total occlusions
GB2369575A (en) 2000-04-20 2002-06-05 Salviac Ltd An embolic protection system
US6334864B1 (en) 2000-05-17 2002-01-01 Aga Medical Corp. Alignment member for delivering a non-symmetric device with a predefined orientation
ATE317675T1 (en) 2000-05-24 2006-03-15 Medtronic Vascular Inc VESSEL FILTER
US6602271B2 (en) 2000-05-24 2003-08-05 Medtronic Ave, Inc. Collapsible blood filter with optimal braid geometry
US6676698B2 (en) 2000-06-26 2004-01-13 Rex Medicol, L.P. Vascular device with valve for approximating vessel wall
US8298257B2 (en) 2000-06-29 2012-10-30 Concentric Medical, Inc. Systems, methods and devices for removing obstructions from a blood vessel
US7285126B2 (en) 2000-06-29 2007-10-23 Concentric Medical, Inc. Systems, methods and devices for removing obstructions from a blood vessel
US6974473B2 (en) 2000-06-30 2005-12-13 Vascular Architects, Inc. Function-enhanced thrombolytic AV fistula and method
US6585760B1 (en) 2000-06-30 2003-07-01 Vascular Architects, Inc AV fistula and function enhancing method
US6572643B1 (en) 2000-07-19 2003-06-03 Vascular Architects, Inc. Endoprosthesis delivery catheter assembly and method
US6554849B1 (en) 2000-09-11 2003-04-29 Cordis Corporation Intravascular embolization device
EP1326672A4 (en) 2000-10-18 2007-03-07 Nmt Medical Inc Over-the-wire interlock attachment/detachment mechanism
US6602286B1 (en) * 2000-10-26 2003-08-05 Ernst Peter Strecker Implantable valve system
US6562064B1 (en) 2000-10-27 2003-05-13 Vascular Architects, Inc. Placement catheter assembly
US6494909B2 (en) 2000-12-01 2002-12-17 Prodesco, Inc. Endovascular valve
US6550480B2 (en) 2001-01-31 2003-04-22 Numed/Tech Llc Lumen occluders made from thermodynamic materials
US20040073252A1 (en) 2001-02-20 2004-04-15 Mark Goldberg Blood clot filtering system
US6623518B2 (en) 2001-02-26 2003-09-23 Ev3 Peripheral, Inc. Implant delivery system with interlock
US6562066B1 (en) 2001-03-02 2003-05-13 Eric C. Martin Stent for arterialization of the coronary sinus and retrograde perfusion of the myocardium
US7798147B2 (en) 2001-03-02 2010-09-21 Pulmonx Corporation Bronchial flow control devices with membrane seal
US20050148925A1 (en) 2001-04-20 2005-07-07 Dan Rottenberg Device and method for controlling in-vivo pressure
EP1401338B1 (en) 2001-05-29 2011-07-20 Microvention, Inc. Method of manufacturing expansile filamentous embolization devices
US6454780B1 (en) 2001-06-21 2002-09-24 Scimed Life Systems, Inc. Aneurysm neck obstruction device
US6599299B2 (en) 2001-06-26 2003-07-29 Leonard S. Schultz Device and method for body lumen occlusion
US7789860B2 (en) 2001-06-27 2010-09-07 Salviac Limited Catheter for delivery and/or retrieval of a medical device
US7011671B2 (en) 2001-07-18 2006-03-14 Atritech, Inc. Cardiac implant device tether system and method
US8715312B2 (en) 2001-07-20 2014-05-06 Microvention, Inc. Aneurysm treatment device and method of use
US8465516B2 (en) 2001-07-26 2013-06-18 Oregon Health Science University Bodily lumen closure apparatus and method
CN2527227Y (en) 2001-09-15 2002-12-25 李彦豪 Portal vein-hepatic vein shunt support
DK1450727T3 (en) 2001-10-04 2010-10-18 Neovasc Medical Ltd Power reducing implant
JP4043216B2 (en) 2001-10-30 2008-02-06 オリンパス株式会社 Stent
US7270668B2 (en) 2001-12-03 2007-09-18 Xtent, Inc. Apparatus and methods for delivering coiled prostheses
US7294146B2 (en) 2001-12-03 2007-11-13 Xtent, Inc. Apparatus and methods for delivery of variable length stents
WO2003055412A2 (en) 2001-12-21 2003-07-10 Salviac Limited A support frame for an embolic protection device
US20030153972A1 (en) 2002-02-14 2003-08-14 Michael Helmus Biodegradable implantable or insertable medical devices with controlled change of physical properties leading to biomechanical compatibility
DE10208202A1 (en) 2002-02-26 2003-09-11 Karlsruhe Forschzent vein graft
US6638257B2 (en) 2002-03-01 2003-10-28 Aga Medical Corporation Intravascular flow restrictor
ATE369088T1 (en) 2002-03-05 2007-08-15 Salviac Ltd SYSTEM FOR PROTECTION AGAINST EMBOLIA
US20030171801A1 (en) 2002-03-06 2003-09-11 Brian Bates Partially covered intraluminal support device
US20030187495A1 (en) 2002-04-01 2003-10-02 Cully Edward H. Endoluminal devices, embolic filters, methods of manufacture and use
JP4060624B2 (en) 2002-04-02 2008-03-12 東芝テック株式会社 Image forming apparatus
US20030191492A1 (en) 2002-04-05 2003-10-09 Scimed Life Systems, Inc. Radial coil expandable medical wire
US7160320B2 (en) 2002-04-16 2007-01-09 The International Heart Institute Of Montana Foundation Reed valve for implantation into mammalian blood vessels and heart with optional temporary or permanent support
US7105016B2 (en) 2002-04-23 2006-09-12 Medtronic Vascular, Inc. Integrated mechanical handle with quick slide mechanism
DE10219014A1 (en) 2002-04-27 2003-11-13 Ruesch Willy Gmbh Self-expanding stent for reinforcing and/or keeping open a hollow organ comprise two elastic tubular layers which bracket and positionally fix at least one helical filament
EP1509271B1 (en) 2002-05-29 2005-11-23 William A. Cook Australia Pty. Ltd. Trigger wire system for a prosthesis deployment device
US7166120B2 (en) 2002-07-12 2007-01-23 Ev3 Inc. Catheter with occluding cuff
US8425549B2 (en) 2002-07-23 2013-04-23 Reverse Medical Corporation Systems and methods for removing obstructive matter from body lumens and treating vascular defects
US8114114B2 (en) 2002-08-27 2012-02-14 Emboline, Inc. Embolic protection device
US7174636B2 (en) 2002-09-04 2007-02-13 Scimed Life Systems, Inc. Method of making an embolic filter
US7666216B2 (en) 2002-12-24 2010-02-23 Novostent Corporation Delivery catheter for ribbon-type prosthesis and methods of use
US7220271B2 (en) 2003-01-30 2007-05-22 Ev3 Inc. Embolic filters having multiple layers and controlled pore size
US20040193141A1 (en) 2003-02-14 2004-09-30 Leopold Eric W. Intravascular flow modifier and reinforcement device and deployment system for same
ES2642584T3 (en) 2003-02-18 2017-11-16 Hampar Karageozian Device to drain fluids and reduce intraocular pressure
DE602004023700D1 (en) 2003-03-18 2009-12-03 Veryan Medical Ltd SPIRAL STONE
US20040193246A1 (en) 2003-03-25 2004-09-30 Microvention, Inc. Methods and apparatus for treating aneurysms and other vascular defects
US7771463B2 (en) 2003-03-26 2010-08-10 Ton Dai T Twist-down implant delivery technologies
ES2346059T3 (en) 2003-03-26 2010-10-08 Biosensors International Group Ltd. IMPLANT SUPPLY CATHETER WITH ELECTROLYTICALLY EROSIONABLE JOINTS.
US6984244B2 (en) 2003-03-27 2006-01-10 Endovascular Technologies, Inc. Delivery system for endoluminal implant
WO2004091696A1 (en) 2003-04-08 2004-10-28 The Board Of Trustees Of The Leland Stanford Junior University Implantable arteriovenous shunt device
US7597704B2 (en) 2003-04-28 2009-10-06 Atritech, Inc. Left atrial appendage occlusion device with active expansion
US7604649B2 (en) 2003-04-29 2009-10-20 Rex Medical, L.P. Distal protection device
US7025768B2 (en) 2003-05-06 2006-04-11 Boston Scientific Scimed, Inc. Systems and methods for ablation of tissue
US7331979B2 (en) 2003-06-04 2008-02-19 Access Closure, Inc. Apparatus and methods for sealing a vascular puncture
CA2527400A1 (en) 2003-06-12 2004-12-23 C.R. Bard, Inc. Stent delivery catheter
US7632291B2 (en) 2003-06-13 2009-12-15 Trivascular2, Inc. Inflatable implant
US20040260384A1 (en) 2003-06-17 2004-12-23 Medtronic Ave Superelastic coiled stent
US7678123B2 (en) 2003-07-14 2010-03-16 Nmt Medical, Inc. Tubular patent foramen ovale (PFO) closure device with catch system
US7011643B2 (en) 2003-08-05 2006-03-14 Cabg Medical, Inc. Grafted network incorporating a multiple channel fluid flow connector
GB2404860A (en) 2003-08-11 2005-02-16 Mohie Eldin Omar Arterial haemodialysis graft
DE602004017750D1 (en) * 2003-08-19 2008-12-24 Nmt Medical Inc Expandable lock hose
US8043357B2 (en) 2003-10-10 2011-10-25 Cook Medical Technologies Llc Ring stent
US7867271B2 (en) 2003-11-20 2011-01-11 Advanced Cardiovascular Systems, Inc. Rapid-exchange delivery systems for self-expanding stents
US8128681B2 (en) 2003-12-19 2012-03-06 Boston Scientific Scimed, Inc. Venous valve apparatus, system, and method
US7704266B2 (en) 2004-01-22 2010-04-27 Rex Medical, L.P. Vein filter
US9713549B2 (en) 2004-02-02 2017-07-25 Bayer Healthcare Llc Contraceptive with permeable and impermeable components
CN101627938B (en) 2004-02-02 2011-12-21 孕体有限公司 Contraceptive with permeable and impermeable components
US8048086B2 (en) 2004-02-25 2011-11-01 Femasys Inc. Methods and devices for conduit occlusion
US7651521B2 (en) 2004-03-02 2010-01-26 Cardiomind, Inc. Corewire actuated delivery system with fixed distal stent-carrying extension
US8313505B2 (en) 2004-03-19 2012-11-20 Aga Medical Corporation Device for occluding vascular defects
US9039724B2 (en) 2004-03-19 2015-05-26 Aga Medical Corporation Device for occluding vascular defects
US8398670B2 (en) 2004-03-19 2013-03-19 Aga Medical Corporation Multi-layer braided structures for occluding vascular defects and for occluding fluid flow through portions of the vasculature of the body
US8777974B2 (en) 2004-03-19 2014-07-15 Aga Medical Corporation Multi-layer braided structures for occluding vascular defects
US8747453B2 (en) 2008-02-18 2014-06-10 Aga Medical Corporation Stent/stent graft for reinforcement of vascular abnormalities and associated method
US7654997B2 (en) 2004-04-21 2010-02-02 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitus and other disorders of the ears, nose and/or throat
US7699056B2 (en) 2004-06-10 2010-04-20 Conceptus, Inc. Medical devices and methods of making and using such devices
WO2006009688A2 (en) 2004-06-16 2006-01-26 Pneumrx, Inc. Intra-bronchial lung volume reduction system
EP2708191B1 (en) 2004-08-02 2021-03-03 V.V.T. Medical Ltd. Device for treating a vessel
US20060052822A1 (en) 2004-08-31 2006-03-09 Mirizzi Michael S Apparatus and material composition for permanent occlusion of a hollow anatomical structure
US8403955B2 (en) 2004-09-02 2013-03-26 Lifescreen Sciences Llc Inflatable intravascular filter
US7927346B2 (en) 2004-09-10 2011-04-19 Stryker Corporation Diversion device to increase cerebral blood flow
WO2006034153A2 (en) 2004-09-17 2006-03-30 Cordis Neurovascular, Inc. Thin film metallic devices for plugging aneurysms or vessels
US20060162731A1 (en) 2004-11-16 2006-07-27 Pulmonx Pulmonary occlusal stent delivery catheter, loading system and methods of use
JP4251131B2 (en) 2004-11-17 2009-04-08 ソニー株式会社 Data processing apparatus and method
JP4402583B2 (en) 2004-12-27 2010-01-20 株式会社パイオラックスメディカルデバイス Vascular obturator
US20080147111A1 (en) 2005-01-03 2008-06-19 Eric Johnson Endoluminal Filter With Fixation
US20060241677A1 (en) 2005-01-03 2006-10-26 Eric Johnson Methods for maintaining a filtering device within a lumen
US8181653B2 (en) 2005-02-15 2012-05-22 Yale University Intrauterine fallopian tube occlusion device
US7476232B2 (en) 2005-03-04 2009-01-13 Boston Scientific Scimed, Inc. Access catheter having dilation capability and related methods
US7740616B2 (en) 2005-03-29 2010-06-22 Angiodynamics, Inc. Implantable catheter and method of using same
DE102005016103B4 (en) 2005-04-08 2014-10-09 Merit Medical Systems, Inc. Duodenumstent
CA2733165C (en) 2005-04-19 2014-11-25 Medinol, Ltd. A covering for an endoprosthetic device and methods of using for aneurysm treatment
GB0512073D0 (en) 2005-06-14 2005-07-20 Vallabhaneni Srinivasa R Device for use in treatment of varicose veins
US8118852B2 (en) 2005-07-13 2012-02-21 Cook Medical Technologies Llc Introducer for self-expandable medical device
US20070088388A1 (en) 2005-09-19 2007-04-19 Opolski Steven W Delivery device for implant with dual attachment sites
US20070078510A1 (en) 2005-09-26 2007-04-05 Ryan Timothy R Prosthetic cardiac and venous valves
US8216302B2 (en) 2005-10-26 2012-07-10 Cardiosolutions, Inc. Implant delivery and deployment system and method
US7955354B2 (en) 2005-11-14 2011-06-07 Occlutech Gmbh Occlusion device and surgical instrument and method for its implantation/explantation
CA2630217C (en) 2005-11-18 2016-10-11 C.R. Bard, Inc. Vena cava filter with filament
US20070135826A1 (en) 2005-12-01 2007-06-14 Steve Zaver Method and apparatus for delivering an implant without bias to a left atrial appendage
US8052715B2 (en) 2005-12-01 2011-11-08 Atritech, Inc. Method and apparatus for recapturing an implant from the left atrial appendage
US20070162108A1 (en) 2005-12-13 2007-07-12 Carlson James M Implantable medical device using palladium
WO2007075892A2 (en) 2005-12-23 2007-07-05 Clinasys Llc An implantable prosthetic valve
US20070156224A1 (en) 2006-01-04 2007-07-05 Iulian Cioanta Handle system for deploying a prosthetic implant
US8778008B2 (en) 2006-01-13 2014-07-15 Aga Medical Corporation Intravascular deliverable stent for reinforcement of vascular abnormalities
US8900287B2 (en) 2006-01-13 2014-12-02 Aga Medical Corporation Intravascular deliverable stent for reinforcement of abdominal aortic aneurysm
US20070163601A1 (en) 2006-01-17 2007-07-19 Neil Pollock Apparatus and method for reversible male and female contraceptive implants
DE102006004123A1 (en) 2006-01-25 2007-08-02 Jotec Gmbh Feed system for the insertion of expandable stents into cardiac arteries uses a hand held grip
US7691124B2 (en) 2006-01-31 2010-04-06 Codman & Shurtleff, Inc. Delivery of therapeutic devices
EP1988851A2 (en) 2006-02-14 2008-11-12 Sadra Medical, Inc. Systems and methods for delivering a medical implant
US8157837B2 (en) 2006-03-13 2012-04-17 Pneumrx, Inc. Minimally invasive lung volume reduction device and method
US7771451B2 (en) 2006-04-05 2010-08-10 Boston Scientific Scimed, Inc. Method and apparatus for the deployment of vaso-occlusive coils
US20090131959A1 (en) 2006-04-20 2009-05-21 Liquidia Technologies Inc. Biological Vessel Flow Control Devices and Methods
WO2007127352A1 (en) 2006-04-27 2007-11-08 William A. Cook Australia Pty. Ltd. Handle for a deployment device
US7758593B2 (en) 2006-05-04 2010-07-20 Ethicon Endo-Surgery, Inc. Medical instrument handle and medical instrument having same
US20070265658A1 (en) 2006-05-12 2007-11-15 Aga Medical Corporation Anchoring and tethering system
US8603530B2 (en) 2006-06-14 2013-12-10 Abbott Cardiovascular Systems Inc. Nanoshell therapy
US7746986B2 (en) 2006-06-15 2010-06-29 Verizon Data Services Llc Methods and systems for a sign language graphical interpreter
US20070299461A1 (en) 2006-06-21 2007-12-27 Boston Scientific Scimed, Inc. Embolic coils and related components, systems, and methods
EP3338735A1 (en) 2006-07-19 2018-06-27 Novate Medical Limited A vascular filter
US7647930B2 (en) 2006-08-02 2010-01-19 ProMed, Inc. Fallopian tube occlusion devices and methods
US20080046092A1 (en) 2006-08-17 2008-02-21 Richard Champion Davis Coil embolization device with stretch resistance fiber
AU2007285800A1 (en) 2006-08-17 2008-02-21 Nfocus Neuromedical, Inc. Isolation devices for the treatment of aneurysms
US20080103522A1 (en) 2006-10-27 2008-05-01 Medtronic Vascular, Inc. Distal Protection Device for Filtering and Occlusion
EP2129425B1 (en) 2006-11-29 2023-12-27 Emboline, INC. Embolic protection device
EP2094343B1 (en) 2006-11-30 2017-10-04 Ingenion Medical Limited System for implanting a catheter
DE602007008281D1 (en) 2006-11-30 2010-09-16 Cook William Europ Push tube for stent implantation device
JP5319546B2 (en) 2006-12-15 2013-10-16 カーディオマインド, インコーポレイテッド Stent system
US20080178890A1 (en) 2006-12-18 2008-07-31 Vacare Tehnologies, Llc Method and apparatus for transcervical reversible cornual sterilization
US8333783B2 (en) 2007-02-16 2012-12-18 Reverse Medical Corporation Occlusion device and method of use
DE102007010305A1 (en) 2007-02-22 2008-08-28 Jotec Gmbh Device for releasing a self-expanding stent into a body vessel
US8348994B2 (en) 2007-03-09 2013-01-08 Novostent Corporation Vascular prosthesis with alternating helical sections
US8002815B2 (en) 2007-03-09 2011-08-23 Novostent Corporation Delivery system and method for vascular prosthesis
US8795316B2 (en) 2007-04-25 2014-08-05 DePuy Syntheses Products, LLC Implantable medical device delivery system with a frangible portion and methods of making and using the same
WO2008153653A1 (en) 2007-05-31 2008-12-18 Rex Medical, L.P. Fallopian tube occlusion device
US8048147B2 (en) 2007-06-27 2011-11-01 Aga Medical Corporation Branched stent/graft and method of fabrication
US8328840B2 (en) 2007-07-09 2012-12-11 Artventive Medical Group, Inc. Methods and apparatus for rapid endovascular vessel occlusion and blood flow interruption
US8034061B2 (en) 2007-07-12 2011-10-11 Aga Medical Corporation Percutaneous catheter directed intravascular occlusion devices
EP4088770A1 (en) * 2007-07-18 2022-11-16 Silk Road Medical, Inc. Methods and systems for establishing retrograde carotid arterial blood flow
US8092510B2 (en) 2007-07-25 2012-01-10 Cook Medical Technologies Llc Retention wire for self-expanding stent
US8361138B2 (en) 2007-07-25 2013-01-29 Aga Medical Corporation Braided occlusion device having repeating expanded volume segments separated by articulation segments
US20090112251A1 (en) 2007-07-25 2009-04-30 Aga Medical Corporation Braided occlusion device having repeating expanded volume segments separated by articulation segments
EP2180839A4 (en) 2007-08-06 2013-08-28 Michael R Henson Thrombectomy system and method
US20090043330A1 (en) 2007-08-09 2009-02-12 Specialized Vascular Technologies, Inc. Embolic protection devices and methods
US20090078270A1 (en) 2007-09-26 2009-03-26 Ethicon, Inc. Removable implant and implantation tool for male contraception
US20090082803A1 (en) 2007-09-26 2009-03-26 Aga Medical Corporation Braided vascular devices having no end clamps
WO2010047644A1 (en) 2008-10-10 2010-04-29 Milux Holding S.A. An apparatus for temporary male contraception
US9414842B2 (en) 2007-10-12 2016-08-16 St. Jude Medical, Cardiology Division, Inc. Multi-component vascular device
US8083789B2 (en) 2007-11-16 2011-12-27 Trivascular, Inc. Securement assembly and method for expandable endovascular device
US8016880B2 (en) 2007-11-16 2011-09-13 Medtronic Vascular, Inc. Stent having spiral channel for drug delivery
US7846199B2 (en) 2007-11-19 2010-12-07 Cook Incorporated Remodelable prosthetic valve
US8956475B2 (en) 2007-12-11 2015-02-17 Howard Riina Method and apparatus for restricting flow through an opening in the side wall of a body lumen, and/or for reinforcing a weakness in the side wall of a body lumen, while still maintaining substantially normal flow through the body lumen
WO2009077845A2 (en) 2007-12-14 2009-06-25 Welldone Weartec N.V. Support implant, in particular a stent, and implantation catheter for the support implant
US20090171386A1 (en) 2007-12-28 2009-07-02 Aga Medical Corporation Percutaneous catheter directed intravascular occlusion devices
US9743918B2 (en) 2008-01-18 2017-08-29 St. Jude Medical, Cardiology Division, Inc. Percutaneous catheter directed intravascular occlusion device
US8163004B2 (en) 2008-02-18 2012-04-24 Aga Medical Corporation Stent graft for reinforcement of vascular abnormalities and associated method
US9259225B2 (en) 2008-02-19 2016-02-16 St. Jude Medical, Cardiology Division, Inc. Medical devices for treating a target site and associated method
US20110040371A1 (en) 2008-02-22 2011-02-17 Hanssen Investment & Consultancy B.V. Coiled assembly for supporting the wall of a lumen
US20090216185A1 (en) 2008-02-26 2009-08-27 Boston Scientific Scimed, Inc. Balloon catheter with durable tip portion
EP2265195A4 (en) 2008-04-04 2012-11-07 Reverse Medical Corp Multi-utilitarian microcatheter system and method of use
JP2011517424A (en) 2008-04-08 2011-06-09 リバース メディカル コーポレイション Occlusion device and method of use
EP2633823B1 (en) 2008-04-21 2016-06-01 Covidien LP Braid-ball embolic devices and delivery systems
US8992591B2 (en) 2008-05-07 2015-03-31 Cook Medical Technologies Llc Delivery system with low longitudinal compressibility
EP2299951B1 (en) 2008-05-16 2012-03-07 Conceptus, Inc. Occlusion device and system for occluding a reproductive body lumen
US8945160B2 (en) 2008-07-03 2015-02-03 Hotspur Technologies, Inc. Apparatus and methods for treating obstructions within body lumens
US20100006105A1 (en) 2008-07-08 2010-01-14 Carter Phillip J Apparatus and methods for occluding a fallopian tube
US8333796B2 (en) 2008-07-15 2012-12-18 Penumbra, Inc. Embolic coil implant system and implantation method
US20100030321A1 (en) 2008-07-29 2010-02-04 Aga Medical Corporation Medical device including corrugated braid and associated method
US20100049307A1 (en) 2008-08-25 2010-02-25 Aga Medical Corporation Stent graft having extended landing area and method for using the same
US8262692B2 (en) 2008-09-05 2012-09-11 Merlin Md Pte Ltd Endovascular device
US20100063578A1 (en) 2008-09-05 2010-03-11 Aga Medical Corporation Bifurcated medical device for treating a target site and associated method
CA2776475A1 (en) 2008-10-10 2010-04-15 Peter Forsell An improved artificial valve
US8202292B2 (en) 2008-10-13 2012-06-19 Stryker Corporation Vaso-occlusive coil delivery system
US20100089406A1 (en) 2008-10-14 2010-04-15 Elena Kachiguina Method and device for male contraception
US9427304B2 (en) 2008-10-27 2016-08-30 St. Jude Medical, Cardiology Division, Inc. Multi-layer device with gap for treating a target site and associated method
US8556960B2 (en) 2008-11-06 2013-10-15 Cook Medical Technologies Llc Frameless vascular valve
US8940015B2 (en) 2008-11-11 2015-01-27 Aga Medical Corporation Asymmetrical medical devices for treating a target site and associated method
WO2010077966A1 (en) 2008-12-17 2010-07-08 Abbott Laboratories Vascular Enterprises Limited Methods and apparatus for filtering a body lumen
WO2010085344A1 (en) 2009-01-22 2010-07-29 Cornell University Method and apparatus for restricting flow through the wall of a lumen
AU2009200350B1 (en) 2009-02-02 2009-07-16 Cook Incorporated Preloaded stent graft delivery device
CN102481153B (en) 2009-02-20 2015-11-25 柯惠有限合伙公司 Be used for the treatment of the veno-occlusive method and apparatus of venous insufficiency
US8843359B2 (en) 2009-02-27 2014-09-23 Andrew Nelthropp Lauder Language translation employing a combination of machine and human translations
AU2010229789B2 (en) 2009-03-26 2014-11-13 Johnson & Johnson Surgical Vision, Inc. Glaucoma shunts with flow management and improved surgical performance
CN102596083B (en) 2009-04-15 2016-11-16 微排放器公司 Implant delivery system
EP2630919B1 (en) 2009-04-16 2015-09-16 Occlutech Holding AG Intravascular delivery device, system and implant
EP2609872B2 (en) 2009-05-06 2019-01-02 Occlutech Holding AG Medical device for a delivery of a medical implant
CN104622599B (en) 2009-05-18 2017-04-12 纽姆克斯股份有限公司 Cross-sectional modification during deployment of an elongate lung volume reduction device
US8360065B2 (en) 2009-05-21 2013-01-29 Boston Scientific Scimed, Inc. Occlusion of fallopian tubes in a vertebrate subject
TR201907891T4 (en) 2009-06-15 2019-06-21 Perflow Medical Ltd Apparatus for maintaining blood flow through a blocked vein.
US9883864B2 (en) 2009-06-17 2018-02-06 Coherex Medical, Inc. Medical device for modification of left atrial appendage and related systems and methods
US9351716B2 (en) 2009-06-17 2016-05-31 Coherex Medical, Inc. Medical device and delivery system for modification of left atrial appendage and methods thereof
US9693781B2 (en) 2009-06-17 2017-07-04 Coherex Medical, Inc. Medical device for modification of left atrial appendage and related systems and methods
US20110022074A1 (en) 2009-07-22 2011-01-27 Alex Powell Permanent arterial emboli dissolution filter to prevent embolic occlusion of a blood vessel
KR20110043799A (en) 2009-10-16 2011-04-28 강호창 Micro-coil assembly
CA2817442A1 (en) 2009-11-23 2011-05-26 Nelson Medical Enterprises, Llc Device and method for extracting tubular structures
US8696698B2 (en) * 2009-12-02 2014-04-15 Surefire Medical, Inc. Microvalve protection device and method of use for protection against embolization agent reflux
US20120296408A1 (en) 2010-01-25 2012-11-22 Jones Donald K Methods and systems for performing vascular reconstruction
WO2011130536A2 (en) 2010-04-14 2011-10-20 Northwestern University Triple balloon occlusion and infusion catheter
US8801775B2 (en) 2010-04-27 2014-08-12 Medtronic Vascular, Inc. Helical stent with opposing and/or alternating pitch angles
CA2799336A1 (en) 2010-05-12 2011-11-17 Medical Device Innovations Inc. Method and device for treatment of arrhythmias and other maladies
US20130204311A1 (en) 2010-05-12 2013-08-08 Helical Solutions, Inc. Implants and methods for treating cardiac arrhythmias
US20130109987A1 (en) 2011-05-12 2013-05-02 Medical Device Innovations Inc. Method and device for treatment of arrhythmias and other maladies
US20110301630A1 (en) 2010-06-02 2011-12-08 Cook Incorporated Occlusion device
WO2011159913A2 (en) 2010-06-16 2011-12-22 The Trustees Of Dartmouth College Magnetic particle heating system and method for occlusion of the fallopian tube
BR122013004123A2 (en) 2010-06-22 2018-06-19 Covidien Lp METHODS AND APPARATUS FOR STORAGE AND / OR INTRODUCTION OF IMPLANTS FOR OCA ANATOMIC STRUCTURE
WO2012002944A1 (en) 2010-06-29 2012-01-05 Artventive Medical Group, Inc. Reducing flow through a tubular structure
US9247942B2 (en) 2010-06-29 2016-02-02 Artventive Medical Group, Inc. Reversible tubal contraceptive device
US20120116350A1 (en) 2010-07-07 2012-05-10 Reverse Medical Corporation Translation dilator and stand alone vascular guide catheter
WO2012040380A1 (en) 2010-09-21 2012-03-29 The Regents Of The University Of Colorado, A Body Corporate Aqueous humor micro bypass shunt
US9149277B2 (en) * 2010-10-18 2015-10-06 Artventive Medical Group, Inc. Expandable device delivery
US9675487B2 (en) 2010-11-17 2017-06-13 Cook Medical Technologies Llc Prosthesis deployment system for vascular repair
US20120172911A1 (en) 2010-12-30 2012-07-05 Cook Medical Technologies Llc Occlusion device
WO2012109367A1 (en) 2011-02-10 2012-08-16 Stryker Corporation Vaso-occlusive device delivery system
US9393133B2 (en) 2011-02-18 2016-07-19 Piolax Medical Devices, Inc. Abdominal cavity-vein shunt stent
US9301769B2 (en) 2011-03-09 2016-04-05 Neuravi Limited Clot retrieval device for removing clot from a blood vessel
US20120245614A1 (en) 2011-03-21 2012-09-27 William Joseph Drasler Branch and Truncal Vessel Occluder
US10201336B2 (en) 2011-03-25 2019-02-12 St. Jude Medical, Cardiology Division, Inc. Device and method for delivering a vascular device
KR20140031858A (en) 2011-04-01 2014-03-13 시네론 뷰티 리미티드 A treatment device
US8834544B2 (en) 2011-04-08 2014-09-16 Sanovas Inc. Photodynamic therapy for tumors with localized delivery
WO2012149167A2 (en) 2011-04-26 2012-11-01 Christopher Gerard Kunis Method and device for treatment of hypertension and other maladies
US20120283768A1 (en) * 2011-05-05 2012-11-08 Sequent Medical Inc. Method and apparatus for the treatment of large and giant vascular defects
US20120289994A1 (en) 2011-05-12 2012-11-15 Boston Scientific Scimed, Inc. Occlusion Devices and Related Methods of Use
US9345499B2 (en) 2011-05-26 2016-05-24 Covidien Lp Pressure activated foreign body removal system and method of use
US8641777B2 (en) 2011-06-03 2014-02-04 Reverse Medical Corporation Embolic implant and method of use
WO2013055703A1 (en) 2011-10-07 2013-04-18 Cornell University Method and apparatus for restricting flow through an opening in a body lumen while maintaining normal flow
WO2013059511A1 (en) 2011-10-18 2013-04-25 Medical Device Innovations Inc. Method and device for treatment of arrhythmias and other maladies
US8771341B2 (en) 2011-11-04 2014-07-08 Reverse Medical Corporation Protuberant aneurysm bridging device and method of use
US9844405B2 (en) 2011-12-20 2017-12-19 Cardiac Pacemakers, Inc. Method and apparatus for monitoring and ablating nerves
US8984733B2 (en) 2013-02-05 2015-03-24 Artventive Medical Group, Inc. Bodily lumen occlusion
US9095344B2 (en) 2013-02-05 2015-08-04 Artventive Medical Group, Inc. Methods and apparatuses for blood vessel occlusion
CA2904862A1 (en) 2013-03-14 2014-10-02 Incumedx Inc. Implants, methods of manufacturing the same, and devices and methods for delivering the implants to a vascular disorder of a patient
US9566071B2 (en) 2013-04-11 2017-02-14 Blockade Medical, LLC Systems and devices for cerebral aneurysm repair
US20150157329A1 (en) 2013-06-14 2015-06-11 Artventive Medical Group, Inc. Luminal device delivery system
CN105530874B (en) 2013-08-20 2018-02-02 斯瑞克公司 Vaso-occlusive coil conveying assembly and vaso-occlusive coil delivery system
US20150290437A1 (en) 2014-02-13 2015-10-15 Artventive Medical Group, Inc. Luminal device delivery system
US10363043B2 (en) 2014-05-01 2019-07-30 Artventive Medical Group, Inc. Treatment of incompetent vessels

Also Published As

Publication number Publication date
EP3007756A4 (en) 2017-02-22
AU2013392058A1 (en) 2016-01-21
CA2915267A1 (en) 2014-12-18
AU2013392058B2 (en) 2017-11-23
US20140371716A1 (en) 2014-12-18
ES2957207T3 (en) 2024-01-15
WO2014200563A1 (en) 2014-12-18
US9737308B2 (en) 2017-08-22
EP3007756B1 (en) 2023-08-02
EP3007756A1 (en) 2016-04-20

Similar Documents

Publication Publication Date Title
US9737308B2 (en) Catheter-assisted tumor treatment
US20210393269A1 (en) Embolisation systems
US10149968B2 (en) Catheter-assisted tumor treatment
US9451965B2 (en) Reducing flow through a tubular structure
US9737307B2 (en) Blood vessel occlusion
US20150157329A1 (en) Luminal device delivery system
US8328840B2 (en) Methods and apparatus for rapid endovascular vessel occlusion and blood flow interruption
EP2739217B1 (en) Systems for treatment of acute ischemic stroke
AU742149B2 (en) Cardioplegia occluder
US20200368499A1 (en) Augmented delivery catheter and method
US11224438B2 (en) Treatment of incompetent vessels
US10004513B2 (en) Bodily lumen occlusion
US20150290437A1 (en) Luminal device delivery system
US20100204684A1 (en) Methods and systems for performing neurointerventional procedures
US20060085028A1 (en) Vessel occlusion system
US10813644B2 (en) Occlusive implant and delivery system
US20210267605A1 (en) Occlusive implant and delivery system
WO2015123593A1 (en) Luminal device delivery system

Legal Events

Date Code Title Description
AS Assignment

Owner name: ARTVENTIVE MEDICAL GROUP, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:RUDAKOV, LEON;REEL/FRAME:032133/0983

Effective date: 20131219

STCF Information on status: patent grant

Free format text: PATENTED CASE

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Year of fee payment: 4